Gene	Variants	Tumor(s)	'Tumor(s)_code'	Publications
42992	copy number gain	Glioblastoma	'GB'	" ### Frattini V, et al. The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet 2013;45(10):1141-9"
ABL1	any mutation	Chronic Myeloid Leukemia/B Lymphoblastic Leukemia/Lymphoma	'CML'/'*BLL'/'LY'	" ### Soverini S, et al. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement. Cancer 2014;120(7):1002-9 ### Soverini S, et al. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk Res 2014;38(1):10-20"
ALK	F1174C	Adenocarcinoma/Non-Small Cell Lung Carcinoma	'*AC2'/'NSCLC'	" ### Sasaki T, et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res 2010;70(24):10038-43 ### Friboulet L, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 2014;4(6):662-73 ### Carpenter EL, et al. Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma. Oncogene 2012;31(46):4859-67 ### Moss√© YP Anaplastic Lymphoma Kinase as a Cancer Target in Pediatric Malignancies. Clin Cancer Res 2016;22(3):546-52"
ALK	L1196Q	Adenocarcinoma/Non-Small Cell Lung Carcinoma	'*AC2'/'NSCLC'	" ### Choi YL, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010;363(18):1734-9 ### Katayama R, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med 2012;4(120):120ra17 ### Friboulet L, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 2014;4(6):662-73"
APC	any frameshift	Adenocarcinoma	'*AC2'	" ### Han SW et al 2013 PloS one;8(5):e64271. Targeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencing. ### Prall F et al 2007 Histopathology;50(3):318-30.Phenotypes of invasion in sporadic colorectal carcinomas related to aberrations of the adenomatous polyposis coli (APC ) gene. ### Kim JT et al 2013 Carcinogenesis;34(5):953-61. Deregulation of Wnt/beta-catenin signaling through genetic or epigenetic alterations in human neuroendocrine tumors. ### Vasovcak P et al 2014, PloS one;6(8):e24114 Molecular genetic analysis of 103 sporadic colorectal tumours in czech patients."
APC	any missense	Adenocarcinoma	'*AC2'	" ### Han SW et al 2013 PloS one;8(5):e64271. Targeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencing. ### Prall F et al 2007 Histopathology;50(3):318-30.Phenotypes of invasion in sporadic colorectal carcinomas related to aberrations of the adenomatous polyposis coli (APC ) gene. ### Kim JT et al 2013 Carcinogenesis;34(5):953-61. Deregulation of Wnt/beta-catenin signaling through genetic or epigenetic alterations in human neuroendocrine tumors. ### Vasovcak P et al 2014, PloS one;6(8):e24114 Molecular genetic analysis of 103 sporadic colorectal tumours in czech patients."
APC	any mutation	Adenocarcinoma	'*AC2'	" ### Khemlina G, et al. Molecular landscape of prostate cancer: implications for current clinical trials. Cancer Treat Rev 2015;41(9):761-6 ### Henrique R, et al. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin Cancer Res 2007;13(20):6122-9 ### Kypta RM, et al. Wnt/Œ≤-catenin signalling in prostate cancer. Nat Rev Urol 2012;9(8):418-28"
APC	any mutation	Glioblastoma/Glial Neoplasm	'GB'/'*GN''	" ### Boman BM, et al. An APC:WNT Counter-Current-Like Mechanism Regulates Cell Division Along the Human Colonic Crypt Axis: A Mechanism That Explains How APC Mutations Induce Proliferative Abnormalities That Drive Colon Cancer Development. Front Oncol 2013;3():244 ### Tang C, et al. Gene mutation profiling of primary glioblastoma through multiple tumor biopsy guided by 1H-magnetic resonance spectroscopy. Int J Clin Exp Pathol 2015;8(5):5327-35 ### Johnson BE, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 2014;343(6167):189-93"
APC	any mutation	Papillary Carcinoma	'THP'	" ### Frayling et al The APC variants I1307K and E1317Q are associated with colorectal tumors, but not always with a family history. Proc. Natl. Acad. Sci. USA Vol. 95, pp. 10722‚Ä?0727. ### Cameselle-Teijeiro et al. Somatic but not germline mutation of the APC gene in a case of cribriform-morular variant of papillary thyroid carcinoma. American journal of clinical pathology 115.4 (2001): 486-493"
APC	any mutation	Squamous Cell Carcinoma/Adenocarcinoma	'SCC'/'*AC2'	" ### Greulich, H. The Genomics of Lung Adenocarcinoma Opportunities for Targeted Therapies. Genes & cancer 1.12 (2010): 1200-1210."
APC	any nonsense	Adenocarcinoma	'*AC2'	" ### Han SW et al 2013 PloS one;8(5):e64271. Targeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencing. ### Prall F et al 2007 Histopathology;50(3):318-30.Phenotypes of invasion in sporadic colorectal carcinomas related to aberrations of the adenomatous polyposis coli (APC ) gene. ### Kim JT et al 2013 Carcinogenesis;34(5):953-61. Deregulation of Wnt/beta-catenin signaling through genetic or epigenetic alterations in human neuroendocrine tumors. ### Vasovcak P et al 2014, PloS one;6(8):e24114 Molecular genetic analysis of 103 sporadic colorectal tumours in czech patients."
APC	E1317Q	Adenocarcinoma/Carcinoma	'*AC2'/'*CA'	" ### Frayling et al The APC variants I1307K and E1317Q are associated with colorectal tumors, but not always with a family history. Proc. Natl. Acad. Sci. USA Vol. 95, pp. 10722‚Ä?0727."
APC	E1317Q	Papillary Carcinoma	'THP'	" ### Frayling et al The APC variants I1307K and E1317Q are associated with colorectal tumors, but not always with a family history. Proc. Natl. Acad. Sci. USA Vol. 95, pp. 10722‚Ä?0727. ### Cameselle-Teijeiro et al. Somatic but not germline mutation of the APC gene in a case of cribriform-morular variant of papillary thyroid carcinoma. American journal of clinical pathology 115.4 (2001): 486-493"
APC	E1317Q	Squamous Cell Carcinoma/Adenocarcinoma	'SCC'/'*AC2'	" ### Greulich, H. The Genomics of Lung Adenocarcinoma Opportunities for Targeted Therapies. Genes & cancer 1.12 (2010): 1200-1210."
AR	any mutation	Adenocarcinoma	'*AC2'	" ### Barbieri CE, et al. The mutational landscape of prostate cancer. Eur Urol 2013;64(4):567-76 ### Cancer Genome Atlas Research Network The Molecular Taxonomy of Primary Prostate Cancer. Cell 2015;163(4):1011-25"
AR	copy number gain	Adenocarcinoma	'*AC2'	" ### Barbieri CE, et al. The mutational landscape of prostate cancer. Eur Urol 2013;64(4):567-76 ### Cancer Genome Atlas Research Network The Molecular Taxonomy of Primary Prostate Cancer. Cell 2015;163(4):1011-25"
AR	H875Y	Adenocarcinoma	'*AC2'	" ### Steinkamp MP, et al. Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res 2009;69(10):4434-42 ### Lallous N, et al. Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients. Genome Biol 2016;17(1):10"
ASXL1	any mutation	Myeloproliferative Neoplasm/Chronic Myelomonocytic Leukemia/Myelodysplastic Syndrome/Acute Myeloid Leukemia/Primary Myelofibrosis/Mast Cell Neoplasm	'*MPN2'/'*CMML'/'MDS'/'AML'/'MY'/'MAS'	" ### Patnaik MM, et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia 2014;28(11):2206-12 ### Guglielmelli P, et al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia 2014;28(9):1804-10 ### Haferlach T, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014;28(2):241-7 ### Larsson CA, et al. The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome. Mol Cancer Res 2013;11(8):815-27 ### Abdel-Wahab O, et al. Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood 2013;121(18):3563-72 ### Gelsi-Boyer V, et al. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J Hematol Oncol 2012;5():12 ### Tefferi A, et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia 2014;28(7):1494-500"
ATM	A1309T	Adenocarcinoma	'*AC2'	" ### Fletcher et al.. Missense Variants in ATM in 26,101 Breast Cancer Cases and 29,842 Controls. Cancer Epidemiol Biomarkers Prev. 2010 September ; 19(9): 2143‚Ä?151 ### Mangone et al‚Ä?ATM gene mutations in sporadic breast cancer patients from Brazil. SpringerPlus DOI 10.1186/s40064-015-0787-z ### Cremona et al ATM signalling and cancer. Oncogene (2014) 33, 3351‚Ä?360 ### Anika Maria Weber et al..ATM and ATR as therapeutic targets in cancer. Pharmacology & Therapeutics Volume 149, May 2015, Pages 124‚Ä?38"
ATM	A1309T	Melanoma	'*M'	" ### Fletcher et al.. Missense Variants in ATM in 26,101 Breast Cancer Cases and 29,842 Controls. Cancer Epidemiol Biomarkers Prev. 2010 September ; 19(9): 2143‚Ä?151 ### TCGA...Integrated Genomic Characterization of Papillary Thyroid Carcinoma. Cell 159, 676‚Ä?90, October 23, 2014 ### Cremona et al ATM signalling and cancer. Oncogene (2014) 33, 3351‚Ä?360"
ATM	A1309T	Papillary Carcinoma	'THP'	" ### Fletcher et al.. Missense Variants in ATM in 26,101 Breast Cancer Cases and 29,842 Controls. Cancer Epidemiol Biomarkers Prev. 2010 September ; 19(9): 2143‚Ä?151 ### TCGA...Integrated Genomic Characterization of Papillary Thyroid Carcinoma. Cell 159, 676‚Ä?90, October 23, 2014 ### Cremona et al ATM signalling and cancer. Oncogene (2014) 33, 3351‚Ä?360"
ATM	any mutation	Adenocarcinoma	'*AC2'	" ### Fletcher et al.. Missense Variants in ATM in 26,101 Breast Cancer Cases and 29,842 Controls. Cancer Epidemiol Biomarkers Prev. 2010 September ; 19(9): 2143‚Ä?151 ### Mangone et al‚Ä?ATM gene mutations in sporadic breast cancer patients from Brazil. SpringerPlus DOI 10.1186/s40064-015-0787-z ### Cremona et al ATM signalling and cancer. Oncogene (2014) 33, 3351‚Ä?360 ### Anika Maria Weber et al..ATM and ATR as therapeutic targets in cancer. Pharmacology & Therapeutics Volume 149, May 2015, Pages 124‚Ä?38"
ATM	any mutation	Chronic Lymphocytic Leukemia/Mantle Cell Lymphoma/T Cell Lymphoproliferative Disorder	'CLL'/'MCL'/'*TLPD'	" ### Rose-Zerilli MJ, et al. ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial. Haematologica 2014;99(4):736-42 ### Stankovic T, et al. The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia. Leuk Lymphoma 2014;55(6):1227-39 ### Meissner B, et al. The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma. Blood 2013;121(16):3161-4 ### Vorechovsk√Ω I, et al. Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia. Nat Genet 1997;17(1):96-9"
ATM	F858L	Adenocarcinoma	'*AC2'	" ### Fletcher et al.. Missense Variants in ATM in 26,101 Breast Cancer Cases and 29,842 Controls. Cancer Epidemiol Biomarkers Prev. 2010 September ; 19(9): 2143‚Ä?151 ### Mangone et al‚Ä?ATM gene mutations in sporadic breast cancer patients from Brazil. SpringerPlus DOI 10.1186/s40064-015-0787-z ### Cremona et al ATM signalling and cancer. Oncogene (2014) 33, 3351‚Ä?360 ### Anika Maria Weber et al..ATM and ATR as therapeutic targets in cancer. Pharmacology & Therapeutics Volume 149, May 2015, Pages 124‚Ä?38"
ATM	F858L	Melanoma	'*M'	" ### Fletcher et al.. Missense Variants in ATM in 26,101 Breast Cancer Cases and 29,842 Controls. Cancer Epidemiol Biomarkers Prev. 2010 September ; 19(9): 2143‚Ä?151 ### TCGA...Integrated Genomic Characterization of Papillary Thyroid Carcinoma. Cell 159, 676‚Ä?90, October 23, 2014 ### Cremona et al ATM signalling and cancer. Oncogene (2014) 33, 3351‚Ä?360"
ATM	F858L	Papillary Carcinoma	'THP'	" ### Fletcher et al.. Missense Variants in ATM in 26,101 Breast Cancer Cases and 29,842 Controls. Cancer Epidemiol Biomarkers Prev. 2010 September ; 19(9): 2143‚Ä?151 ### TCGA...Integrated Genomic Characterization of Papillary Thyroid Carcinoma. Cell 159, 676‚Ä?90, October 23, 2014 ### Cremona et al ATM signalling and cancer. Oncogene (2014) 33, 3351‚Ä?360"
ATM	P604S	Adenocarcinoma	'*AC2'	" ### Fletcher et al.. Missense Variants in ATM in 26,101 Breast Cancer Cases and 29,842 Controls. Cancer Epidemiol Biomarkers Prev. 2010 September ; 19(9): 2143‚Ä?151 ### Mangone et al‚Ä?ATM gene mutations in sporadic breast cancer patients from Brazil. SpringerPlus DOI 10.1186/s40064-015-0787-z ### Cremona et al ATM signalling and cancer. Oncogene (2014) 33, 3351‚Ä?360 ### Anika Maria Weber et al..ATM and ATR as therapeutic targets in cancer. Pharmacology & Therapeutics Volume 149, May 2015, Pages 124‚Ä?38"
ATM	P604S	Melanoma	'*M'	" ### Fletcher et al.. Missense Variants in ATM in 26,101 Breast Cancer Cases and 29,842 Controls. Cancer Epidemiol Biomarkers Prev. 2010 September ; 19(9): 2143‚Ä?151 ### TCGA...Integrated Genomic Characterization of Papillary Thyroid Carcinoma. Cell 159, 676‚Ä?90, October 23, 2014 ### Cremona et al ATM signalling and cancer. Oncogene (2014) 33, 3351‚Ä?360"
ATM	P604S	Papillary Carcinoma	'THP'	" ### Fletcher et al.. Missense Variants in ATM in 26,101 Breast Cancer Cases and 29,842 Controls. Cancer Epidemiol Biomarkers Prev. 2010 September ; 19(9): 2143‚Ä?151 ### TCGA...Integrated Genomic Characterization of Papillary Thyroid Carcinoma. Cell 159, 676‚Ä?90, October 23, 2014 ### Cremona et al ATM signalling and cancer. Oncogene (2014) 33, 3351‚Ä?360"
BAP1	any mutation	Clear Cell Renal Cell Carcinoma	'RCCC'	" ### Hakimi AA, et al. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol 2013;63(5):848-54 ### Gossage L, et al. Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma. Genes Chromosomes Cancer 2014;53(1):38-51 ### Liao L, et al. The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer. Cancer Genet 2015;208(5):206-14 ### Randall JM, et al. Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art. Cancer Metastasis Rev 2014;33(4):1109-24"
BCOR	any mutation	Chronic Myelomonocytic Leukemia/Myelodysplastic Syndrome/Acute Myeloid Leukemia	'*CMML'/'MDS'/'AML'	" ### Damm F, et al. BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. Blood 2013;122(18):3169-77 ### Tiacci E, et al. The corepressors BCOR and BCORL1: two novel players in acute myeloid leukemia. Haematologica 2012;97(1):3-5 ### Grossmann V, et al. Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Blood 2011;118(23):6153-63"
BCORL1	any mutation	Acute Myeloid Leukemia/Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia	'AML'/'MDS'/'*CMML'	" ### Damm F, et al. BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. Blood 2013;122(18):3169-77 ### Li M, et al. Somatic mutations in the transcriptional corepressor gene BCORL1 in adult acute myelogenous leukemia. Blood 2011;118(22):5914-7 ### Tiacci E, et al. The corepressors BCOR and BCORL1: two novel players in acute myeloid leukemia. Haematologica 2012;97(1):3-5"
BRAF	any mutation	Hairy Cell Leukemia/Langerhans Cell Histiocytosis/Histiocytic and Dendritic Cell Neoplasms/Chronic Lymphocytic Leukemia/Diffuse Large B Cell Lymphoma	'HCL'/'HISLC'/'*HDC'/'CLL'/'DLBCL'	" ### Machnicki MM, et al. BRAF--a new player in hematological neoplasms. Blood Cells Mol Dis 2014;53(1-2):77-83 ### Alonso CM, et al. BRAF V600E mutation in adult acute lymphoblastic leukemia. Leuk Lymphoma 2013;54(5):1105-6 ### Langabeer SE, et al. Incidence of the BRAF V600E mutation in chronic lymphocytic leukaemia and prolymphocytic leukaemia. Leuk Res 2012;36(4):483-4 ### Jebaraj BM, et al. BRAF mutations in chronic lymphocytic leukemia. Leuk Lymphoma 2013;54(6):1177-82 ### Ping N, et al. Absence of BRAF V600E mutation in hematologic malignancies excluding hairy-cell leukemia. Leuk Lymphoma 2012;53(12):2498-9 ### Samuel J, et al. Efficacy of vemurafenib in hairy-cell leukemia. N Engl J Med 2014;370(3):286-8"
BRAF	any mutation	Medulloblastoma	'MB'	" ### Deichmann M, et al. B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome. Oncology 2004;66(5):411-9 ### Deichmann M, et al. The oncogenic B-raf V599E mutation occurs more frequently in melanomas at sun-protected body sites. Int J Oncol 2006;29(1):139-45 ### Robinson G, et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 2012;488(7409):43-8 ### Pugh TJ, et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 2012;488(7409):106-10"
BRAF	codon(s) 464 any	Adenocarcinoma	'*AC2'	" ### Davies, H., Bignell, G. R., et al. Mutations of the BRAF gene in human cancer. Nature (2002) 417, 949-954"
BRAF	codon(s) 469 any	Adenocarcinoma	'*AC2'	" ### Sen et al Kinase Impaired BRAF Mutations Confer Lung Cancer Sensitivity to Dasatinib. Sci Transl Med. 2012 May 30; 4(136): ### Davies, H., Bignell, G. R., et al. Mutations of the BRAF gene in human cancer. Nature (2002) 417, 949-954"
BRAF	codon(s) 594 any	Melanoma/Adenocarcinoma	'*M'/'*AC2'	### Heidorn et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell. 2010 Jan 22;140(2):209-21
BRAF	codon(s) 600 any	Adenocarcinoma	'*AC2'	" ### Davies, H., Bignell, G. R., et al. Mutations of the BRAF gene in human cancer. Nature (2002) 417, 949-954. ### Di Nicolantonio, F., et al. Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer. J Clin. Oncol. (2008) 26, 5705-5712. ### Maestro, M.L. et al. Role of the BRAF Mutations in the Microsatellite Instability Genetic Pathway in Sporadic Colorectal Cancer.Ann. Surg. Oncol. (2007) 14, 1229‚Ä?236. ### Tol, J. et al. BRAF Mutation in Metastatic Colorectal Cancer. N. Engl. J. Med. (2009) 361, 98-99. ### Sharma, S.G., and M.L. Gulley. BRAF mutation testing in colorectal cancer. Arch. Pathol. Lab. Med. (2010) 134, 1225-1228 ### Prahallad et al.. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.Nature. 2012 Jan 26;483(7387):100-3. ### Gravalos C et al.. Integration of panitumumab into the treatment of colorectal cancer. Crit Rev Oncol Hematol. 2010 Apr;74(1):16-26."
BRAF	codon(s) 600 any	Adenocarcinoma	'*AC2'	" ### Robinson SD et al . BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib. Lung Cancer. 2014 Aug;85(2):326-30. ### Paik PK et al.. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncology, 2011 May 20;29(15):2046-51."
BRAF	codon(s) 600 any	Glial Neoplasm	'*GN''	" ### Robinson et al ..Complete clinical regression of a BRAF V600Emutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. BMC Cancer 2014, 14:258 ### Chi et al..BRAF V600E Mutation Identifies a Subset of Low-Grade Diffusely Infiltrating Gliomas in Adults. Journal of Clinical Oncology, Vol 31, No 14 (May 10), 2013: pp e233-e236 ### Schindler G, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol.121(3),397‚Ä?05 (2011)."
BRAF	codon(s) 600 any	Hairy Cell Leukemia/Langerhans Cell Histiocytosis/Histiocytic and Dendritic Cell Neoplasms/Chronic Lymphocytic Leukemia/Diffuse Large B Cell Lymphoma	'HCL'/'HISLC'/'*HDC'/'CLL'/'DLBCL'	" ### Machnicki MM, et al. BRAF--a new player in hematological neoplasms. Blood Cells Mol Dis 2014;53(1-2):77-83 ### Alonso CM, et al. BRAF V600E mutation in adult acute lymphoblastic leukemia. Leuk Lymphoma 2013;54(5):1105-6 ### Langabeer SE, et al. Incidence of the BRAF V600E mutation in chronic lymphocytic leukaemia and prolymphocytic leukaemia. Leuk Res 2012;36(4):483-4 ### Jebaraj BM, et al. BRAF mutations in chronic lymphocytic leukemia. Leuk Lymphoma 2013;54(6):1177-82 ### Ping N, et al. Absence of BRAF V600E mutation in hematologic malignancies excluding hairy-cell leukemia. Leuk Lymphoma 2012;53(12):2498-9 ### Samuel J, et al. Efficacy of vemurafenib in hairy-cell leukemia. N Engl J Med 2014;370(3):286-8"
BRAF	codon(s) 600 any	Histiocytic and Dendritic Cell Neoplasms	'*HDC'	" ### Go et al Frequent detection of BRAF V600E mutations in histiocytic and dendritic cell neoplasms Histopathology 2014, 65, 261‚Ä?72. ### Idbaih et al Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib. Neurology. 2014 Oct 14;83(16):1478-80 ### Michonneau et al...BRAF(V600E) mutation in a histiocytic sarcoma arising from hairy cell leukemia.J Clin Oncol 2014 Dec 24;32(35)"
BRAF	codon(s) 600 any	Langerhans Cell Histiocytosis	'HISLC'	" ### Badalian-Very G, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010;116(11):1919-23 ### Emile JF, et al. Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood 2014;124(19):3016-9"
BRAF	codon(s) 600 any	Melanoma	'*M'	" ### Salama AK, et al. BRAF in melanoma: current strategies and future directions. Clin Cancer Res 2013;19(16):4326-34 ### Davies H, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417(6892):949-54 ### Mandal√† M, et al. Targeting BRAF in melanoma: biological and clinical challenges. Crit Rev Oncol Hematol 2013;87(3):239-55 ### Flaherty KT BRAF inhibitors and melanoma. Cancer J 2011;17(6):505-11 ### Capovilla M [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge]. Ann Pathol 2013;33(6):375-85"
BRAF	codon(s) 600 any	Papillary Carcinoma	'THP'	" ### Davies, H., Bignell, G. R., et al. Mutations of the BRAF gene in human cancer. Nature (2002) 417, 949-954. ### Integrated Genomic Characterization of Papillary Thyroid Carcinoma.The Cancer Genome Atlas Research Network. Cell 159, 676‚Ä?90, October 23, 2014 ### Yarchoan M, et al. BRAF mutation and thyroid cancer recurrence. J Clin Oncol 2015;33(1):7-8"
BRAF	codon(s) 601 any	Adenocarcinoma	'*AC2'	" ### Dahlman et al., Concer Discov, 2:791, 2012."
BRAF	D594E	Melanoma/Adenocarcinoma	'*M'/'*AC2'	### Heidorn et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell. 2010 Jan 22;140(2):209-21
BRAF	F595S	Medulloblastoma	'MB'	" ### Deichmann M, et al. B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome. Oncology 2004;66(5):411-9 ### Deichmann M, et al. The oncogenic B-raf V599E mutation occurs more frequently in melanomas at sun-protected body sites. Int J Oncol 2006;29(1):139-45 ### Robinson G, et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 2012;488(7409):43-8 ### Pugh TJ, et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 2012;488(7409):106-10"
BRAF	G464V	Adenocarcinoma	'*AC2'	" ### Davies, H., Bignell, G. R., et al. Mutations of the BRAF gene in human cancer. Nature (2002) 417, 949-954"
BRAF	K601E	Adenocarcinoma	'*AC2'	" ### Dahlman et al., Concer Discov, 2:791, 2012."
BRAF	K601E	Papillary Carcinoma/Follicular Carcinoma	'THP'/'THF'	" ### Afkhami M, et al. Histopathologic and Clinical Characterization of Thyroid Tumors Carrying the BRAF(K601E) Mutation. Thyroid 2016;26(2):242-7 ### Pennelli G, et al. BRAF(K601E) mutation in a patient with a follicular thyroid carcinoma. Thyroid 2011;21(12):1393-6 ### McCabe MJ Use of histoacryl tissue adhesive to manage an avulsed tooth. BMJ 1990;301(6742):20-1 ### Cancer Genome Atlas Research Network Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014;159(3):676-90"
BRAF	L597V	Melanoma	'*M'	" ### Bahadoran P, et al. Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma. J Clin Oncol 2013;31(19):e324-6 ### Dahlman KB, et al. BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov 2012;2(9):791-7 ### Salama AK, et al. BRAF in melanoma: current strategies and future directions. Clin Cancer Res 2013;19(16):4326-34"
BRAF	N581S	Melanoma	'*M'	" ### Heidorn SJ, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010;140(2):209-21 ### Hodis E, et al. A landscape of driver mutations in melanoma. Cell 2012;150(2):251-63 ### Hill VK, et al. The genetics of melanoma: recent advances. Annu Rev Genomics Hum Genet 2013;14():257-79 ### Michaloglou C, et al. BRAF(E600) in benign and malignant human tumours. Oncogene 2008;27(7):877-95 ### Fratev FF, et al. An in silico study of the molecular basis of B-RAF activation and conformational stability. BMC Struct Biol 2009;9():47"
BRAF	T599_V600insT	Glial Neoplasm	'*GN''	" ### Eisenhardt A et al‚Ä?Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma. Int. J. Cancer: 129, 2297‚Ä?303 (2011)"
BRAF	Val599Ins	Papillary Carcinoma	'THP'	" ### Moretti S, et al. Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma. Oncogene 2006;25(30):4235-40"
BRCC3	any mutation	Myelodysplastic Syndrome	'MDS'	" ### Haferlach T, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014;28(2):241-7 ### https://ash.confex.com/ash/2013/webprogram/Paper60672.html"
CALR	exon(s) 9 frameshift	Myeloproliferative Neoplasm/Essential Thrombocythemia/Primary Myelofibrosis/MDS with Ring Sideroblasts/Myelodysplastic Syndrome	'*MPN2'/'*ET'/'MY'/'*MDS-RAS'/'MDS'	" ### Klampfl T, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013;369(25):2379-90 ### Nangalia J, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013;369(25):2391-405 ### Tefferi A, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 2014;28(7):1472-7 ### Tefferi A, et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia 2014;28(7):1494-500 ### Tefferi A, et al. Calreticulin mutations and long-term survival in essential thrombocythemia. Leukemia 2014;28(12):2300-3"
CBL	any mutation	Chronic Myelomonocytic Leukemia/Acute Myeloid Leukemia/Myelodysplastic Syndrome	'*CMML'/'AML'/'MDS'	" ### Schwaab J, et al. Activating CBL mutations are associated with a distinct MDS/MPN phenotype. Ann Hematol 2012;91(11):1713-20 ### Ib√°√±ez M, et al. Rapid screening of ASXL1, IDH1, IDH2, and c-CBL mutations in de novo acute myeloid leukemia by high-resolution melting. J Mol Diagn 2012;14(6):594-601 ### Aranaz P, et al. CBL RING finger deletions are common in core-binding factor acute myeloid leukemias. Leuk Lymphoma 2013;54(2):428-31 ### Schnittger S, et al. Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases. Haematologica 2012;97(12):1890-4 ### P√©rez B, et al. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia. Br J Haematol 2010;151(5):460-8 ### Makishima H, et al. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol 2009;27(36):6109-16"
CBLB	any mutation	Chronic Myeloid Leukemia/Acute Myeloid Leukemia	'CML'/'AML'	" ### Nicholson L, et al. Casitas B lymphoma mutations in childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer 2012;51(3):250-6 ### Makishima H, et al. CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood 2011;117(21):e198-206"
CD79B	any mutation	Diffuse Large B Cell Lymphoma	'DLBCL'	" ### Kraan W, et al. High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma. Leukemia 2014;28(3):719-20 ### Kim Y, et al. CD79B and MYD88 mutations in diffuse large B-cell lymphoma. Hum Pathol 2014;45(3):556-64 ### Davis RE, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010;463(7277):88-92"
CDH1	any indel	Invasive Lobular Carcinoma	'*ILC'	" ### Dossus L, et al. Lobular breast cancer: incidence and genetic and non-genetic risk factors. Breast Cancer Res 2015;17():37 ### Hansford S, et al. Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. JAMA Oncol 2015;1(1):23-32 ### Petridis C, et al. Germline CDH1 mutations in bilateral lobular carcinoma in situ. Br J Cancer 2014;110(4):1053-7 ### van der Post RS, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet 2015;52(6):361-74 ### Ciriello G, et al. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell 2015;163(2):506-19"
CDH1	any mutation	Adenocarcinoma	'*AC2'	" ### Hansford S, et al. Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. JAMA Oncol 2015;1(1):23-32 ### Corso G, et al. Somatic mutations and deletions of the E-cadherin gene predict poor survival of patients with gastric cancer. J Clin Oncol 2013;31(7):868-75 ### van der Post RS, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet 2015;52(6):361-74"
CDH1	any mutation	Invasive Lobular Carcinoma	'*ILC'	" ### Dossus L, et al. Lobular breast cancer: incidence and genetic and non-genetic risk factors. Breast Cancer Res 2015;17():37 ### Hansford S, et al. Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. JAMA Oncol 2015;1(1):23-32 ### Petridis C, et al. Germline CDH1 mutations in bilateral lobular carcinoma in situ. Br J Cancer 2014;110(4):1053-7 ### van der Post RS, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet 2015;52(6):361-74 ### Ciriello G, et al. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell 2015;163(2):506-19"
CDKN2A	any mutation	Adenocarcinoma	'*AC2'	" ### Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489(7417):519-25 ### Hill VK, et al. The genetics of melanoma: recent advances. Annu Rev Genomics Hum Genet 2013;14():257-79 ### Harinck F, et al. Indication for CDKN2A-mutation analysis in familial pancreatic cancer families without melanomas. J Med Genet 2012;49(6):362-5 ### Lim AM, et al. Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome. Int J Cancer 2014;135(4):887-95 ### Purkait S, et al. CDKN2A deletion in pediatric versus adult glioblastomas and predictive value of p16 immunohistochemistry. Neuropathology 2013;33(4):405-12"
CDKN2A	any mutation	Adenocarcinoma	'*AC2'	" ### Cancer Genome Atlas Research Network Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513(7517):202-9 ### Huang S, et al. CDK4/6 inhibitor suppresses gastric cancer with CDKN2A mutation. Int J Clin Exp Med 2015;8(7):11692-700"
CDKN2A	any mutation	Adenocarcinoma/Squamous Cell Carcinoma	'*AC2'/'SCC'	" ### Rayess H, et al. Cellular senescence and tumor suppressor gene p16. Int J Cancer 2012;130(8):1715-25 ### Collado M, et al. Cellular senescence in cancer and aging. Cell 2007;130(2):223-33 ### Xing X, et al. The prognostic value of CDKN2A hypermethylation in colorectal cancer: a meta-analysis. Br J Cancer 2013;108(12):2542-8"
CDKN2A	any mutation	Cholangiocarcinoma/Adenocarcinoma	'CH'/'*AC2'	" ### Maroni L, et al. The significance of genetics for cholangiocarcinoma development. Ann Transl Med 2013;1(3):28 ### Churi CR, et al. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One 2014;9(12):e115383"
CDKN2A	any mutation	Hepatocellular Carcinoma	'*HCC'	" ### Shibata T, et al. Exploration of liver cancer genomes. Nat Rev Gastroenterol Hepatol 2014;11(6):340-9 ### Ahn SM, et al. Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. Hepatology 2014;60(6):1972-82"
CDKN2A	any mutation	Melanoma	'*M'	" ### Hill VK, et al. The genetics of melanoma: recent advances. Annu Rev Genomics Hum Genet 2013;14():257-79 ### Hodis E, et al. A landscape of driver mutations in melanoma. Cell 2012;150(2):251-63 ### Shain AH, et al. Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. Nat Genet 2015;47(10):1194-9"
CDKN2A	any mutation	Papillary Carcinoma/Follicular Carcinoma	'THP'/'THF'	" ### Rayess H, et al. Cellular senescence and tumor suppressor gene p16. Int J Cancer 2012;130(8):1715-25 ### Collado M, et al. Cellular senescence in cancer and aging. Cell 2007;130(2):223-33 ### Elisei R, et al. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas. Cancer 1998;83:2185‚Ä?193"
CDKN2A	any mutation	Squamous Cell Carcinoma	'SCC'	" ### Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489(7417):519-25 ### Hill VK, et al. The genetics of melanoma: recent advances. Annu Rev Genomics Hum Genet 2013;14():257-79 ### Harinck F, et al. Indication for CDKN2A-mutation analysis in familial pancreatic cancer families without melanomas. J Med Genet 2012;49(6):362-5 ### Lim AM, et al. Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome. Int J Cancer 2014;135(4):887-95 ### Purkait S, et al. CDKN2A deletion in pediatric versus adult glioblastomas and predictive value of p16 immunohistochemistry. Neuropathology 2013;33(4):405-12"
CDKN2A	copy number loss	Adenocarcinoma	'*AC2'	" ### Cancer Genome Atlas Research Network Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513(7517):202-9 ### Huang S, et al. CDK4/6 inhibitor suppresses gastric cancer with CDKN2A mutation. Int J Clin Exp Med 2015;8(7):11692-700"
CDKN2A	copy number loss	Glioblastoma	'GB'	" ### Brennan CW, et al. The somatic genomic landscape of glioblastoma. Cell 2013;155(2):462-77"
CDKN2A	copy number loss	Hepatocellular Carcinoma	'*HCC'	" ### Shibata T, et al. Exploration of liver cancer genomes. Nat Rev Gastroenterol Hepatol 2014;11(6):340-9 ### Ahn SM, et al. Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. Hepatology 2014;60(6):1972-82"
CDKN2A	copy number loss	Melanoma	'*M'	" ### Hill VK, et al. The genetics of melanoma: recent advances. Annu Rev Genomics Hum Genet 2013;14():257-79 ### Hodis E, et al. A landscape of driver mutations in melanoma. Cell 2012;150(2):251-63 ### Shain AH, et al. Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. Nat Genet 2015;47(10):1194-9"
CDKN2A	copy number loss	Papillary Carcinoma/Follicular Carcinoma	'THP'/'THF'	" ### Rayess H, et al. Cellular senescence and tumor suppressor gene p16. Int J Cancer 2012;130(8):1715-25 ### Collado M, et al. Cellular senescence in cancer and aging. Cell 2007;130(2):223-33 ### Elisei R, et al. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas. Cancer 1998;83:2185‚Ä?193"
CDKN2B	copy number loss	Glioblastoma	'GB'	" ### Brennan CW, et al. The somatic genomic landscape of glioblastoma. Cell 2013;155(2):462-77"
CEBPA	any mutation	Acute Myeloid Leukemia	'AML'	" ### Port M, et al. Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis. Ann Hematol 2014;93(8):1279-86 ### Pastore F, et al. Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia. J Clin Oncol 2014;32(15):1586-94 ### Paz-Priel I, et al. C/EBPŒ± dysregulation in AML and ALL. Crit Rev Oncog 2011;16(1-2):93-102"
CHD1	any indel	Adenocarcinoma	'*AC2'	" ### Liu W, et al. Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer. Oncogene 2012;31(35):3939-48 ### Baca SC, et al. Punctuated evolution of prostate cancer genomes. Cell 2013;153(3):666-77 ### Barbieri CE, et al. Reprint of: The prostate cancer genome: Perspectives and potential. Urol Oncol 2015;33(2):95-102"
CHD1	any mutation	Adenocarcinoma	'*AC2'	" ### Liu W, et al. Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer. Oncogene 2012;31(35):3939-48 ### Baca SC, et al. Punctuated evolution of prostate cancer genomes. Cell 2013;153(3):666-77 ### Barbieri CE, et al. Reprint of: The prostate cancer genome: Perspectives and potential. Urol Oncol 2015;33(2):95-102"
CNOT3	any mutation	T Lymphoblastic Leukemia/Lymphoma	'*TLL'/'LY'	" ### De Keersmaecker K, et al. Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. Nat Genet 2013;45(2):186-90"
CREBBP	any mutation	B Lymphoblastic Leukemia/Lymphoma/Diffuse Large B Cell Lymphoma/Follicular Lymphoma	'*BLL'/'LY'/'DLBCL'/'FL'	" ### Inthal A, et al. CREBBP HAT domain mutations prevail in relapse cases of high hyperdiploid childhood acute lymphoblastic leukemia. Leukemia 2012;26(8):1797-803 ### Mar BG, et al. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nat Commun 2014;5():3469 ### Chung YR, et al. Epigenetic alterations in hematopoietic malignancies. Int J Hematol 2012;96(4):413-27 ### Mullighan CG, et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 2011;471(7337):235-9"
CRLF2	any mutation	B Lymphoblastic Leukemia/Lymphoma	'*BLL'/'LY'	" ### Shochat C, et al. Novel activating mutations lacking cysteine in type I cytokine receptors in acute lymphoblastic leukemia. Blood 2014;124(1):106-10 ### Chapiro E, et al. Activating mutation in the TSLPR gene in B-cell precursor lymphoblastic leukemia. Leukemia 2010;24(3):642-5 ### Yoda A, et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 2010;107(1):252-7"
CSF1R	any mutation	Acute Myeloid Leukemia/Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia	'AML'/'MDS'/'*CMML'	" ### Tobal K, et al. Mutation of the human FMS gene (M-CSF receptor) in myelodysplastic syndromes and acute myeloid leukemia. Leukemia 1990;4(7):486-9 ### Ridge SA, et al. FMS mutations in myelodysplastic, leukemic, and normal subjects. Proc Natl Acad Sci U S A 1990;87(4):1377-80 ### Springall F, et al. c-fms point mutations in acute myeloid leukemia: fact or fiction? Leukemia 1993;7(7):978-85 ### Natazuka T, et al. Rare point mutation at codon 301 and 969 of FMS/M-CSF receptor in acute myelomonocytic and monocytic leukemia. Leuk Res 1992;16(5):541-3 ### Gu TL, et al. A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia. Blood 2007;110(1):323-33 ### Lilljebj√∂rn H, et al. RNA-seq identifies clinically relevant fusion genes in leukemia including a novel MEF2D/CSF1R fusion responsive to imatinib. Leukemia 2014;28(4):977-9 ### Rademakers R, et al. Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nat Genet 2011;44(2):200-5"
CSF3R	any frameshift	Myeloproliferative Neoplasm/Chronic Neutrophilic Leukemia/Atypical Chronic Myeloid Leukemia	'*MPN2'/'CNL'/'ACML'	" ### Pardanani A, et al. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia 2013;27(9):1870-3 ### Maxson JE, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med 2013;368(19):1781-90 ### Plo I, et al. An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia. J Exp Med 2009;206(8):1701-7"
CSF3R	any nonsense	Myeloproliferative Neoplasm/Chronic Neutrophilic Leukemia/Atypical Chronic Myeloid Leukemia	'*MPN2'/'CNL'/'ACML'	" ### Pardanani A, et al. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia 2013;27(9):1870-3 ### Maxson JE, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med 2013;368(19):1781-90 ### Plo I, et al. An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia. J Exp Med 2009;206(8):1701-7"
CTCF	any mutation	Acute Myeloid Leukemia/B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma/Myelodysplastic Syndrome	'AML'/'*BLL'/'LY'/'*TLL'/'LY'/'MDS'	" ### Yoshida K, et al. The landscape of somatic mutations in Down syndrome-related myeloid disorders. Nat Genet 2013;45(11):1293-9 ### Dolnik A, et al. Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing. Blood 2012;120(18):e83-92 ### Mullighan CG, et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 2011;471(7337):235-9"
CTNNB1	any mutation	Adenocarcinoma	'*AC2'	" ### Cancer Genome Atlas Research Network The Molecular Taxonomy of Primary Prostate Cancer. Cell 2015;163(4):1011-25 ### Gerstein AV, et al. APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers. Genes Chromosomes Cancer 2002;34(1):9-16 ### Sidaway P Prostate cancer: Wnt signalling induces resistance. Nat Rev Urol 2015;12(11):597 ### Yardy GW, et al. Wnt signalling and prostate cancer. Prostate Cancer Prostatic Dis 2005;8(2):119-26 ### Francis JC, et al. Œ≤-catenin is required for prostate development and cooperates with Pten loss to drive invasive carcinoma. PLoS Genet 2013;9(1):e1003180"
CTNNB1	any mutation	Adenocarcinoma	'*AC2'	" ### Mirabelli-Primdahl L, et al. Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res 1999;59(14):3346-51 ### Bougatef K, et al. Prevalence of mutations in APC, CTNNB1, and BRAF in Tunisian patients with sporadic colorectal cancer. Cancer Genet Cytogenet 2008;187(1):12-8 ### Kim IJ, et al. Development and applications of a beta-catenin oligonucleotide microarray: beta-catenin mutations are dominantly found in the proximal colon cancers with microsatellite instability. Clin Cancer Res 2003;9(8):2920-5 ### Tenbaum SP, et al. Œ≤-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med 2012;18(6):892-901 ### Popat S, et al. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23(3):609-18"
CTNNB1	any mutation	Craniopharyngioma	'*B'	### Brastianos et al‚Ä¶Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet. 2014 February ; 46(2): 161‚Ä?65
CTNNB1	any mutation	Myelodysplastic Syndrome/Acute Myeloid Leukemia	'MDS'/'AML'	" ### Thakur R, et al. Pharmacological modulation of beta-catenin and its applications in cancer therapy. J Cell Mol Med 2013;17(4):449-56 ### Kode A, et al. Leukaemogenesis induced by an activating Œ≤-catenin mutation in osteoblasts. Nature 2014;506(7487):240-4 ### Wang L, et al. Œ≤-Catenin and AKT are promising targets for combination therapy in acute myeloid leukemia. Leuk Res 2013;37(10):1329-40 ### Sercan Z, et al. Beta-catenin mutations are not observed in chronic myeloid leukemia. Tumori 2009;95(6):836-9 ### Groen RW, et al. Illegitimate WNT pathway activation by beta-catenin mutation or autocrine stimulation in T-cell malignancies. Cancer Res 2008;68(17):6969-77 ### Hoshida Y, et al. Analysis of p53, K-ras, c-kit, and beta-catenin gene mutations in sinonasal NK/T cell lymphoma in northeast district of China. Cancer Sci 2003;94(3):297-301"
CTNNB1	any mutation	Non-Small Cell Lung Carcinoma	'NSCLC'	" ### Shigemitsu K, et al. Genetic alteration of the beta-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletion. Oncogene 2001;20(31):4249-57 ### Mazieres J, et al. Wnt signaling in lung cancer. Cancer Lett 2005;222(1):1-10 ### Stewart DJ Wnt signaling pathway in non-small cell lung cancer. J Natl Cancer Inst 2014;106(1):djt356"
CTNNB1	any mutation	Sarcoma	'S'	" ### Samarnthai N, et al. Molecular profiling of endometrial malignancies. Obstet Gynecol Int 2010;2010():162363 ### van Broekhoven DL, et al. Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis. Ann Surg Oncol 2015;22(5):1464-70"
CTNNB1	" codon(s) 32, 33, 34, 35, 36, 37, 41, 45 any"	Adenocarcinoma	'*AC2'	### Greulich. The Genomics of Lung Adenocarcinoma: Opportunities for Targeted Therapies. ÔªøGenes & Cancer 1(12) 1200‚Ä?210
CTNNB1	" codon(s) 32, 33, 34, 35, 36, 37, 41, 45 any"	Craniopharyngioma	'*B'	### Brastianos et al‚Ä¶Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet. 2014 February ; 46(2): 161‚Ä?65
CTNNB1	" codon(s) 32, 33, 34, 35, 36, 37, 41, 45 any"	Melanoma	'*M'	### Delmas et al.. Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev. 2007 Nov 15;21(22):2923-35
CTNNB1	" codon(s) 32, 33, 34, 35, 36, 37, 41, 45 any"	Myelodysplastic Syndrome/Acute Myeloid Leukemia	'MDS'/'AML'	" ### Thakur R, et al. Pharmacological modulation of beta-catenin and its applications in cancer therapy. J Cell Mol Med 2013;17(4):449-56 ### Kode A, et al. Leukaemogenesis induced by an activating Œ≤-catenin mutation in osteoblasts. Nature 2014;506(7487):240-4 ### Wang L, et al. Œ≤-Catenin and AKT are promising targets for combination therapy in acute myeloid leukemia. Leuk Res 2013;37(10):1329-40 ### Sercan Z, et al. Beta-catenin mutations are not observed in chronic myeloid leukemia. Tumori 2009;95(6):836-9 ### Groen RW, et al. Illegitimate WNT pathway activation by beta-catenin mutation or autocrine stimulation in T-cell malignancies. Cancer Res 2008;68(17):6969-77 ### Hoshida Y, et al. Analysis of p53, K-ras, c-kit, and beta-catenin gene mutations in sinonasal NK/T cell lymphoma in northeast district of China. Cancer Sci 2003;94(3):297-301"
CTNNB1	" codon(s) 32, 33, 34, 35, 36, 37, 41, 45 any"	Sarcoma	'S'	" ### Samarnthai N, et al. Molecular profiling of endometrial malignancies. Obstet Gynecol Int 2010;2010():162363 ### van Broekhoven DL, et al. Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis. Ann Surg Oncol 2015;22(5):1464-70"
CTNNB1	" codon(s) 41, 45 any"	Adenocarcinoma	'*AC2'	" ### Mirabelli-Primdahl L, et al. Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res 1999;59(14):3346-51 ### Bougatef K, et al. Prevalence of mutations in APC, CTNNB1, and BRAF in Tunisian patients with sporadic colorectal cancer. Cancer Genet Cytogenet 2008;187(1):12-8 ### Kim IJ, et al. Development and applications of a beta-catenin oligonucleotide microarray: beta-catenin mutations are dominantly found in the proximal colon cancers with microsatellite instability. Clin Cancer Res 2003;9(8):2920-5 ### Tenbaum SP, et al. Œ≤-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med 2012;18(6):892-901 ### Popat S, et al. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23(3):609-18"
CTNNB1	" codon(s) 41, 45 any"	Fibromatosis	'*FIBM'	" ### Taeeun Kim et al. Prevalence of the CTNNB1 mutation genotype in surgically resected fibromatosis of the breast. Histopathology. Volume 60, Issue 2, pages 347‚Ä?56, January 2012. ### Sebastian Huss et al .Œ≤-Catenin (CTNNB1) mutations and clinicopathological features of mesenteric desmoid-type fibromatosis. Histopathology. Volume 62, Issue 2, pages 294‚Ä?04, January 2013. ### Danique Broekhoven et al. Prognostic Value of CTNNB1 Gene Mutation in Primary Sporadic Aggressive Fibromatosis. Annals of Surgical Oncology. May 2015, Volume 22, Issue 5, pp 1464-1470. ### Sophie Le Guellec et al. CTNNB1 mutation analysis is a useful tool for the diagnosis of desmoid tumors: a study of 260 desmoid tumors and 191 potential morphologic mimics. Modern Pathology (2012) 25, 1551‚Ä?558; doi:10.1038/modpathol.2012.115; published online 6 July 2012. ### http://atlasgeneticsoncology.org/Tumors/DesmoidFibromatosisID5179.html."
CTNNB1	" codon(s) 41, 45 any"	Myelodysplastic Syndrome/Acute Myeloid Leukemia	'MDS'/'AML'	" ### Thakur R, et al. Pharmacological modulation of beta-catenin and its applications in cancer therapy. J Cell Mol Med 2013;17(4):449-56 ### Kode A, et al. Leukaemogenesis induced by an activating Œ≤-catenin mutation in osteoblasts. Nature 2014;506(7487):240-4 ### Wang L, et al. Œ≤-Catenin and AKT are promising targets for combination therapy in acute myeloid leukemia. Leuk Res 2013;37(10):1329-40 ### Sercan Z, et al. Beta-catenin mutations are not observed in chronic myeloid leukemia. Tumori 2009;95(6):836-9 ### Groen RW, et al. Illegitimate WNT pathway activation by beta-catenin mutation or autocrine stimulation in T-cell malignancies. Cancer Res 2008;68(17):6969-77 ### Hoshida Y, et al. Analysis of p53, K-ras, c-kit, and beta-catenin gene mutations in sinonasal NK/T cell lymphoma in northeast district of China. Cancer Sci 2003;94(3):297-301"
CTNNB1	G34E	Adenocarcinoma	'*AC2'	### Greulich. The Genomics of Lung Adenocarcinoma: Opportunities for Targeted Therapies. ÔªøGenes & Cancer 1(12) 1200‚Ä?210
CTNNB1	G34E	Myelodysplastic Syndrome/Acute Myeloid Leukemia	'MDS'/'AML'	" ### Thakur R, et al. Pharmacological modulation of beta-catenin and its applications in cancer therapy. J Cell Mol Med 2013;17(4):449-56 ### Kode A, et al. Leukaemogenesis induced by an activating Œ≤-catenin mutation in osteoblasts. Nature 2014;506(7487):240-4 ### Wang L, et al. Œ≤-Catenin and AKT are promising targets for combination therapy in acute myeloid leukemia. Leuk Res 2013;37(10):1329-40 ### Sercan Z, et al. Beta-catenin mutations are not observed in chronic myeloid leukemia. Tumori 2009;95(6):836-9 ### Groen RW, et al. Illegitimate WNT pathway activation by beta-catenin mutation or autocrine stimulation in T-cell malignancies. Cancer Res 2008;68(17):6969-77 ### Hoshida Y, et al. Analysis of p53, K-ras, c-kit, and beta-catenin gene mutations in sinonasal NK/T cell lymphoma in northeast district of China. Cancer Sci 2003;94(3):297-301"
CTNNB1	S37F	Adenocarcinoma	'*AC2'	### Greulich. The Genomics of Lung Adenocarcinoma: Opportunities for Targeted Therapies. ÔªøGenes & Cancer 1(12) 1200‚Ä?210
CTNNB1	S37F	Myelodysplastic Syndrome/Acute Myeloid Leukemia	'MDS'/'AML'	" ### Thakur R, et al. Pharmacological modulation of beta-catenin and its applications in cancer therapy. J Cell Mol Med 2013;17(4):449-56 ### Kode A, et al. Leukaemogenesis induced by an activating Œ≤-catenin mutation in osteoblasts. Nature 2014;506(7487):240-4 ### Wang L, et al. Œ≤-Catenin and AKT are promising targets for combination therapy in acute myeloid leukemia. Leuk Res 2013;37(10):1329-40 ### Sercan Z, et al. Beta-catenin mutations are not observed in chronic myeloid leukemia. Tumori 2009;95(6):836-9 ### Groen RW, et al. Illegitimate WNT pathway activation by beta-catenin mutation or autocrine stimulation in T-cell malignancies. Cancer Res 2008;68(17):6969-77 ### Hoshida Y, et al. Analysis of p53, K-ras, c-kit, and beta-catenin gene mutations in sinonasal NK/T cell lymphoma in northeast district of China. Cancer Sci 2003;94(3):297-301"
CTNNB1	S45P	Adenocarcinoma	'*AC2'	### Greulich. The Genomics of Lung Adenocarcinoma: Opportunities for Targeted Therapies. ÔªøGenes & Cancer 1(12) 1200‚Ä?210
CTNNB1	S45P	Myelodysplastic Syndrome/Acute Myeloid Leukemia	'MDS'/'AML'	" ### Thakur R, et al. Pharmacological modulation of beta-catenin and its applications in cancer therapy. J Cell Mol Med 2013;17(4):449-56 ### Kode A, et al. Leukaemogenesis induced by an activating Œ≤-catenin mutation in osteoblasts. Nature 2014;506(7487):240-4 ### Wang L, et al. Œ≤-Catenin and AKT are promising targets for combination therapy in acute myeloid leukemia. Leuk Res 2013;37(10):1329-40 ### Sercan Z, et al. Beta-catenin mutations are not observed in chronic myeloid leukemia. Tumori 2009;95(6):836-9 ### Groen RW, et al. Illegitimate WNT pathway activation by beta-catenin mutation or autocrine stimulation in T-cell malignancies. Cancer Res 2008;68(17):6969-77 ### Hoshida Y, et al. Analysis of p53, K-ras, c-kit, and beta-catenin gene mutations in sinonasal NK/T cell lymphoma in northeast district of China. Cancer Sci 2003;94(3):297-301"
CUX1	any mutation	Myeloproliferative Neoplasm/Acute Myeloid Leukemia/Myelodysplastic Syndrome/Chronic Lymphocytic Leukemia/Chronic Myelomonocytic Leukemia	'*MPN2'/'AML'/'MDS'/'CLL'/'*CMML'	" ### McNerney ME, et al. CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia. Blood 2013;121(6):975-83 ### Wong CC, et al. Inactivating CUX1 mutations promote tumorigenesis. Nat Genet 2014;46(1):33-8 ### Thoennissen NH, et al. Novel CUX1 missense mutation in association with 7q- at leukemic transformation of MPN. Am J Hematol 2011;86(8):703-5"
CXCR4	any mutation	Lymphoplasmacytic Lymphoma	'LPL'	" ### Hunter ZR, et al. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood 2014;123(11):1637-46 ### Lagane B, et al. CXCR4 dimerization and beta-arrestin-mediated signaling account for the enhanced chemotaxis to CXCL12 in WHIM syndrome. Blood 2008;112(1):34-44 ### Poulain S, et al. Genomic Landscape of CXCR4 Mutations in Waldenstr√∂m Macroglobulinemia. Clin Cancer Res 2015;(): ### Treon SP, et al. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood 2014;123(18):2791-6 ### Treon SP, et al. Ibrutinib in previously treated Waldenstr√∂m's macroglobulinemia. N Engl J Med 2015;372(15):1430-40"
DNAJB1-PRKACA	rearrangement	Hepatocellular Carcinoma	'*HCC'	" ### Honeyman JN, et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science 2014;343(6174):1010-4 ### Cornella H, et al. Unique genomic profile of fibrolamellar hepatocellular carcinoma. Gastroenterology 2015;148(4):806-18.e10"
DNMT3A	any mutation	Myeloproliferative Neoplasm/Acute Myeloid Leukemia/T Lymphoblastic Leukemia/Lymphoma/Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia	'*MPN2'/'AML'/'*TLL'/'LY'/'MDS'/'*CMML'	" ### Larsson CA, et al. The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome. Mol Cancer Res 2013;11(8):815-27 ### Ley TJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010;363(25):2424-33 ### Yan XJ, et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 2011;43(4):309-15 ### Walter MJ, et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 2011;25(7):1153-8 ### Stegelmann F, et al. DNMT3A mutations in myeloproliferative neoplasms. Leukemia 2011;25(7):1217-9 ### Thol F, et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol 2011;29(21):2889-96 ### Neumann M, et al. Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations. Blood 2013;121(23):4749-52 ### Jankowska AM, et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 2011;118(14):3932-41"
EED	any mutation	T Lymphoblastic Leukemia/Lymphoma/Chronic Myelomonocytic Leukemia/Acute Myeloid Leukemia/Myelodysplastic Syndrome	'*TLL'/'LY'/'*CMML'/'AML'/'MDS'	" ### Zhang J, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012;481(7380):157-63 ### Ueda T, et al. EED mutants impair polycomb repressive complex 2 in myelodysplastic syndrome and related neoplasms. Leukemia 2012;26(12):2557-60"
EGFR	A289D	Glioblastoma	'GB'	" ### Longo et al. Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models. Invest New Drugs (2012) 30:2161‚Ä?172 ### Vivanco I, Robins HI, Rohle D, et al. Differential Sensitivity of Glioma- versus Lung Cancer-specific EGFR mutations to EGFR Kinase Inhibitors. Cancer Discovery. 2012;2(5):458-471. doi:10.1158/2159-8290.CD-11-0284. ### Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, DeBiasi RM, Yoshimoto K, King JC, Nghiemphu P, Yuza Y, Xu Q, Greulich H, Thomas RK, Paez JG, Peck TC, Linhart DJ, Glatt KA, Getz G, Onofrio R, Ziaugra L, Levine RL, Gabriel S, Kawaguchi T, O'Neill K, Khan H, Liau LM, Nelson SF, Rao PN, Mischel P, Pieper RO, Cloughesy T, Leahy DJ, Sellers WR, Sawyers CL, Meyerson M, Mellinghoff IK. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med. 2006 Dec;3(12):e485. PubMed PMID: 17177598; PubMed Central PMCID: PMC1702556."
EGFR	any mutation	Acute Myeloid Leukemia	'AML'	" ### Deangelo DJ, et al. A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia. Leuk Res 2014;38(4):430-4"
EGFR	any mutation	Adenocarcinoma	'*AC2'	" ### Li et al ..Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts. British Journal of Cancer (2014) 110, 2812‚Ä?820"
EGFR	any mutation	Adenocarcinoma	'*AC2'	" ### Liu Z, et al. Epidermal growth factor receptor mutation in gastric cancer. Pathology 2011;43(3):234-8 ### Wong H, et al. Molecular targeted therapies in advanced gastric cancer: does tumor histology matter? Therap Adv Gastroenterol 2013;6(1):15-31 ### Moutinho C, et al. Epidermal growth factor receptor structural alterations in gastric cancer. BMC Cancer 2008;8():10 ### Dragovich T, et al. Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept. J Oncol 2009;2009():804108"
EGFR	any mutation	Adenocarcinoma	'*AC2'	" ### Oh BY, et al. Epidermal growth factor receptor mutations in colorectal cancer patients. J Korean Soc Coloproctol 2011;27(3):127-32 ### Barber TD, et al. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 2004;351(27):2883 ### Krasinskas AM EGFR Signaling in Colorectal Carcinoma. Patholog Res Int 2011;2011():932932 ### Metzger B, et al. The human epidermal growth factor receptor (EGFR) gene in European patients with advanced colorectal cancer harbors infrequent mutations in its tyrosine kinase domain. BMC Med Genet 2011;12():144 ### van Noesel J, et al. Activating germline R776H mutation in the epidermal growth factor receptor associated with lung cancer with squamous differentiation. J Clin Oncol 2013;31(10):e161-4 ### Misale S, et al. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov 2014;4(11):1269-80 ### Ruan Z, et al. Mechanistic Insights into R776H Mediated Activation of Epidermal Growth Factor Receptor Kinase. Biochemistry 2015;54(27):4216-25"
EGFR	any mutation	Papillary Carcinoma/Follicular Carcinoma	'THP'/'THF'	" ### Landa I, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest 2016;126(3):1052-66 ### Mitsiades CS, et al. Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. J Clin Endocrinol Metab 2006;91(9):3662-6 ### Masago K, et al. Good clinical response to erlotinib in a patient with anaplastic thyroid carcinoma harboring an epidermal growth factor somatic mutation, L858R, in exon 21. J Clin Oncol 2011;29(16):e465-7"
EGFR	" codon(s) 289, 596, 598 any"	Glioblastoma	'GB'	" ### Longo et al. Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models. Invest New Drugs (2012) 30:2161‚Ä?172 ### Vivanco I, Robins HI, Rohle D, et al. Differential Sensitivity of Glioma- versus Lung Cancer-specific EGFR mutations to EGFR Kinase Inhibitors. Cancer Discovery. 2012;2(5):458-471. doi:10.1158/2159-8290.CD-11-0284. ### Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, DeBiasi RM, Yoshimoto K, King JC, Nghiemphu P, Yuza Y, Xu Q, Greulich H, Thomas RK, Paez JG, Peck TC, Linhart DJ, Glatt KA, Getz G, Onofrio R, Ziaugra L, Levine RL, Gabriel S, Kawaguchi T, O'Neill K, Khan H, Liau LM, Nelson SF, Rao PN, Mischel P, Pieper RO, Cloughesy T, Leahy DJ, Sellers WR, Sawyers CL, Meyerson M, Mellinghoff IK. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med. 2006 Dec;3(12):e485. PubMed PMID: 17177598; PubMed Central PMCID: PMC1702556."
EGFR	codon(s) 761 any	Adenocarcinoma	'*AC2'	" ### Balak et al Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res. 2006 Nov 1;12(21):6494-501 ### Pao et al..Rational, biologically based treatment of EGFR-mutant nonsmall-cell lung cancer. Nat Rev Cancer. 2010 November ; 10(11): 760‚Ä?74"
EGFR	codon(s) 790 any	Adenocarcinoma	'*AC2'	" ### Sequist LV et al., First-Line Gefitinib in Patients With Advanced Non‚ÄìSmall-Cell Lung Cancer Harboring SomaticEGFR Mutations J. Clin. Oncol , 2008, 26, 2442-2449 ### Pao W, et al. EGF receptor gene mutations are common in lung cancers from ""never smokers"" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101:13306‚Ä?3311 ### Ma. C et al. T790M and acquired resistance of EGFR TKI: a literature review of clinical reports. J of thoracic Disease 2011. 3; 10-18. ### Pirker R. Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol. 2015 Dec 30. PubMed PMID: 26720671."
EGFR	codon(s) 861 any	Adenocarcinoma	'*AC2'	" ### Chiu CH, Yang CT, Shih JY, Huang MS, Su WC, Lai RS, Wang CC, Hsiao SH, Lin YC, Ho CL, Hsia TC, Wu MF, Lai CL, Lee KY, Lin CB, Yu-Wung Yeh D, Chuang CY, Chang FK, Tsai CM, Perng RP, Chih-Hsin Yang J. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations. J Thorac Oncol. 2015 May;10(5):793-9. doi: 10.1097/JTO.0000000000000504. PubMed PMID: 25668120. ### Sequist LV et al., First-Line Gefitinib in Patients With Advanced Non‚ÄìSmall-Cell Lung Cancer Harboring SomaticEGFR Mutations J. Clin. Oncol , 2008, 26, 2442-2449 ### Pao W, et al. EGF receptor gene mutations are common in lung cancers from ""never smokers"" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101:13306‚Ä?3311 ### Watanabe S, Minegishi Y, Yoshizawa H, Maemondo M, Inoue A, Sugawara S, Isobe H, Harada M, Ishii Y, Gemma A, Hagiwara K, Kobayashi K. Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q. J Thorac Oncol. 2014 Feb;9(2):189-94. doi: 10.1097/JTO.0000000000000048. PubMed PMID: 24419415; PubMed Central PMCID: PMC4132025."
EGFR	copy number gain	Adenocarcinoma	'*AC2'	" ### Dragovich T, et al. Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept. J Oncol 2009;2009():804108"
EGFR	copy number gain	Glioblastoma	'GB'	" ### Marie CL, Ligon KL. Molecular pathologic diagnosis of epidermal growth factor receptor. Neuro Oncol 2014;16(suppl 8):viii1‚Ä?."
EGFR	copy number gain	Urothelial Carcinoma	'UTH'	" ### Mooso BA, et al. The role of EGFR family inhibitors in muscle invasive bladder cancer: a review of clinical data and molecular evidence. J Urol 2015;193(1):19-29"
EGFR	D761N	Adenocarcinoma	'*AC2'	" ### Balak et al Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res. 2006 Nov 1;12(21):6494-501 ### Pao et al..Rational, biologically based treatment of EGFR-mutant nonsmall-cell lung cancer. Nat Rev Cancer. 2010 November ; 10(11): 760‚Ä?74"
EGFR	E709K	Adenocarcinoma	'*AC2'	" ### Chen Z, Feng J, Saldivar JS, Gu D, Bockholt A, Sommer SS. EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: one-third of doublets occur at five pairs of amino acids. Oncogene. 2008 Jul 17;27(31):4336-43. doi: 10.1038/onc.2008.71. Epub 2008 Mar 31. PubMed PMID: 18372921. ### Peng L, Song Z, Jiao S. Comparison of uncommon EGFR exon 21 L858R compound mutations with single mutation. Onco Targets Ther. 2015 Apr 21;8:905-10. doi: 10.2147/OTT.S78984. eCollection 2015. PubMed PMID: 25960661; PubMed Central PMCID: PMC4410901. ### Chen YR, Fu YN, Lin CH, Yang ST, Hu SF, Chen YT, Tsai SF, Huang SF. Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants. Oncogene. 2006 Feb 23;25(8):1205-15. PubMed PMID: 16205628. ### Huang SF, Liu HP, Li LH, Ku YC, Fu YN, Tsai HY, Chen YT, Lin YF, Chang WC, Kuo HP, Wu YC, Chen YR, Tsai SF. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res. 2004 Dec 15;10(24):8195-203. PubMed PMID: 15623594."
EGFR	E709K	Glioblastoma	'GB'	" ### Chen Z, Feng J, Saldivar JS, Gu D, Bockholt A, Sommer SS. EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: one-third of doublets occur at five pairs of amino acids. Oncogene. 2008 Jul 17;27(31):4336-43. doi: 10.1038/onc.2008.71. Epub 2008 Mar 31. PubMed PMID: 18372921. ### Longo et al. Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models. Invest New Drugs (2012) 30:2161‚Ä?172 ### Vivanco I, Robins HI, Rohle D, et al. Differential Sensitivity of Glioma- versus Lung Cancer-specific EGFR mutations to EGFR Kinase Inhibitors. Cancer Discovery. 2012;2(5):458-471. doi:10.1158/2159-8290.CD-11-0284. ### Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, DeBiasi RM, Yoshimoto K, King JC, Nghiemphu P, Yuza Y, Xu Q, Greulich H, Thomas RK, Paez JG, Peck TC, Linhart DJ, Glatt KA, Getz G, Onofrio R, Ziaugra L, Levine RL, Gabriel S, Kawaguchi T, O'Neill K, Khan H, Liau LM, Nelson SF, Rao PN, Mischel P, Pieper RO, Cloughesy T, Leahy DJ, Sellers WR, Sawyers CL, Meyerson M, Mellinghoff IK. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med. 2006 Dec;3(12):e485. PubMed PMID: 17177598; PubMed Central PMCID: PMC1702556. ### Sequist LV et al., First-Line Gefitinib in Patients With Advanced Non‚ÄìSmall-Cell Lung Cancer Harboring SomaticEGFR Mutations J. Clin. Oncol , 2008, 26, 2442-2449"
EGFR	E709_T710delinsD	Adenocarcinoma/Non-Small Cell Lung Carcinoma	'*AC2'/'NSCLC'	" ### Ackerman A, et al. EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer. J Thorac Oncol 2012;7(10):e19-20 ### Kobayashi Y, et al. EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs. Clin Cancer Res 2015;21(23):5305-13 ### Sequist LV, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26(15):2442-9 ### Pao W, et al. EGF receptor gene mutations are common in lung cancers from ""never smokers"" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101(36):13306-11 ### Ma C, et al. T790M and acquired resistance of EGFR TKI: a literature review of clinical reports. J Thorac Dis 2011;3(1):10-8 ### Pirker R Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol 2016;28(2):115-21"
EGFR	E746_A750delELREA	Adenocarcinoma	'*AC2'	" ### Sequist LV et al., First-Line Gefitinib in Patients With Advanced Non‚ÄìSmall-Cell Lung Cancer Harboring SomaticEGFR Mutations J. Clin. Oncol , 2008, 26, 2442-2449 ### Pao W, et al. EGF receptor gene mutations are common in lung cancers from ""never smokers"" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101:13306‚Ä?3311 ### Marchetti A et al, Complex Mutations & Subpopulations of Deletions at Exon 19 of EGFR in NSCLC Revealed by Next Generation Sequencing: Potential Clinical Implications. PLoS ONE , 2012, 7(7): e42164 ### Gu et al. Databa se of Somatic Mutations in EGFR WithAnalyses Revealing Indel Hotspots But No Smoking-Associat ed Signature. 2007. Hum Mutat 28(8),760‚Ä?70. ### Pirker R. Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol. 2015 Dec 30. PubMed PMID: 26720671."
EGFR	E746_A750delinsIle	Adenocarcinoma	'*AC2'	" ### Sequist LV et al., First-Line Gefitinib in Patients With Advanced Non‚ÄìSmall-Cell Lung Cancer Harboring SomaticEGFR Mutations J. Clin. Oncol , 2008, 26, 2442-2449 ### Pao W, et al. EGF receptor gene mutations are common in lung cancers from ""never smokers"" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101:13306‚Ä?3311 ### Marchetti A et al, Complex Mutations & Subpopulations of Deletions at Exon 19 of EGFR in NSCLC Revealed by Next Generation Sequencing: Potential Clinical Implications. PLoS ONE , 2012, 7(7): e42164 ### Gu et al. Databa se of Somatic Mutations in EGFR WithAnalyses Revealing Indel Hotspots But No Smoking-Associat ed Signature. 2007. Hum Mutat 28(8),760‚Ä?70. ### Pirker R. Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol. 2015 Dec 30. PubMed PMID: 26720671."
EGFR	" exon(s) 18, 19, 20, 21 any"	Adenocarcinoma	'*AC2'	" ### Sequist LV et al., First-Line Gefitinib in Patients With Advanced Non‚ÄìSmall-Cell Lung Cancer Harboring SomaticEGFR Mutations J. Clin. Oncol , 2008, 26, 2442-2449 ### Pao W, et al. EGF receptor gene mutations are common in lung cancers from ""never smokers"" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101:13306‚Ä?3311 ### Ma. C et al. T790M and acquired resistance of EGFR TKI: a literature review of clinical reports. J of thoracic Disease 2011. 3; 10-18 ### Pirker R. Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol. 2015 Dec 30. PubMed PMID: 26720671."
EGFR	exon(s) 18 deletion	Adenocarcinoma/Non-Small Cell Lung Carcinoma	'*AC2'/'NSCLC'	" ### Ackerman A, et al. EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer. J Thorac Oncol 2012;7(10):e19-20 ### Kobayashi Y, et al. EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs. Clin Cancer Res 2015;21(23):5305-13 ### Sequist LV, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26(15):2442-9 ### Pao W, et al. EGF receptor gene mutations are common in lung cancers from ""never smokers"" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101(36):13306-11 ### Ma C, et al. T790M and acquired resistance of EGFR TKI: a literature review of clinical reports. J Thorac Dis 2011;3(1):10-8 ### Pirker R Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol 2016;28(2):115-21"
EGFR	exon(s) 18 indel	Adenocarcinoma/Non-Small Cell Lung Carcinoma	'*AC2'/'NSCLC'	" ### Ackerman A, et al. EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer. J Thorac Oncol 2012;7(10):e19-20 ### Kobayashi Y, et al. EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs. Clin Cancer Res 2015;21(23):5305-13 ### Sequist LV, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26(15):2442-9 ### Pao W, et al. EGF receptor gene mutations are common in lung cancers from ""never smokers"" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101(36):13306-11 ### Ma C, et al. T790M and acquired resistance of EGFR TKI: a literature review of clinical reports. J Thorac Dis 2011;3(1):10-8 ### Pirker R Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol 2016;28(2):115-21"
EGFR	exon(s) 19 deletion	Adenocarcinoma	'*AC2'	" ### Sequist LV et al., First-Line Gefitinib in Patients With Advanced Non‚ÄìSmall-Cell Lung Cancer Harboring SomaticEGFR Mutations J. Clin. Oncol , 2008, 26, 2442-2449 ### Pao W, et al. EGF receptor gene mutations are common in lung cancers from ""never smokers"" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101:13306‚Ä?3311 ### Marchetti A et al, Complex Mutations & Subpopulations of Deletions at Exon 19 of EGFR in NSCLC Revealed by Next Generation Sequencing: Potential Clinical Implications. PLoS ONE , 2012, 7(7): e42164 ### Gu et al. Databa se of Somatic Mutations in EGFR WithAnalyses Revealing Indel Hotspots But No Smoking-Associat ed Signature. 2007. Hum Mutat 28(8),760‚Ä?70. ### Pirker R. Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol. 2015 Dec 30. PubMed PMID: 26720671."
EGFR	exon(s) 20 any	Adenocarcinoma	'*AC2'	" ### Arcila et al EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics. Mol Cancer Ther; 12(2); 220‚Ä?"
EGFR	exon(s) 20 insertion	Adenocarcinoma	'*AC2'	" ### Arcila et al EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics. Mol Cancer Ther; 12(2); 220‚Ä?. ### Naidoo J, Sima CS, Rodriguez K, Busby N, Nafa K, Ladanyi M, Riely GJ, Kris MG, Arcila ME, Yu HA. Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib. Cancer. 2015 Sep 15;121(18):3212-20. doi: 10.1002/cncr.29493. Epub 2015 Jun 10. PubMed PMID: 26096453."
EGFR	exon(s) 20 insertion	Glioblastoma	'GB'	" ### Arcila et al EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics. Mol Cancer Ther; 12(2); 220‚Ä?. ### Naidoo J, Sima CS, Rodriguez K, Busby N, Nafa K, Ladanyi M, Riely GJ, Kris MG, Arcila ME, Yu HA. Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib. Cancer. 2015 Sep 15;121(18):3212-20. doi: 10.1002/cncr.29493. Epub 2015 Jun 10. PubMed PMID: 26096453."
EGFR	G724S	Adenocarcinoma/Squamous Cell Carcinoma	'*AC2'/'SCC'	" ### Sequist LV, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26(15):2442-9 ### Pao W, et al. EGF receptor gene mutations are common in lung cancers from ""never smokers"" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101(36):13306-11 ### Pirker R Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol 2016;28(2):115-21 ### Arcila ME, et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther 2013;12(2):220-9 ### Hellmann MD, et al. Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib. J Thorac Oncol 2014;9(10):e73-4"
EGFR	G863D	Adenocarcinoma	'*AC2'	### Liu et al..Epidermal growth factor receptor mutation in gastric cancer.Pathology. 2011 Apr;43(3):234-8
EGFR	H773L	Adenocarcinoma	'*AC2'	" ### Sequist et al., First-Line Gefitinib in Patients With Advanced Non‚ÄìSmall-Cell Lung Cancer Harboring Somatic EGFR Mutations J. Clin. Oncol , 2008, 26, 2442-2449. ### Beau-Faller et al. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Annals of oncology 25.1 (2014): 126-131. ### Vidhula et al. Designing inhibitors for EGFR to improve anti-cancer therapy: An in silico approach. Eur J Biotech and Bioscien, 2014, 2(5):9-14."
EGFR	K745_E746insIPVAIK	Adenocarcinoma/Pleomorphic Carcinoma	'*AC2'/'*PMC'	" ### He M, et al. EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. Clin Cancer Res 2012;18(6):1790-7 ### Agbarya A, et al. Getting out of a wheelchair: an uncommon insertion mutation in exon 19 of EGFR responsive to erlotinib. Springerplus 2014;3():507 ### Iyevleva AG, et al. Lung carcinomas with EGFR exon 19 insertions are sensitive to gefitinib treatment. J Thorac Oncol 2014;9(4):e31-3 ### Park J, et al. EGFR exon 19 insertions show good response to gefitinib, but short time to progression in Japanese patients. J Thorac Oncol 2014;9(2):e10-1"
EGFR	L747P	Adenocarcinoma/Non-Small Cell Lung Carcinoma	'*AC2'/'NSCLC'	" ### Sequist LV, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26(15):2442-9 ### Pao W, et al. EGF receptor gene mutations are common in lung cancers from ""never smokers"" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101(36):13306-11 ### van der Wekken AJ, et al. A novel EGFR mutation in exon 19 showed stable disease after TKI treatment. J Thorac Oncol 2012;7(8):e8 ### Wu JY, et al. Effectiveness of tyrosine kinase inhibitors on ""uncommon"" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res 2011;17(11):3812-21 ### Yu G, et al. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma. Int J Clin Exp Pathol 2015;8(7):8603-6 ### Wu SG, et al. Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma. Eur Respir J 2008;32(4):924-30"
EGFR	P596L	Glioblastoma	'GB'	" ### Longo et al. Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models. Invest New Drugs (2012) 30:2161‚Ä?172 ### Vivanco I, Robins HI, Rohle D, et al. Differential Sensitivity of Glioma- versus Lung Cancer-specific EGFR mutations to EGFR Kinase Inhibitors. Cancer Discovery. 2012;2(5):458-471. doi:10.1158/2159-8290.CD-11-0284. ### Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, DeBiasi RM, Yoshimoto K, King JC, Nghiemphu P, Yuza Y, Xu Q, Greulich H, Thomas RK, Paez JG, Peck TC, Linhart DJ, Glatt KA, Getz G, Onofrio R, Ziaugra L, Levine RL, Gabriel S, Kawaguchi T, O'Neill K, Khan H, Liau LM, Nelson SF, Rao PN, Mischel P, Pieper RO, Cloughesy T, Leahy DJ, Sellers WR, Sawyers CL, Meyerson M, Mellinghoff IK. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med. 2006 Dec;3(12):e485. PubMed PMID: 17177598; PubMed Central PMCID: PMC1702556."
EGFR	R776H	Adenocarcinoma	'*AC2'	" ### Oh BY, et al. Epidermal growth factor receptor mutations in colorectal cancer patients. J Korean Soc Coloproctol 2011;27(3):127-32 ### Barber TD, et al. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 2004;351(27):2883 ### Krasinskas AM EGFR Signaling in Colorectal Carcinoma. Patholog Res Int 2011;2011():932932 ### Metzger B, et al. The human epidermal growth factor receptor (EGFR) gene in European patients with advanced colorectal cancer harbors infrequent mutations in its tyrosine kinase domain. BMC Med Genet 2011;12():144 ### van Noesel J, et al. Activating germline R776H mutation in the epidermal growth factor receptor associated with lung cancer with squamous differentiation. J Clin Oncol 2013;31(10):e161-4 ### Misale S, et al. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov 2014;4(11):1269-80 ### Ruan Z, et al. Mechanistic Insights into R776H Mediated Activation of Epidermal Growth Factor Receptor Kinase. Biochemistry 2015;54(27):4216-25"
EGFR	V774M	Adenocarcinoma	'*AC2'	" ### Sequist et al., First-Line Gefitinib in Patients With Advanced Non‚ÄìSmall-Cell Lung Cancer Harboring Somatic EGFR Mutations J. Clin. Oncol , 2008, 26, 2442-2449. ### Beau-Faller et al. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Annals of oncology 25.1 (2014): 126-131. ### Vidhula et al. Designing inhibitors for EGFR to improve anti-cancer therapy: An in silico approach. Eur J Biotech and Bioscien, 2014, 2(5):9-14."
EP300	any mutation	T Lymphoblastic Leukemia/Lymphoma/Diffuse Large B Cell Lymphoma/Follicular Lymphoma	'*TLL'/'LY'/'DLBCL'/'FL'	" ### Zhang J, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012;481(7380):157-63 ### Chung YR, et al. Epigenetic alterations in hematopoietic malignancies. Int J Hematol 2012;96(4):413-27"
ERBB2	exon(s) 20 insertion	Adenosarcoma	'*AS2'	" ### Arcila ME, et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res 2012;18(18):4910-8 ### Shimamura T, et al. Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Res 2006;66(13):6487-91 ### Hu H, et al. Oncogenic mutations are associated with histological subtypes but do not have an independent prognostic value in lung adenocarcinoma. Onco Targets Ther 2014;7():1423-37"
ERBB2	G776delinsVC	Adenocarcinoma	'*AC2'	" ### Arcila ME, Chaft JE, Nafa K, Roy-Chowdhuri S, Lau C, Zaidinski M, Paik PK, Zakowski MF, Kris MG, Ladanyi M. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res. 2012 Sep 15;18(18):4910-8. ### Shimamura T, Ji H, Minami Y, Thomas RK, Lowell AM, Shah K, Greulich H, Glatt KA, Meyerson M, Shapiro GI, Wong KK. Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Res. 2006 Jul 1;66(13):6487-91"
ERG-TMPRSS2	rearrangement	Adenocarcinoma	'*AC2'	" ### Barbieri CE, et al. The prostate cancer genome: perspectives and potential. Urol Oncol 2014;32(1):53.e15-22 ### Tomlins SA, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310(5748):644-8 ### Nam RK, et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 2007;97(12):1690-5 ### Park K, et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 2010;12(7):590-8"
ETV6	any mutation	T Lymphoblastic Leukemia/Lymphoma	'*TLL'/'LY'	" ### De Braekeleer E, et al. ETV6 fusion genes in hematological malignancies: a review. Leuk Res 2012;36(8):945-61 ### Van Vlierberghe P, et al. ETV6 mutations in early immature human T cell leukemias. J Exp Med 2011;208(13):2571-9 ### Kr√∂nke J, et al. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood 2013;122(1):100-8"
EZH2	any mutation	Diffuse Large B Cell Lymphoma/Follicular Lymphoma/Acute Myeloid Leukemia/Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia/Atypical Chronic Myeloid Leukemia/Primary Myelofibrosis/T Lymphoblastic Leukemia/Lymphoma	'DLBCL'/'FL'/'AML'/'MDS'/'*CMML'/'ACML'/'MY'/'*TLL'/'LY'	" ### Lund K, et al. EZH2 in normal and malignant hematopoiesis. Leukemia 2014;28(1):44-9 ### Khan SN, et al. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies. Leukemia 2013;27(6):1301-9 ### Guglielmelli P, et al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia 2014;28(9):1804-10 ### Itzykson R, et al. Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes. Best Pract Res Clin Haematol 2013;26(4):355-64 ### Wang J, et al. TET2, ASXL1 and EZH2 mutations in Chinese with myelodysplastic syndromes. Leuk Res 2013;37(3):305-11 ### Ntziachristos P, et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med 2012;18(2):298-301"
FANCL	any mutation	Myelodysplastic Syndrome	'MDS'	" ### Ameziane N, et al. Diagnosis of fanconi anemia: mutation analysis by next-generation sequencing. Anemia 2012;2012():132856 ### Chandrasekharappa SC, et al. Massively parallel sequencing, aCGH, and RNA-Seq technologies provide a comprehensive molecular diagnosis of Fanconi anemia. Blood 2013;121(22):e138-48 ### Haferlach T, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014;28(2):241-7"
FBXW7	any mutation	Adenocarcinoma	'*AC2'	### Comprehensive molecular characterization of human colon and rectal cancer. Cancer Genome Atlas Network 2012 Nature;487(7407):330-7 ### Jardim et al 2014. FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors. PLoS ONE 9(2). ### Gu Z et al ..The FBXW7 beta-form is suppressed in human glioma cells. Biochemical and biophysical research communications; 2007. 354(4):992-8 ### Aydin et al FBXW7 Mutations in Melanoma and a New Therapeutic Paradigm. JNCI J Natl Cancer Inst (2014) 106
FBXW7	any mutation	T Lymphoblastic Leukemia/Lymphoma/B Lymphoblastic Leukemia/Lymphoma/Chronic Lymphocytic Leukemia	'*TLL'/'LY'/'*BLL'/'LY'/'CLL'	" ### Trinquand A, et al. Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. J Clin Oncol 2013;31(34):4333-42 ### Song JH, et al. FBXW7 mutation in adult T-cell and B-cell acute lymphocytic leukemias. Leuk Res 2008;32(11):1751-5 ### O'Neil J, et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med 2007;204(8):1813-24 ### Asnafi V, et al. NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. Blood 2009;113(17):3918-24 ### Baldus CD, et al. Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia. Haematologica 2009;94(10):1383-90 ### Jeromin S, et al. SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. Leukemia 2014;28(1):108-17 ### Wang L, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011;365(26):2497-506"
FBXW7	D761N	Adenocarcinoma	'*AC2'	### Comprehensive molecular characterization of human colon and rectal cancer. Cancer Genome Atlas Network 2012 Nature;487(7407):330-7 ### Jardim et al 2014. FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors. PLoS ONE 9(2). ### Gu Z et al ..The FBXW7 beta-form is suppressed in human glioma cells. Biochemical and biophysical research communications; 2007. 354(4):992-8 ### Aydin et al FBXW7 Mutations in Melanoma and a New Therapeutic Paradigm. JNCI J Natl Cancer Inst (2014) 106
FBXW7	D761N	Melanoma	'*M'	### Comprehensive molecular characterization of human colon and rectal cancer. Cancer Genome Atlas Network 2012 Nature;487(7407):330-7 ### Jardim et al 2014. FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors. PLoS ONE 9(2). ### Gu Z et al ..The FBXW7 beta-form is suppressed in human glioma cells. Biochemical and biophysical research communications; 2007. 354(4):992-8 ### Aydin et al FBXW7 Mutations in Melanoma and a New Therapeutic Paradigm. JNCI J Natl Cancer Inst (2014) 106
FBXW7	R479Q	Adenocarcinoma	'*AC2'	### Comprehensive molecular characterization of human colon and rectal cancer. Cancer Genome Atlas Network 2012 Nature;487(7407):330-7 ### Jardim et al 2014. FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors. PLoS ONE 9(2). ### Gu Z et al ..The FBXW7 beta-form is suppressed in human glioma cells. Biochemical and biophysical research communications; 2007. 354(4):992-8 ### Aydin et al FBXW7 Mutations in Melanoma and a New Therapeutic Paradigm. JNCI J Natl Cancer Inst (2014) 106
FBXW7	R479Q	Melanoma	'*M'	### Comprehensive molecular characterization of human colon and rectal cancer. Cancer Genome Atlas Network 2012 Nature;487(7407):330-7 ### Jardim et al 2014. FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors. PLoS ONE 9(2). ### Gu Z et al ..The FBXW7 beta-form is suppressed in human glioma cells. Biochemical and biophysical research communications; 2007. 354(4):992-8 ### Aydin et al FBXW7 Mutations in Melanoma and a New Therapeutic Paradigm. JNCI J Natl Cancer Inst (2014) 106
FGFR1	copy number gain	Adenocarcinoma	'*AC2'	" ### Lehnen NC, et al. Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma. Histopathology 2013;63(2):157-66"
FGFR1	copy number gain	Invasive Ductal Carcinoma	'*IDC'	" ### Turner N, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 2010;70(5):2085-94 ### Brady N, et al. The FGF/FGFR axis as a therapeutic target in breast cancer. Expert Rev Endocrinol Metab 2013;8(4):391-402"
FGFR2	any mutation	Adenocarcinoma	'*AC2'	" ### Tabernero J, et al. Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors. J Clin Oncol 2015;33(30):3401-8 ### Block MS, et al. Second-line dovitinib in metastatic endometrial cancer. Lancet Oncol 2015;16(6):604-6 ### Konecny GE, et al. Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study. Lancet Oncol 2015;16(6):686-94 ### Powell MA, et al. A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol 2014;135(1):38-43 ### Katoh M, et al. FGF receptors: cancer biology and therapeutics. Med Res Rev 2014;34(2):280-300"
FGFR2	P253R	Invasive Ductal Carcinoma/Lobular Carcinoma	'*IDC'/'*LC'	" ### Reintjes N, et al. Activating somatic FGFR2 mutations in breast cancer. PLoS One 2013;8(3):e60264 ### Ahmad I, et al. Mechanisms of FGFR-mediated carcinogenesis. Biochim Biophys Acta 2012;1823(4):850-60 ### Dutt A, et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A 2008;105(25):8713-7 ### Easton DF, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007;447(7148):1087-93 ### Hunter DJ, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007;39(7):870-4"
FGFR3	any mutation	Glial Neoplasm	'*GN''	" ### Brennan CW, et al. The somatic genomic landscape of glioblastoma. Cell 2013;155(2):462-77 ### Chesi M, et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 2001;97(3):729-36"
FGFR3	any mutation	Thymic Carcinoma	'THYM'	" ### Brennan CW, et al. The somatic genomic landscape of glioblastoma. Cell 2013;155(2):462-77 ### Chesi M, et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 2001;97(3):729-36"
FGFR3	F384L	Adenocarcinoma	'*AC2'	" ### Nakanishi Y, et al. The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor. Mol Cancer Ther 2014;13(11):2547-58 ### Lafitte M, et al. FGFR3 has tumor suppressor properties in cells with epithelial phenotype. Mol Cancer 2013;12():83 ### Kanazawa TY, et al. Frequency of the allelic variant c.1150T &amp;gt; C in exon 10 of the fibroblast growth factor receptor 3 (FGFR3) gene is not increased in patients with pathogenic mutations and related chondrodysplasia phenotypes. Genet Mol Biol 2014;37(4):622-4"
FLCN	any mutation	Renal Cell Carcinoma	'R'	" ### Vocke CD, et al. High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dub√©-associated renal tumors. J Natl Cancer Inst 2005;97(12):931-5 ### Menko FH, et al. Birt-Hogg-Dub√© syndrome: diagnosis and management. Lancet Oncol 2009;10(12):1199-206"
FLT3	codon(s) 676 missense	Acute Myeloid Leukemia/B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma	'AML'/'*BLL'/'LY'/'*TLL'/'LY'	" ### Nakao M, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996;10(12):1911-8 ### Yokota S, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 1997;11(10):1605-9 ### Kiyoi H, et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998;12(9):1333-7 ### Yamamoto Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001;97(8):2434-9 ### Schnittger S, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002;100(1):59-66 ### Sudhindra A, et al. FLT3 inhibitors in AML: are we there yet? Curr Hematol Malig Rep 2014;9(2):174-85 ### Kihara R, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia 2014;28(8):1586-95 ### Hou HA, et al. Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia. Leukemia 2014;28(1):50-8 ### Neumann M, et al. FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors. PLoS One 2013;8(1):e53190 ### Hoehn D, et al. CD117 expression is a sensitive but nonspecific predictor of FLT3 mutation in T acute lymphoblastic leukemia and T/myeloid acute leukemia. Am J Clin Pathol 2012;137(2):213-9 ### Armstrong SA, et al. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood 2004;103(9):3544-6 ### Stam RW, et al. D-HPLC analysis of the entire FLT3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia. Haematologica 2007;92(11):1565-8 ### Ma HS, et al. FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia. Cancer Res 2014;74(18):5206-17 ### Pauwels D, et al. The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220. Haematologica 2012;97(11):1773-4 ### Smith CC, et al. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood 2013;121(16):3165-71"
FLT3	codon(s) 691 missense	Acute Myeloid Leukemia/B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma	'AML'/'*BLL'/'LY'/'*TLL'/'LY'	" ### Nakao M, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996;10(12):1911-8 ### Yokota S, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 1997;11(10):1605-9 ### Kiyoi H, et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998;12(9):1333-7 ### Yamamoto Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001;97(8):2434-9 ### Schnittger S, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002;100(1):59-66 ### Sudhindra A, et al. FLT3 inhibitors in AML: are we there yet? Curr Hematol Malig Rep 2014;9(2):174-85 ### Kihara R, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia 2014;28(8):1586-95 ### Hou HA, et al. Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia. Leukemia 2014;28(1):50-8 ### Neumann M, et al. FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors. PLoS One 2013;8(1):e53190 ### Hoehn D, et al. CD117 expression is a sensitive but nonspecific predictor of FLT3 mutation in T acute lymphoblastic leukemia and T/myeloid acute leukemia. Am J Clin Pathol 2012;137(2):213-9 ### Armstrong SA, et al. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood 2004;103(9):3544-6 ### Stam RW, et al. D-HPLC analysis of the entire FLT3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia. Haematologica 2007;92(11):1565-8 ### Ma HS, et al. FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia. Cancer Res 2014;74(18):5206-17 ### Pauwels D, et al. The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220. Haematologica 2012;97(11):1773-4 ### Smith CC, et al. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood 2013;121(16):3165-71"
FLT3	codon(s) 697 missense	Acute Myeloid Leukemia/B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma	'AML'/'*BLL'/'LY'/'*TLL'/'LY'	" ### Nakao M, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996;10(12):1911-8 ### Yokota S, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 1997;11(10):1605-9 ### Kiyoi H, et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998;12(9):1333-7 ### Yamamoto Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001;97(8):2434-9 ### Schnittger S, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002;100(1):59-66 ### Sudhindra A, et al. FLT3 inhibitors in AML: are we there yet? Curr Hematol Malig Rep 2014;9(2):174-85 ### Kihara R, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia 2014;28(8):1586-95 ### Hou HA, et al. Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia. Leukemia 2014;28(1):50-8 ### Neumann M, et al. FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors. PLoS One 2013;8(1):e53190 ### Hoehn D, et al. CD117 expression is a sensitive but nonspecific predictor of FLT3 mutation in T acute lymphoblastic leukemia and T/myeloid acute leukemia. Am J Clin Pathol 2012;137(2):213-9 ### Armstrong SA, et al. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood 2004;103(9):3544-6 ### Stam RW, et al. D-HPLC analysis of the entire FLT3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia. Haematologica 2007;92(11):1565-8 ### Ma HS, et al. FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia. Cancer Res 2014;74(18):5206-17 ### Pauwels D, et al. The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220. Haematologica 2012;97(11):1773-4 ### Smith CC, et al. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood 2013;121(16):3165-71"
FLT3	codon(s) 835 missense	Acute Myeloid Leukemia/B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma	'AML'/'*BLL'/'LY'/'*TLL'/'LY'	" ### Nakao M, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996;10(12):1911-8 ### Yokota S, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 1997;11(10):1605-9 ### Kiyoi H, et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998;12(9):1333-7 ### Yamamoto Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001;97(8):2434-9 ### Schnittger S, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002;100(1):59-66 ### Sudhindra A, et al. FLT3 inhibitors in AML: are we there yet? Curr Hematol Malig Rep 2014;9(2):174-85 ### Kihara R, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia 2014;28(8):1586-95 ### Hou HA, et al. Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia. Leukemia 2014;28(1):50-8 ### Neumann M, et al. FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors. PLoS One 2013;8(1):e53190 ### Hoehn D, et al. CD117 expression is a sensitive but nonspecific predictor of FLT3 mutation in T acute lymphoblastic leukemia and T/myeloid acute leukemia. Am J Clin Pathol 2012;137(2):213-9 ### Armstrong SA, et al. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood 2004;103(9):3544-6 ### Stam RW, et al. D-HPLC analysis of the entire FLT3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia. Haematologica 2007;92(11):1565-8 ### Ma HS, et al. FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia. Cancer Res 2014;74(18):5206-17 ### Pauwels D, et al. The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220. Haematologica 2012;97(11):1773-4 ### Smith CC, et al. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood 2013;121(16):3165-71"
FLT3	codon(s) 839 missense	Acute Myeloid Leukemia/B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma	'AML'/'*BLL'/'LY'/'*TLL'/'LY'	" ### Nakao M, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996;10(12):1911-8 ### Yokota S, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 1997;11(10):1605-9 ### Kiyoi H, et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998;12(9):1333-7 ### Yamamoto Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001;97(8):2434-9 ### Schnittger S, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002;100(1):59-66 ### Sudhindra A, et al. FLT3 inhibitors in AML: are we there yet? Curr Hematol Malig Rep 2014;9(2):174-85 ### Kihara R, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia 2014;28(8):1586-95 ### Hou HA, et al. Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia. Leukemia 2014;28(1):50-8 ### Neumann M, et al. FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors. PLoS One 2013;8(1):e53190 ### Hoehn D, et al. CD117 expression is a sensitive but nonspecific predictor of FLT3 mutation in T acute lymphoblastic leukemia and T/myeloid acute leukemia. Am J Clin Pathol 2012;137(2):213-9 ### Armstrong SA, et al. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood 2004;103(9):3544-6 ### Stam RW, et al. D-HPLC analysis of the entire FLT3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia. Haematologica 2007;92(11):1565-8 ### Ma HS, et al. FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia. Cancer Res 2014;74(18):5206-17 ### Pauwels D, et al. The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220. Haematologica 2012;97(11):1773-4 ### Smith CC, et al. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood 2013;121(16):3165-71"
FLT3	codon(s) 842 missense	Acute Myeloid Leukemia/B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma	'AML'/'*BLL'/'LY'/'*TLL'/'LY'	" ### Nakao M, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996;10(12):1911-8 ### Yokota S, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 1997;11(10):1605-9 ### Kiyoi H, et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998;12(9):1333-7 ### Yamamoto Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001;97(8):2434-9 ### Schnittger S, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002;100(1):59-66 ### Sudhindra A, et al. FLT3 inhibitors in AML: are we there yet? Curr Hematol Malig Rep 2014;9(2):174-85 ### Kihara R, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia 2014;28(8):1586-95 ### Hou HA, et al. Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia. Leukemia 2014;28(1):50-8 ### Neumann M, et al. FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors. PLoS One 2013;8(1):e53190 ### Hoehn D, et al. CD117 expression is a sensitive but nonspecific predictor of FLT3 mutation in T acute lymphoblastic leukemia and T/myeloid acute leukemia. Am J Clin Pathol 2012;137(2):213-9 ### Armstrong SA, et al. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood 2004;103(9):3544-6 ### Stam RW, et al. D-HPLC analysis of the entire FLT3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia. Haematologica 2007;92(11):1565-8 ### Ma HS, et al. FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia. Cancer Res 2014;74(18):5206-17 ### Pauwels D, et al. The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220. Haematologica 2012;97(11):1773-4 ### Smith CC, et al. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood 2013;121(16):3165-71"
FLT3	D835A	Acute Myeloid Leukemia/B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma	'AML'/'*BLL'/'LY'/'*TLL'/'LY'	" ### Nakao M, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996;10(12):1911-8 ### Yokota S, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 1997;11(10):1605-9 ### Kiyoi H, et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998;12(9):1333-7 ### Yamamoto Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001;97(8):2434-9 ### Schnittger S, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002;100(1):59-66 ### Sudhindra A, et al. FLT3 inhibitors in AML: are we there yet? Curr Hematol Malig Rep 2014;9(2):174-85 ### Kihara R, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia 2014;28(8):1586-95 ### Hou HA, et al. Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia. Leukemia 2014;28(1):50-8 ### Neumann M, et al. FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors. PLoS One 2013;8(1):e53190 ### Hoehn D, et al. CD117 expression is a sensitive but nonspecific predictor of FLT3 mutation in T acute lymphoblastic leukemia and T/myeloid acute leukemia. Am J Clin Pathol 2012;137(2):213-9 ### Armstrong SA, et al. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood 2004;103(9):3544-6 ### Stam RW, et al. D-HPLC analysis of the entire FLT3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia. Haematologica 2007;92(11):1565-8 ### Ma HS, et al. FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia. Cancer Res 2014;74(18):5206-17 ### Pauwels D, et al. The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220. Haematologica 2012;97(11):1773-4 ### Smith CC, et al. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood 2013;121(16):3165-71"
FLT3	D835E	Acute Myeloid Leukemia/B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma	'AML'/'*BLL'/'LY'/'*TLL'/'LY'	" ### Nakao M, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996;10(12):1911-8 ### Yokota S, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 1997;11(10):1605-9 ### Kiyoi H, et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998;12(9):1333-7 ### Yamamoto Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001;97(8):2434-9 ### Schnittger S, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002;100(1):59-66 ### Sudhindra A, et al. FLT3 inhibitors in AML: are we there yet? Curr Hematol Malig Rep 2014;9(2):174-85 ### Kihara R, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia 2014;28(8):1586-95 ### Hou HA, et al. Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia. Leukemia 2014;28(1):50-8 ### Neumann M, et al. FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors. PLoS One 2013;8(1):e53190 ### Hoehn D, et al. CD117 expression is a sensitive but nonspecific predictor of FLT3 mutation in T acute lymphoblastic leukemia and T/myeloid acute leukemia. Am J Clin Pathol 2012;137(2):213-9 ### Armstrong SA, et al. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood 2004;103(9):3544-6 ### Stam RW, et al. D-HPLC analysis of the entire FLT3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia. Haematologica 2007;92(11):1565-8 ### Ma HS, et al. FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia. Cancer Res 2014;74(18):5206-17 ### Pauwels D, et al. The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220. Haematologica 2012;97(11):1773-4 ### Smith CC, et al. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood 2013;121(16):3165-71"
FLT3	D835H	Acute Myeloid Leukemia/B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma	'AML'/'*BLL'/'LY'/'*TLL'/'LY'	" ### Nakao M, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996;10(12):1911-8 ### Yokota S, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 1997;11(10):1605-9 ### Kiyoi H, et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998;12(9):1333-7 ### Yamamoto Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001;97(8):2434-9 ### Schnittger S, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002;100(1):59-66 ### Sudhindra A, et al. FLT3 inhibitors in AML: are we there yet? Curr Hematol Malig Rep 2014;9(2):174-85 ### Kihara R, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia 2014;28(8):1586-95 ### Hou HA, et al. Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia. Leukemia 2014;28(1):50-8 ### Neumann M, et al. FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors. PLoS One 2013;8(1):e53190 ### Hoehn D, et al. CD117 expression is a sensitive but nonspecific predictor of FLT3 mutation in T acute lymphoblastic leukemia and T/myeloid acute leukemia. Am J Clin Pathol 2012;137(2):213-9 ### Armstrong SA, et al. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood 2004;103(9):3544-6 ### Stam RW, et al. D-HPLC analysis of the entire FLT3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia. Haematologica 2007;92(11):1565-8 ### Ma HS, et al. FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia. Cancer Res 2014;74(18):5206-17 ### Pauwels D, et al. The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220. Haematologica 2012;97(11):1773-4 ### Smith CC, et al. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood 2013;121(16):3165-71"
FLT3	D835N	Acute Myeloid Leukemia/B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma	'AML'/'*BLL'/'LY'/'*TLL'/'LY'	" ### Nakao M, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996;10(12):1911-8 ### Yokota S, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 1997;11(10):1605-9 ### Kiyoi H, et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998;12(9):1333-7 ### Yamamoto Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001;97(8):2434-9 ### Schnittger S, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002;100(1):59-66 ### Sudhindra A, et al. FLT3 inhibitors in AML: are we there yet? Curr Hematol Malig Rep 2014;9(2):174-85 ### Kihara R, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia 2014;28(8):1586-95 ### Hou HA, et al. Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia. Leukemia 2014;28(1):50-8 ### Neumann M, et al. FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors. PLoS One 2013;8(1):e53190 ### Hoehn D, et al. CD117 expression is a sensitive but nonspecific predictor of FLT3 mutation in T acute lymphoblastic leukemia and T/myeloid acute leukemia. Am J Clin Pathol 2012;137(2):213-9 ### Armstrong SA, et al. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood 2004;103(9):3544-6 ### Stam RW, et al. D-HPLC analysis of the entire FLT3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia. Haematologica 2007;92(11):1565-8 ### Ma HS, et al. FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia. Cancer Res 2014;74(18):5206-17 ### Pauwels D, et al. The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220. Haematologica 2012;97(11):1773-4 ### Smith CC, et al. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood 2013;121(16):3165-71"
FLT3	D835V	Acute Myeloid Leukemia/B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma	'AML'/'*BLL'/'LY'/'*TLL'/'LY'	" ### Nakao M, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996;10(12):1911-8 ### Yokota S, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 1997;11(10):1605-9 ### Kiyoi H, et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998;12(9):1333-7 ### Yamamoto Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001;97(8):2434-9 ### Schnittger S, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002;100(1):59-66 ### Sudhindra A, et al. FLT3 inhibitors in AML: are we there yet? Curr Hematol Malig Rep 2014;9(2):174-85 ### Kihara R, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia 2014;28(8):1586-95 ### Hou HA, et al. Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia. Leukemia 2014;28(1):50-8 ### Neumann M, et al. FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors. PLoS One 2013;8(1):e53190 ### Hoehn D, et al. CD117 expression is a sensitive but nonspecific predictor of FLT3 mutation in T acute lymphoblastic leukemia and T/myeloid acute leukemia. Am J Clin Pathol 2012;137(2):213-9 ### Armstrong SA, et al. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood 2004;103(9):3544-6 ### Stam RW, et al. D-HPLC analysis of the entire FLT3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia. Haematologica 2007;92(11):1565-8 ### Ma HS, et al. FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia. Cancer Res 2014;74(18):5206-17 ### Pauwels D, et al. The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220. Haematologica 2012;97(11):1773-4 ### Smith CC, et al. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood 2013;121(16):3165-71"
FLT3	exon(s) 14 insertion	Acute Myeloid Leukemia/B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma	'AML'/'*BLL'/'LY'/'*TLL'/'LY'	" ### Nakao M, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996;10(12):1911-8 ### Yokota S, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 1997;11(10):1605-9 ### Kiyoi H, et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998;12(9):1333-7 ### Yamamoto Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001;97(8):2434-9 ### Schnittger S, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002;100(1):59-66 ### Sudhindra A, et al. FLT3 inhibitors in AML: are we there yet? Curr Hematol Malig Rep 2014;9(2):174-85 ### Kihara R, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia 2014;28(8):1586-95 ### Hou HA, et al. Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia. Leukemia 2014;28(1):50-8 ### Neumann M, et al. FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors. PLoS One 2013;8(1):e53190 ### Hoehn D, et al. CD117 expression is a sensitive but nonspecific predictor of FLT3 mutation in T acute lymphoblastic leukemia and T/myeloid acute leukemia. Am J Clin Pathol 2012;137(2):213-9 ### Armstrong SA, et al. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood 2004;103(9):3544-6 ### Stam RW, et al. D-HPLC analysis of the entire FLT3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia. Haematologica 2007;92(11):1565-8 ### Ma HS, et al. FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia. Cancer Res 2014;74(18):5206-17 ### Pauwels D, et al. The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220. Haematologica 2012;97(11):1773-4 ### Smith CC, et al. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood 2013;121(16):3165-71"
FLT3	exon(s) 15 insertion	Acute Myeloid Leukemia/B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma	'AML'/'*BLL'/'LY'/'*TLL'/'LY'	" ### Nakao M, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996;10(12):1911-8 ### Yokota S, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 1997;11(10):1605-9 ### Kiyoi H, et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998;12(9):1333-7 ### Yamamoto Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001;97(8):2434-9 ### Schnittger S, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002;100(1):59-66 ### Sudhindra A, et al. FLT3 inhibitors in AML: are we there yet? Curr Hematol Malig Rep 2014;9(2):174-85 ### Kihara R, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia 2014;28(8):1586-95 ### Hou HA, et al. Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia. Leukemia 2014;28(1):50-8 ### Neumann M, et al. FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors. PLoS One 2013;8(1):e53190 ### Hoehn D, et al. CD117 expression is a sensitive but nonspecific predictor of FLT3 mutation in T acute lymphoblastic leukemia and T/myeloid acute leukemia. Am J Clin Pathol 2012;137(2):213-9 ### Armstrong SA, et al. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood 2004;103(9):3544-6 ### Stam RW, et al. D-HPLC analysis of the entire FLT3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia. Haematologica 2007;92(11):1565-8 ### Ma HS, et al. FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia. Cancer Res 2014;74(18):5206-17 ### Pauwels D, et al. The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220. Haematologica 2012;97(11):1773-4 ### Smith CC, et al. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood 2013;121(16):3165-71"
FLT3	Y842C	Acute Myeloid Leukemia/B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma	'AML'/'*BLL'/'LY'/'*TLL'/'LY'	" ### Nakao M, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996;10(12):1911-8 ### Yokota S, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 1997;11(10):1605-9 ### Kiyoi H, et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998;12(9):1333-7 ### Yamamoto Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001;97(8):2434-9 ### Schnittger S, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002;100(1):59-66 ### Sudhindra A, et al. FLT3 inhibitors in AML: are we there yet? Curr Hematol Malig Rep 2014;9(2):174-85 ### Kihara R, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia 2014;28(8):1586-95 ### Hou HA, et al. Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia. Leukemia 2014;28(1):50-8 ### Neumann M, et al. FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors. PLoS One 2013;8(1):e53190 ### Hoehn D, et al. CD117 expression is a sensitive but nonspecific predictor of FLT3 mutation in T acute lymphoblastic leukemia and T/myeloid acute leukemia. Am J Clin Pathol 2012;137(2):213-9 ### Armstrong SA, et al. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood 2004;103(9):3544-6 ### Stam RW, et al. D-HPLC analysis of the entire FLT3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia. Haematologica 2007;92(11):1565-8 ### Ma HS, et al. FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia. Cancer Res 2014;74(18):5206-17 ### Pauwels D, et al. The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220. Haematologica 2012;97(11):1773-4 ### Smith CC, et al. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood 2013;121(16):3165-71"
GATA1	any mutation	Acute Myeloid Leukemia	'AML'	" ### Yoshida K, et al. The landscape of somatic mutations in Down syndrome-related myeloid disorders. Nat Genet 2013;45(11):1293-9 ### Shimizu R, et al. Contribution of GATA1 dysfunction to multi-step leukemogenesis. Cancer Sci 2012;103(12):2039-44"
GATA2	any mutation	Acute Myeloid Leukemia/Chronic Myeloid Leukemia/Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia	'AML'/'CML'/'MDS'/'*CMML'	" ### Niimi K, et al. GATA2 zinc finger 2 mutation found in acute myeloid leukemia impairs myeloid differentiation. Leuk Res Rep 2013;2(1):21-5 ### West AH, et al. Familial myelodysplastic syndrome/acute leukemia syndromes: a review and utility for translational investigations. Ann N Y Acad Sci 2014;1310():111-8 ### West RR, et al. Acquired ASXL1 mutations are common in patients with inherited GATA2 mutations and correlate with myeloid transformation. Haematologica 2014;99(2):276-81 ### Shiba N, et al. Mutations of the GATA2 and CEBPA genes in paediatric acute myeloid leukaemia. Br J Haematol 2014;164(1):142-5 ### Fasan A, et al. GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis. Leukemia 2013;27(2):482-5 ### Greif PA, et al. GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia. Blood 2012;120(2):395-403"
GATA3	any mutation	T Lymphoblastic Leukemia/Lymphoma	'*TLL'/'LY'	" ### Zhang J, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012;481(7380):157-63"
GNA11	any mutation	Melanoma	'*M'	" ### Van Raamsdonk CD, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010;363(23):2191-9 ### Ho AL, et al. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype. PLoS One 2012;7(7):e40439 ### Khalili JS, et al. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res 2012;18(16):4345-55 ### Carvajal RD, et al. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA 2014;311(23):2397-405 ### Sheng X, et al. GNAQ and GNA11 mutations occur in 9.5% of mucosal melanoma and are associated with poor prognosis. Eur J Cancer 2016;65():156-63"
GNAS	any mutation	Intraductal Papillary Mucinous Neoplasm/Adenocarcinoma	'*IPMN'/'*AC2'	" ### Wu J, et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med 2011;3(92):92ra66 ### Matthaei H, et al. GNAS sequencing identifies IPMN-specific mutations in a subgroup of diminutive pancreatic cysts referred to as ""incipient IPMNs"". Am J Surg Pathol 2014;38(3):360-3 ### Frampton AE, et al. Activating mutations of GNAS and KRAS in cystic fluid can help detect intraductal papillary mucinous neoplasms of the pancreas. Expert Rev Mol Diagn 2015;15(3):325-8 ### Singhi AD, et al. Preoperative GNAS and KRAS testing in the diagnosis of pancreatic mucinous cysts. Clin Cancer Res 2014;20(16):4381-9 ### Furukawa T, et al. Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci Rep 2011;1():161"
GNAS	any mutation	Myelodysplastic Syndrome	'MDS'	" ### Bejar R, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011;364(26):2496-506 ### Weinstein LS, et al. Minireview: GNAS: normal and abnormal functions. Endocrinology 2004;145(12):5459-64"
GNAS	" codon(s) 201, 844 any"	Adenocarcinoma	'*AC2'	" ### Jeff P. Bruce, et al. Exome analysis of an exceptional responder uncovers an activating GNAS mutation that may confer sensitivity to cytotoxic chemotherapy. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl)"
GNAS	" codon(s) 201, 844 any"	Intraductal Papillary Mucinous Neoplasm/Adenocarcinoma	'*IPMN'/'*AC2'	" ### Wu J, et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med 2011;3(92):92ra66 ### Matthaei H, et al. GNAS sequencing identifies IPMN-specific mutations in a subgroup of diminutive pancreatic cysts referred to as ""incipient IPMNs"". Am J Surg Pathol 2014;38(3):360-3 ### Frampton AE, et al. Activating mutations of GNAS and KRAS in cystic fluid can help detect intraductal papillary mucinous neoplasms of the pancreas. Expert Rev Mol Diagn 2015;15(3):325-8 ### Singhi AD, et al. Preoperative GNAS and KRAS testing in the diagnosis of pancreatic mucinous cysts. Clin Cancer Res 2014;20(16):4381-9 ### Furukawa T, et al. Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci Rep 2011;1():161"
GNAS	" codon(s) 201, 844 any"	Myelodysplastic Syndrome	'MDS'	" ### Bejar R, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011;364(26):2496-506 ### Weinstein LS, et al. Minireview: GNAS: normal and abnormal functions. Endocrinology 2004;145(12):5459-64"
GNAS	Q227L	Adenocarcinoma	'*AC2'	" ### Han JY, et al. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma. Lung Cancer 2014;85(2):161-7 ### Takada M, et al. Prediction of lymph node metastasis by analysis of gene expression profiles in non-small cell lung cancer. J Surg Res 2004;122(1):61-9 ### Sun W, et al. Identification of differentially expressed genes in human lung squamous cell carcinoma using suppression subtractive hybridization. Cancer Lett 2004;212(1):83-93 ### Masters SB, et al. Mutations in the GTP-binding site of GS alpha alter stimulation of adenylyl cyclase. J Biol Chem 1989;264(26):15467-74"
GNB1	codon(s) 57 missense	Myelodysplastic Syndrome/Acute Myeloid Leukemia	'MDS'/'AML'	" ### Walter MJ, et al. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia 2013;27(6):1275-82"
HRAS	" codon(s) 12, 13, 61 any"	Cholangiocarcinoma	'CH'	" ### Hollestelle et al., Phosphatidylinositol-3-OH Kinase or RAS Pathway Mutations in Human Breast Cancer Cell Lines, Mol Cancer Res 2007;5(2):195‚Ä?01. ### Scherf et al., A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000; 24:236-44."
HRAS	" codon(s) 12, 13, 61 any"	Melanoma	'*M'	" ### Identification of HRAS mutations and absence of GNAQ or GNA11 mutations in deep penetrating nevi. Bender RP et a 2013 Modern pathology : an official journal of the United States and Canadian ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Czerniak et al..Concurrent mutations of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas. Hum Pathol. 1992 Nov;23(11):1199-204 ### Ascierto PA et al.. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 2013 Mar;14(3):249-56"
HRAS	" codon(s) 12, 13, 61 any"	Papillary Carcinoma/Follicular Carcinoma	'THP'/'THF'	" ### Nikiforov YE Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med 2011;135(5):569-77 ### Radkay LA, et al. Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics. Cancer Cytopathol 2014;122(12):873-82"
HRAS	" codon(s) 12, 13, 61 any"	Squamous Cell Carcinoma	'SCC'	" ### Stransky N, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011;333(6046):1157-60 ### Cancer Genome Atlas Network Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015;517(7536):576-82 ### Trietsch MD, et al. CDKN2A(p16) and HRAS are frequently mutated in vulvar squamous cell carcinoma. Gynecol Oncol 2014;135(1):149-55"
HRAS	" codon(s) 12, 13, 61 any"	Urothelial Carcinoma	'UTH'	" ### Identification of HRAS mutations and absence of GNAQ or GNA11 mutations in deep penetrating nevi. Bender RP et a 2013 Modern pathology : an official journal of the United States and Canadian ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Czerniak et al..Concurrent mutations of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas. Hum Pathol. 1992 Nov;23(11):1199-204 ### Ascierto PA et al.. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 2013 Mar;14(3):249-56 ### Bagrodia A, et al. Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma. J Urol 2016;():"
HRAS	Q61K	Squamous Cell Carcinoma	'SCC'	" ### Stransky N, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011;333(6046):1157-60 ### Cancer Genome Atlas Network Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015;517(7536):576-82 ### Trietsch MD, et al. CDKN2A(p16) and HRAS are frequently mutated in vulvar squamous cell carcinoma. Gynecol Oncol 2014;135(1):149-55"
HRAS	Q61R	Cholangiocarcinoma	'CH'	" ### Hollestelle et al., Phosphatidylinositol-3-OH Kinase or RAS Pathway Mutations in Human Breast Cancer Cell Lines, Mol Cancer Res 2007;5(2):195‚Ä?01. ### Scherf et al., A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000; 24:236-44."
HRAS	Q61R	Squamous Cell Carcinoma	'SCC'	" ### Stransky N, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011;333(6046):1157-60 ### Cancer Genome Atlas Network Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015;517(7536):576-82 ### Trietsch MD, et al. CDKN2A(p16) and HRAS are frequently mutated in vulvar squamous cell carcinoma. Gynecol Oncol 2014;135(1):149-55"
IDH1	codon(s) 132 any	Adenocarcinoma	'*AC2'	" ### Julie-Aurore Losman et al...What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes & Dev. 2013. 27: 836-852 ### Cohen et al...IDH1 and IDH2 Mutations in Gliomas. Curr Neurol Neurosci Rep. 2013 May; 13(5): 345. ### Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. Patel JP, G√∂nen M, et al N Engl J Med. 2012 Mar 22;366(12):1079-89. doi: 10.1056/NEJMoa1112304. Epub 2012 Mar 14. ### Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Borger DR, Tanabe KK, Fan KC et al, Oncologist. 2012;17(1):72-9. doi: 10.1634/theoncologist.2011-0386. Epub 2011 Dec 16. ### Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. AnnOncol. 2011;22:2616‚Ä?624"
IDH1	codon(s) 132 any	Adenocarcinoma	'*AC2'	" ### Julie-Aurore Losman et al...What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes & Dev. 2013. 27: 836-852 ### Cohen et al...IDH1 and IDH2 Mutations in Gliomas. Curr Neurol Neurosci Rep. 2013 May; 13(5): 345. ### Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. Patel JP, G√∂nen M, et al N Engl J Med. 2012 Mar 22;366(12):1079-89. doi: 10.1056/NEJMoa1112304. Epub 2012 Mar 14. ### Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate.Fathi AT, Sadrzadeh H et al, Oncologist. 2014 Jun;19(6):602-7. doi: 10.1634/theoncologist.2013-0417. Epub 2014 Apr 23 ### Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Borger DR, Tanabe KK, Fan KC et al, Oncologist. 2012;17(1):72-9. doi: 10.1634/theoncologist.2011-0386. Epub 2011 Dec 16. ### Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. AnnOncol. 2011;22:2616‚Ä?624"
IDH1	codon(s) 132 any	Cholangiocarcinoma	'CH'	" ### Julie-Aurore Losman et al...What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes & Dev. 2013. 27: 836-852 ### Cohen et al...IDH1 and IDH2 Mutations in Gliomas. Curr Neurol Neurosci Rep. 2013 May; 13(5): 345. ### Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. Patel JP, G√∂nen M, et al N Engl J Med. 2012 Mar 22;366(12):1079-89. doi: 10.1056/NEJMoa1112304. Epub 2012 Mar 14. ### Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate.Fathi AT, Sadrzadeh H et al, Oncologist. 2014 Jun;19(6):602-7. doi: 10.1634/theoncologist.2013-0417. Epub 2014 Apr 23 ### Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Borger DR, Tanabe KK, Fan KC et al,  Oncologist. 2012;17(1):72-9. doi: 10.1634/theoncologist.2011-0386. Epub 2011 Dec 16. ### Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. AnnOncol. 2011;22:2616‚Ä?624"
IDH1	codon(s) 132 any	Glial Neoplasm/Glioblastoma	'*GN''/'GB'	" ### Julie-Aurore Losman et al...What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes & Dev. 2013. 27: 836-852 ### Cohen et al...IDH1 and IDH2 Mutations in Gliomas. Curr Neurol Neurosci Rep. 2013 May; 13(5): 345. ### Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. Patel JP, G√∂nen M, et al N Engl J Med. 2012 Mar 22;366(12):1079-89. doi: 10.1056/NEJMoa1112304. Epub 2012 Mar 14. ### Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate.Fathi AT, Sadrzadeh H et al, Oncologist. 2014 Jun;19(6):602-7. doi: 10.1634/theoncologist.2013-0417. Epub 2014 Apr 23 ### Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Borger DR, Tanabe KK, Fan KC et al, Oncologist. 2012;17(1):72-9. doi: 10.1634/theoncologist.2011-0386. Epub 2011 Dec 16. ### Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. AnnOncol. 2011;22:2616‚Ä?624 ### Venneti S, et al. The evolving molecular genetics of low-grade glioma. Adv Anat Pathol 2015;22(2):94-101 ### Losman JA, et al. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev 2013;27(8):836-52 ### Cohen AL, et al. IDH1 and IDH2 mutations in gliomas. Curr Neurol Neurosci Rep 2013;13(5):345"
IDH1	codon(s) 132 any	Melanoma	'*M'	" ### Shibata et al. Mutant IDH1 Confers an in Vivo Growth in a Melanoma Cell Line with BRAF Mutation. The American Journal of Pathology, Vol. 178, No. 3, March 2011 ### Lopez et al IDH1 mutation identified in human melanoma. Biochem Biophys Res Commun. 2010 July 30; 398(3): 585‚Ä?87"
IDH1	codon(s) 132 any	Myeloproliferative Neoplasm/Acute Myeloid Leukemia/Myelodysplastic Syndrome/Primary Myelofibrosis	'*MPN2'/'AML'/'MDS'/'MY'	" ### Chaturvedi A, et al. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood 2013;122(16):2877-87 ### Mardis ER, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009;361(11):1058-66 ### Green A, et al. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med 2010;362(4):369-70 ### Pardanani A, et al. IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia 2010;24(6):1146-51 ### Wagner K, et al. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol 2010;28(14):2356-64 ### Marcucci G, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010;28(14):2348-55 ### Kosmider O, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia 2010;24(5):1094-6 ### Ho PA, et al. Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study. Leukemia 2010;24(5):909-13 ### Thol F, et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 2010;95(10):1668-74 ### Tefferi A, et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 2010;24(7):1302-9 ### Paschka P, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010;28(22):3636-43 ### Itzykson R, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 2013;31(19):2428-36 ### Im AP, et al. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia 2014;28(9):1774-83 ### McKenney AS, et al. Isocitrate dehydrogenase mutations in leukemia. J Clin Invest 2013;123(9):3672-7"
IDH1	R132C	Adenocarcinoma	'*AC2'	" ### Julie-Aurore Losman et al...What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes & Dev. 2013. 27: 836-852 ### Cohen et al...IDH1 and IDH2 Mutations in Gliomas. Curr Neurol Neurosci Rep. 2013 May; 13(5): 345. ### Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. Patel JP, G√∂nen M, et al N Engl J Med. 2012 Mar 22;366(12):1079-89. doi: 10.1056/NEJMoa1112304. Epub 2012 Mar 14. ### Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate.Fathi AT, Sadrzadeh H et al, Oncologist. 2014 Jun;19(6):602-7. doi: 10.1634/theoncologist.2013-0417. Epub 2014 Apr 23 ### Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Borger DR, Tanabe KK, Fan KC et al, Oncologist. 2012;17(1):72-9. doi: 10.1634/theoncologist.2011-0386. Epub 2011 Dec 16. ### Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. AnnOncol. 2011;22:2616‚Ä?624"
IDH1	R132C	Cholangiocarcinoma	'CH'	" ### Julie-Aurore Losman et al...What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes & Dev. 2013. 27: 836-852 ### Cohen et al...IDH1 and IDH2 Mutations in Gliomas. Curr Neurol Neurosci Rep. 2013 May; 13(5): 345. ### Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. Patel JP, G√∂nen M, et al N Engl J Med. 2012 Mar 22;366(12):1079-89. doi: 10.1056/NEJMoa1112304. Epub 2012 Mar 14. ### Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate.Fathi AT, Sadrzadeh H et al, Oncologist. 2014 Jun;19(6):602-7. doi: 10.1634/theoncologist.2013-0417. Epub 2014 Apr 23 ### Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Borger DR, Tanabe KK, Fan KC et al,  Oncologist. 2012;17(1):72-9. doi: 10.1634/theoncologist.2011-0386. Epub 2011 Dec 16. ### Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. AnnOncol. 2011;22:2616‚Ä?624"
IDH1	R132C	Glial Neoplasm/Glioblastoma	'*GN''/'GB'	" ### Julie-Aurore Losman et al...What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes & Dev. 2013. 27: 836-852 ### Cohen et al...IDH1 and IDH2 Mutations in Gliomas. Curr Neurol Neurosci Rep. 2013 May; 13(5): 345. ### Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. Patel JP, G√∂nen M, et al N Engl J Med. 2012 Mar 22;366(12):1079-89. doi: 10.1056/NEJMoa1112304. Epub 2012 Mar 14. ### Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate.Fathi AT, Sadrzadeh H et al, Oncologist. 2014 Jun;19(6):602-7. doi: 10.1634/theoncologist.2013-0417. Epub 2014 Apr 23 ### Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Borger DR, Tanabe KK, Fan KC et al, Oncologist. 2012;17(1):72-9. doi: 10.1634/theoncologist.2011-0386. Epub 2011 Dec 16. ### Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. AnnOncol. 2011;22:2616‚Ä?624 ### Venneti S, et al. The evolving molecular genetics of low-grade glioma. Adv Anat Pathol 2015;22(2):94-101 ### Losman JA, et al. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev 2013;27(8):836-52 ### Cohen AL, et al. IDH1 and IDH2 mutations in gliomas. Curr Neurol Neurosci Rep 2013;13(5):345"
IDH1	R132C	Melanoma	'*M'	" ### Shibata et al. Mutant IDH1 Confers an in Vivo Growth in a Melanoma Cell Line with BRAF Mutation. The American Journal of Pathology, Vol. 178, No. 3, March 2011 ### Lopez et al IDH1 mutation identified in human melanoma. Biochem Biophys Res Commun. 2010 July 30; 398(3): 585‚Ä?87"
IDH1	R132C	Myeloproliferative Neoplasm/Acute Myeloid Leukemia/Myelodysplastic Syndrome/Primary Myelofibrosis	'*MPN2'/'AML'/'MDS'/'MY'	" ### Chaturvedi A, et al. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood 2013;122(16):2877-87 ### Mardis ER, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009;361(11):1058-66 ### Green A, et al. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med 2010;362(4):369-70 ### Pardanani A, et al. IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia 2010;24(6):1146-51 ### Wagner K, et al. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol 2010;28(14):2356-64 ### Marcucci G, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010;28(14):2348-55 ### Kosmider O, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia 2010;24(5):1094-6 ### Ho PA, et al. Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study. Leukemia 2010;24(5):909-13 ### Thol F, et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 2010;95(10):1668-74 ### Tefferi A, et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 2010;24(7):1302-9 ### Paschka P, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010;28(22):3636-43 ### Itzykson R, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 2013;31(19):2428-36 ### Im AP, et al. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia 2014;28(9):1774-83 ### McKenney AS, et al. Isocitrate dehydrogenase mutations in leukemia. J Clin Invest 2013;123(9):3672-7"
IDH1	R132H	Adenocarcinoma	'*AC2'	" ### Julie-Aurore Losman et al...What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes & Dev. 2013. 27: 836-852 ### Cohen et al...IDH1 and IDH2 Mutations in Gliomas. Curr Neurol Neurosci Rep. 2013 May; 13(5): 345. ### Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. Patel JP, G√∂nen M, et al N Engl J Med. 2012 Mar 22;366(12):1079-89. doi: 10.1056/NEJMoa1112304. Epub 2012 Mar 14. ### Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate.Fathi AT, Sadrzadeh H et al, Oncologist. 2014 Jun;19(6):602-7. doi: 10.1634/theoncologist.2013-0417. Epub 2014 Apr 23 ### Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Borger DR, Tanabe KK, Fan KC et al, Oncologist. 2012;17(1):72-9. doi: 10.1634/theoncologist.2011-0386. Epub 2011 Dec 16. ### Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. AnnOncol. 2011;22:2616‚Ä?624"
IDH1	R132H	Cholangiocarcinoma	'CH'	" ### Julie-Aurore Losman et al...What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes & Dev. 2013. 27: 836-852 ### Cohen et al...IDH1 and IDH2 Mutations in Gliomas. Curr Neurol Neurosci Rep. 2013 May; 13(5): 345. ### Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. Patel JP, G√∂nen M, et al N Engl J Med. 2012 Mar 22;366(12):1079-89. doi: 10.1056/NEJMoa1112304. Epub 2012 Mar 14. ### Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate.Fathi AT, Sadrzadeh H et al, Oncologist. 2014 Jun;19(6):602-7. doi: 10.1634/theoncologist.2013-0417. Epub 2014 Apr 23 ### Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Borger DR, Tanabe KK, Fan KC et al,  Oncologist. 2012;17(1):72-9. doi: 10.1634/theoncologist.2011-0386. Epub 2011 Dec 16. ### Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. AnnOncol. 2011;22:2616‚Ä?624"
IDH1	R132H	Glial Neoplasm/Glioblastoma	'*GN''/'GB'	" ### Julie-Aurore Losman et al...What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes & Dev. 2013. 27: 836-852 ### Cohen et al...IDH1 and IDH2 Mutations in Gliomas. Curr Neurol Neurosci Rep. 2013 May; 13(5): 345. ### Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. Patel JP, G√∂nen M, et al N Engl J Med. 2012 Mar 22;366(12):1079-89. doi: 10.1056/NEJMoa1112304. Epub 2012 Mar 14. ### Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate.Fathi AT, Sadrzadeh H et al, Oncologist. 2014 Jun;19(6):602-7. doi: 10.1634/theoncologist.2013-0417. Epub 2014 Apr 23 ### Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Borger DR, Tanabe KK, Fan KC et al, Oncologist. 2012;17(1):72-9. doi: 10.1634/theoncologist.2011-0386. Epub 2011 Dec 16. ### Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. AnnOncol. 2011;22:2616‚Ä?624 ### Venneti S, et al. The evolving molecular genetics of low-grade glioma. Adv Anat Pathol 2015;22(2):94-101 ### Losman JA, et al. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev 2013;27(8):836-52 ### Cohen AL, et al. IDH1 and IDH2 mutations in gliomas. Curr Neurol Neurosci Rep 2013;13(5):345"
IDH1	R132H	Myeloproliferative Neoplasm/Acute Myeloid Leukemia/Myelodysplastic Syndrome/Primary Myelofibrosis	'*MPN2'/'AML'/'MDS'/'MY'	" ### Chaturvedi A, et al. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood 2013;122(16):2877-87 ### Mardis ER, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009;361(11):1058-66 ### Green A, et al. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med 2010;362(4):369-70 ### Pardanani A, et al. IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia 2010;24(6):1146-51 ### Wagner K, et al. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol 2010;28(14):2356-64 ### Marcucci G, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010;28(14):2348-55 ### Kosmider O, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia 2010;24(5):1094-6 ### Ho PA, et al. Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study. Leukemia 2010;24(5):909-13 ### Thol F, et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 2010;95(10):1668-74 ### Tefferi A, et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 2010;24(7):1302-9 ### Paschka P, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010;28(22):3636-43 ### Itzykson R, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 2013;31(19):2428-36 ### Im AP, et al. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia 2014;28(9):1774-83 ### McKenney AS, et al. Isocitrate dehydrogenase mutations in leukemia. J Clin Invest 2013;123(9):3672-7"
IDH1	R132L	Adenocarcinoma	'*AC2'	" ### Julie-Aurore Losman et al...What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes & Dev. 2013. 27: 836-852 ### Cohen et al...IDH1 and IDH2 Mutations in Gliomas. Curr Neurol Neurosci Rep. 2013 May; 13(5): 345. ### Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. Patel JP, G√∂nen M, et al N Engl J Med. 2012 Mar 22;366(12):1079-89. doi: 10.1056/NEJMoa1112304. Epub 2012 Mar 14. ### Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Borger DR, Tanabe KK, Fan KC et al, Oncologist. 2012;17(1):72-9. doi: 10.1634/theoncologist.2011-0386. Epub 2011 Dec 16. ### Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. AnnOncol. 2011;22:2616‚Ä?624"
IDH1	R132L	Adenocarcinoma	'*AC2'	" ### Julie-Aurore Losman et al...What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes & Dev. 2013. 27: 836-852 ### Cohen et al...IDH1 and IDH2 Mutations in Gliomas. Curr Neurol Neurosci Rep. 2013 May; 13(5): 345. ### Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. Patel JP, G√∂nen M, et al N Engl J Med. 2012 Mar 22;366(12):1079-89. doi: 10.1056/NEJMoa1112304. Epub 2012 Mar 14. ### Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate.Fathi AT, Sadrzadeh H et al, Oncologist. 2014 Jun;19(6):602-7. doi: 10.1634/theoncologist.2013-0417. Epub 2014 Apr 23 ### Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Borger DR, Tanabe KK, Fan KC et al, Oncologist. 2012;17(1):72-9. doi: 10.1634/theoncologist.2011-0386. Epub 2011 Dec 16. ### Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. AnnOncol. 2011;22:2616‚Ä?624"
IDH1	R132L	Cholangiocarcinoma	'CH'	" ### Julie-Aurore Losman et al...What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes & Dev. 2013. 27: 836-852 ### Cohen et al...IDH1 and IDH2 Mutations in Gliomas. Curr Neurol Neurosci Rep. 2013 May; 13(5): 345. ### Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. Patel JP, G√∂nen M, et al N Engl J Med. 2012 Mar 22;366(12):1079-89. doi: 10.1056/NEJMoa1112304. Epub 2012 Mar 14. ### Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate.Fathi AT, Sadrzadeh H et al, Oncologist. 2014 Jun;19(6):602-7. doi: 10.1634/theoncologist.2013-0417. Epub 2014 Apr 23 ### Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Borger DR, Tanabe KK, Fan KC et al,  Oncologist. 2012;17(1):72-9. doi: 10.1634/theoncologist.2011-0386. Epub 2011 Dec 16. ### Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. AnnOncol. 2011;22:2616‚Ä?624"
IDH1	R132L	Glial Neoplasm/Glioblastoma	'*GN''/'GB'	" ### Julie-Aurore Losman et al...What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes & Dev. 2013. 27: 836-852 ### Cohen et al...IDH1 and IDH2 Mutations in Gliomas. Curr Neurol Neurosci Rep. 2013 May; 13(5): 345. ### Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. Patel JP, G√∂nen M, et al N Engl J Med. 2012 Mar 22;366(12):1079-89. doi: 10.1056/NEJMoa1112304. Epub 2012 Mar 14. ### Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate.Fathi AT, Sadrzadeh H et al, Oncologist. 2014 Jun;19(6):602-7. doi: 10.1634/theoncologist.2013-0417. Epub 2014 Apr 23 ### Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Borger DR, Tanabe KK, Fan KC et al, Oncologist. 2012;17(1):72-9. doi: 10.1634/theoncologist.2011-0386. Epub 2011 Dec 16. ### Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. AnnOncol. 2011;22:2616‚Ä?624 ### Venneti S, et al. The evolving molecular genetics of low-grade glioma. Adv Anat Pathol 2015;22(2):94-101 ### Losman JA, et al. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev 2013;27(8):836-52 ### Cohen AL, et al. IDH1 and IDH2 mutations in gliomas. Curr Neurol Neurosci Rep 2013;13(5):345"
IDH1	R132L	Myeloproliferative Neoplasm/Acute Myeloid Leukemia/Myelodysplastic Syndrome/Primary Myelofibrosis	'*MPN2'/'AML'/'MDS'/'MY'	" ### Chaturvedi A, et al. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood 2013;122(16):2877-87 ### Mardis ER, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009;361(11):1058-66 ### Green A, et al. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med 2010;362(4):369-70 ### Pardanani A, et al. IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia 2010;24(6):1146-51 ### Wagner K, et al. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol 2010;28(14):2356-64 ### Marcucci G, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010;28(14):2348-55 ### Kosmider O, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia 2010;24(5):1094-6 ### Ho PA, et al. Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study. Leukemia 2010;24(5):909-13 ### Thol F, et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 2010;95(10):1668-74 ### Tefferi A, et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 2010;24(7):1302-9 ### Paschka P, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010;28(22):3636-43 ### Itzykson R, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 2013;31(19):2428-36 ### Im AP, et al. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia 2014;28(9):1774-83 ### McKenney AS, et al. Isocitrate dehydrogenase mutations in leukemia. J Clin Invest 2013;123(9):3672-7"
IDH2	any mutation	Adenocarcinoma/Squamous Cell Carcinoma/Non-Small Cell Lung Carcinoma	'*AC2'/'SCC'/'NSCLC'	" ### Cancer Genome Atlas Research Network Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511(7511):543-50 ### Imielinski M, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012;150(6):1107-20 ### Chen C, et al. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes Dev 2013;27(18):1974-85 ### McKenney AS, et al. Isocitrate dehydrogenase mutations in leukemia. J Clin Invest 2013;123(9):3672-7"
IDH2	" codon(s) 140, 172 any"	Adenocarcinoma/Squamous Cell Carcinoma/Non-Small Cell Lung Carcinoma	'*AC2'/'SCC'/'NSCLC'	" ### Cancer Genome Atlas Research Network Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511(7511):543-50 ### Imielinski M, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012;150(6):1107-20 ### Chen C, et al. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes Dev 2013;27(18):1974-85 ### McKenney AS, et al. Isocitrate dehydrogenase mutations in leukemia. J Clin Invest 2013;123(9):3672-7"
IDH2	" codon(s) 140, 172 any"	Glial Neoplasm/Glioblastoma	'*GN''/'GB'	" ### Julie-Aurore Losman et al...What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes & Dev. 2013. 27: 836-852 ### Cohen et al...IDH1 and IDH2 Mutations in Gliomas. Curr Neurol Neurosci Rep. 2013 May; 13(5): 345. ### Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate.Fathi AT, Sadrzadeh H et al, Oncologist. 2014 Jun;19(6):602-7. doi: 10.1634/theoncologist.2013-0417. Epub 2014 Apr 23 ### Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Borger DR, Tanabe KK, Fan KC et al, Oncologist. 2012;17(1):72-9. doi: 10.1634/theoncologist.2011-0386. Epub 2011 Dec 16. ### Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. AnnOncol. 2011;22:2616‚Ä?624 ### of non-small-cell lung cancers into routine clinical practice. AnnOncol. ### Cohen et al...IDH1 and IDH2 Mutations in Gliomas. Curr Neurol Neurosci Rep. 2013 May; 13(5): 345 ### Venneti S, et al. The evolving molecular genetics of low-grade glioma. Adv Anat Pathol 2015;22(2):94-101 ### Losman JA, et al. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev 2013;27(8):836-52 ### Cohen AL, et al. IDH1 and IDH2 mutations in gliomas. Curr Neurol Neurosci Rep 2013;13(5):345"
IDH2	" codon(s) 140, 172 any"	Myeloproliferative Neoplasm/Acute Myeloid Leukemia/Myelodysplastic Syndrome/Primary Myelofibrosis	'*MPN2'/'AML'/'MDS'/'MY'	" ### Chen C, et al. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes Dev 2013;27(18):1974-85 ### Im AP, et al. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia 2014;28(9):1774-83 ### McKenney AS, et al. Isocitrate dehydrogenase mutations in leukemia. J Clin Invest 2013;123(9):3672-7"
IDH2	codon(s) 140 missense	Myeloproliferative Neoplasm/Acute Myeloid Leukemia/Myelodysplastic Syndrome/Primary Myelofibrosis	'*MPN2'/'AML'/'MDS'/'MY'	" ### Chen C, et al. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes Dev 2013;27(18):1974-85 ### Im AP, et al. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia 2014;28(9):1774-83 ### McKenney AS, et al. Isocitrate dehydrogenase mutations in leukemia. J Clin Invest 2013;123(9):3672-7"
IDH2	codon(s) 172 missense	Myeloproliferative Neoplasm/Acute Myeloid Leukemia/Myelodysplastic Syndrome/Primary Myelofibrosis	'*MPN2'/'AML'/'MDS'/'MY'	" ### Chen C, et al. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes Dev 2013;27(18):1974-85 ### Im AP, et al. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia 2014;28(9):1774-83 ### McKenney AS, et al. Isocitrate dehydrogenase mutations in leukemia. J Clin Invest 2013;123(9):3672-7"
IDH2	R140Q	Adenocarcinoma/Squamous Cell Carcinoma/Non-Small Cell Lung Carcinoma	'*AC2'/'SCC'/'NSCLC'	" ### Cancer Genome Atlas Research Network Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511(7511):543-50 ### Imielinski M, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012;150(6):1107-20 ### Chen C, et al. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes Dev 2013;27(18):1974-85 ### McKenney AS, et al. Isocitrate dehydrogenase mutations in leukemia. J Clin Invest 2013;123(9):3672-7"
IDH2	R140Q	Glial Neoplasm/Glioblastoma	'*GN''/'GB'	" ### Julie-Aurore Losman et al...What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes & Dev. 2013. 27: 836-852 ### Cohen et al...IDH1 and IDH2 Mutations in Gliomas. Curr Neurol Neurosci Rep. 2013 May; 13(5): 345. ### Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate.Fathi AT, Sadrzadeh H et al, Oncologist. 2014 Jun;19(6):602-7. doi: 10.1634/theoncologist.2013-0417. Epub 2014 Apr 23 ### Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Borger DR, Tanabe KK, Fan KC et al, Oncologist. 2012;17(1):72-9. doi: 10.1634/theoncologist.2011-0386. Epub 2011 Dec 16. ### Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. AnnOncol. 2011;22:2616‚Ä?624 ### of non-small-cell lung cancers into routine clinical practice. AnnOncol. ### Cohen et al...IDH1 and IDH2 Mutations in Gliomas. Curr Neurol Neurosci Rep. 2013 May; 13(5): 345 ### Venneti S, et al. The evolving molecular genetics of low-grade glioma. Adv Anat Pathol 2015;22(2):94-101 ### Losman JA, et al. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev 2013;27(8):836-52 ### Cohen AL, et al. IDH1 and IDH2 mutations in gliomas. Curr Neurol Neurosci Rep 2013;13(5):345"
IDH2	R140Q	Myeloproliferative Neoplasm/Acute Myeloid Leukemia/Myelodysplastic Syndrome/Primary Myelofibrosis	'*MPN2'/'AML'/'MDS'/'MY'	" ### Chen C, et al. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes Dev 2013;27(18):1974-85 ### Im AP, et al. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia 2014;28(9):1774-83 ### McKenney AS, et al. Isocitrate dehydrogenase mutations in leukemia. J Clin Invest 2013;123(9):3672-7"
IKZF1	any mutation	B Lymphoblastic Leukemia/Lymphoma	'*BLL'/'LY'	" ### Mullighan CG, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009;360(5):470-80 ### van der Veer A, et al. IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. Blood 2014;123(11):1691-8 ### G√≥rniak P, et al. Polymorphism in IKZF1 gene affects age at onset of childhood acute lymphoblastic leukemia. Leuk Lymphoma 2014;55(9):2174-8 ### Burmeister T, et al. Germline variants in IKZF1, ARID5B, and CEBPE as risk factors for adult-onset acute lymphoblastic leukemia: an analysis from the GMALL study group. Haematologica 2014;99(2):e23-5 ### Qazi S, et al. Incidence and biological significance of IKZF1/Ikaros gene deletions in pediatric Philadelphia chromosome negative and Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia. Haematologica 2013;98(12):e151-2 ### Palmi C, et al. Impact of IKZF1 deletions on IKZF1 expression and outcome in Philadelphia chromosome negative childhood BCP-ALL. Reply to ""incidence and biological significance of IKZF1/Ikaros gene deletions in pediatric Philadelphia chromosome negative and Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia"". Haematologica 2013;98(12):e164-5"
IKZF2	any mutation	B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma	'*BLL'/'LY'/'*TLL'/'LY'	" ### Holmfeldt L, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 2013;45(3):242-52"
IKZF3	any mutation	Chronic Myeloid Leukemia	'CML'	" ### Menezes J, et al. ASXL1, TP53 and IKZF3 mutations are present in the chronic phase and blast crisis of chronic myeloid leukemia. Blood Cancer J 2013;3():e157 ### Menezes J, et al. Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. Leukemia 2014;28(4):823-9 ### Holmfeldt L, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 2013;45(3):242-52"
IL7R	any mutation	B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma	'*BLL'/'LY'/'*TLL'/'LY'	" ### Shochat C, et al. Gain-of-function mutations in interleukin-7 receptor-Œ± (IL7R) in childhood acute lymphoblastic leukemias. J Exp Med 2011;208(5):901-8 ### Shochat C, et al. Novel activating mutations lacking cysteine in type I cytokine receptors in acute lymphoblastic leukemia. Blood 2014;124(1):106-10 ### Zenatti PP, et al. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet 2011;43(10):932-9 ### Kim MS, et al. Somatic mutation of IL7R exon 6 in acute leukemias and solid cancers. Hum Pathol 2013;44(4):551-5"
IRS2	copy number gain	Adenocarcinoma/Cholangiocarcinoma/Glioblastoma	'*AC2'/'CH'/'GB'	" ### Day E, et al. IRS2 is a candidate driver oncogene on 13q34 in colorectal cancer. Int J Exp Pathol 2013;94(3):203-11 ### Liu TT, et al. Recurrent Amplification at 13q34 Targets at CUL4A, IRS2, and TFDP1 As an Independent Adverse Prognosticator in Intrahepatic Cholangiocarcinoma. PLoS One 2015;10(12):e0145388 ### Knobbe CB, et al. Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3'-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol 2003;13(4):507-18 ### Nishimura R, et al. Characterization of genetic lesions in rhabdomyosarcoma using a high-density single nucleotide polymorphism array. Cancer Sci 2013;104(7):856-64 ### Huang F, et al. IRS2 copy number gain, KRAS and BRAF mutation status as predictive biomarkers for response to the IGF-1R/IR inhibitor BMS-754807 in colorectal cancer cell lines. Mol Cancer Ther 2015;14(2):620-30 ### Bertotti A, et al. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature 2015;526(7572):263-7"
JAK1	any mutation	T Lymphoblastic Leukemia/Lymphoma/Acute Myeloid Leukemia	'*TLL'/'LY'/'AML'	" ### Flex E, et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med 2008;205(4):751-8 ### Aranaz P, et al. A new potential oncogenic mutation in the FERM domain of JAK2 in BCR/ABL1-negative and V617F-negative chronic myeloproliferative neoplasms revealed by a comprehensive screening of 17 tyrosine kinase coding genes. Cancer Genet Cytogenet 2010;199(1):1-8 ### Asnafi V, et al. JAK1 mutations are not frequent events in adult T-ALL: a GRAALL study. Br J Haematol 2010;148(1):178-9 ### Zhang J, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012;481(7380):157-63 ### Wang Q, et al. Mutations of PHF6 are associated with mutations of NOTCH1, JAK1 and rearrangement of SET-NUP214 in T-cell acute lymphoblastic leukemia. Haematologica 2011;96(12):1808-14 ### Hornakova T, et al. Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors. Haematologica 2011;96(6):845-53 ### Hornakova T, et al. ALL-associated JAK1 mutations confer hypersensitivity to the antiproliferative effect of type I interferon. Blood 2010;115(16):3287-95 ### Mullighan CG, et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 2009;106(23):9414-8 ### Xiang Z, et al. Identification of somatic JAK1 mutations in patients with acute myeloid leukemia. Blood 2008;111(9):4809-12"
JAK2	codon(s) 683 missense	B Lymphoblastic Leukemia/Lymphoma	'*BLL'/'LY'	" ### Bhagwat N, et al. Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms. Int J Hematol 2013;97(6):695-702 ### Vainchenker W, et al. JAK/STAT signaling in hematological malignancies. Oncogene 2013;32(21):2601-13 ### Scott LM The JAK2 exon 12 mutations: a comprehensive review. Am J Hematol 2011;86(8):668-76 ### Kearney L, et al. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood 2009;113(3):646-8 ### Yoda A, et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 2010;107(1):252-7"
JAK2	exon(s) 12 deletion	Myeloproliferative Neoplasm/Essential Thrombocythemia/Primary Myelofibrosis/Polycythemia Vera	'*MPN2'/'*ET'/'MY'/'PV'	" ### Bhagwat N, et al. Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms. Int J Hematol 2013;97(6):695-702 ### Vainchenker W, et al. JAK/STAT signaling in hematological malignancies. Oncogene 2013;32(21):2601-13 ### Scott LM The JAK2 exon 12 mutations: a comprehensive review. Am J Hematol 2011;86(8):668-76 ### Kearney L, et al. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood 2009;113(3):646-8 ### Yoda A, et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 2010;107(1):252-7"
JAK2	exon(s) 12 insertion	Myeloproliferative Neoplasm/Essential Thrombocythemia/Primary Myelofibrosis/Polycythemia Vera	'*MPN2'/'*ET'/'MY'/'PV'	" ### Bhagwat N, et al. Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms. Int J Hematol 2013;97(6):695-702 ### Vainchenker W, et al. JAK/STAT signaling in hematological malignancies. Oncogene 2013;32(21):2601-13 ### Scott LM The JAK2 exon 12 mutations: a comprehensive review. Am J Hematol 2011;86(8):668-76 ### Kearney L, et al. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood 2009;113(3):646-8 ### Yoda A, et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 2010;107(1):252-7"
JAK3	any mutation	T Cell Lymphoproliferative Disorder/NK Cell Lymphoproliferative Disorder/T Lymphoblastic Leukemia/Lymphoma	'*TLPD'/'*NCLD'/'*TLL'/'LY'	" ### Bergmann AK, et al. Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia. Genes Chromosomes Cancer 2014;53(4):309-16 ### Ross JA, et al. Inhibition of JAK3 with a novel, selective and orally active small molecule induces therapeutic response in T-cell malignancies. Leukemia 2014;28(4):941-4 ### Sakaguchi H, et al. Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nat Genet 2013;45(8):937-41 ### Bouchekioua A, et al. JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma. Leukemia 2014;28(2):338-48 ### Elliott NE, et al. FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma. Blood 2011;118(14):3911-21 ### Bains T, et al. Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia. Leukemia 2012;26(9):2144-6 ### Zhang J, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012;481(7380):157-63 ### Riera L, et al. Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects. Leuk Lymphoma 2011;52(9):1742-50 ### Blink M, et al. Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia. Leukemia 2011;25(8):1365-8 ### Hama A, et al. Molecular lesions in childhood and adult acute megakaryoblastic leukaemia. Br J Haematol 2012;156(3):316-25"
JAK3	V722I	Adenocarcinoma	'*AC2'	" ### Van Allen EM, et al. Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation. Cancer Immunol Res 2015;3(8):855-63"
KDM5C	any mutation	Clear Cell Renal Cell Carcinoma/Renal Cell Carcinoma	'RCCC'/'R'	" ### Randall JM, et al. Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art. Cancer Metastasis Rev 2014;33(4):1109-24 ### Hakimi AA, et al. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol 2013;63(5):848-54 ### Dalgliesh GL, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010;463(7279):360-3"
KDM6A	any mutation	Clear Cell Renal Cell Carcinoma/Renal Cell Carcinoma	'RCCC'/'R'	" ### Liao L, et al. The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer. Cancer Genet 2015;208(5):206-14 ### Randall JM, et al. Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art. Cancer Metastasis Rev 2014;33(4):1109-24 ### Nickerson ML, et al. Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer. Clin Cancer Res 2014;20(18):4935-48"
KIT	any mutation	Acute Myeloid Leukemia/Mast Cell Neoplasm	'AML'/'MAS'	" ### Kihara R, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia 2014;28(8):1586-95 ### Erben P, et al. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. Ann Hematol 2014;93(1):81-8 ### Kristensen T, et al. Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis. Am J Hematol 2014;89(5):493-8 ### Agarwal R, et al. KIT D816V mutation detection: a comparative study using peripheral blood, bone marrow aspirate and bone marrow trephine samples for detection of KIT mutations in patients with systemic mastocytosis. Leuk Lymphoma 2014;55(9):2202-3 ### Furitsu T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993;92(4):1736-44 ### Kanakura Y, et al. Activating mutations of the c-kit proto-oncogene in a human mast cell leukemia cell line. Leukemia 1994;8 Suppl 1():S18-22 ### Nagata H, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 1995;92(23):10560-4 ### Beghini A, et al. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation. Blood Cells Mol Dis 1998;24(2):262-70 ### Pullarkat VA, et al. Mast cell disease associated with acute myeloid leukemia: detection of a new c-kit mutation Asp816His. Am J Hematol 2000;65(4):307-9 ### Frost MJ, et al. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 2002;1(12):1115-24 ### Zermati Y, et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 2003;22(5):660-4 ### Pullarkat VA, et al. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations. Am J Hematol 2003;73(1):12-7 ### Akin C, et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004;103(8):3222-5 ### Zhang LY, et al. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. Leuk Res 2006;30(4):373-8 ### Garcia-Montero AC, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006;108(7):2366-72 ### Corless CL, et al. Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia. J Mol Diagn 2006;8(5):604-12 ### Manara E, et al. Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002/01 trial: screening and prognostic impact of c-KIT mutations. Leukemia 2014;28(5):1132-4 ### Su L, et al. NPM1, FLT3-ITD, CEBPA, and c-kit mutations in 312 Chinese patients with de novo acute myeloid leukemia. Hematology 2014;19(6):324-8 ### Kim HJ, et al. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement. Ann Hematol 2013;92(2):163-71 ### 23181448 (review mastocytosis) ### 20425418 (review AML)"
KIT	any mutation	Adenocarcinoma	'*AC2'	" ### Yorke R, et al. c-kit proto-oncogene product is rarely detected in colorectal adenocarcinoma. J Clin Oncol 2003;21(20):3885-6; discussion 3886-7 ### El-Serafi MM, et al. The prognostic value of c-Kit, K-ras codon 12, and p53 codon 72 mutations in Egyptian patients with stage II colorectal cancer. Cancer 2010;116(21):4954-64 ### Reed J, et al. Immunohistochemical staining for c-Kit (CD117) is a rare event in human colorectal carcinoma. Clin Colorectal Cancer 2002;2(2):119-22 ### Bellone G, et al. Aberrant activation of c-kit protects colon carcinoma cells against apoptosis and enhances their invasive potential. Cancer Res 2001;61(5):2200-6"
KIT	any mutation	Thymic Carcinoma	'THYM'	" ### Yoh K, et al. Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer 2008;62(3):316-20 ### Schirosi L, et al. Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. Ann Oncol 2012;23(9):2409-14 ### Str√∂bel P, et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med 2004;350(25):2625-6 ### Buti S, et al. Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma. J Clin Oncol 2011;29(33):e803-5"
KIT	E554K	Gastrointestinal Stromal Tumor	'GIST'	### http://www.cancer.gov/cancertopics/pdq/treatment/gist/HealthProfessiona l/page2
KIT	exon(s) 10 missense	Acute Myeloid Leukemia/Mast Cell Neoplasm	'AML'/'MAS'	" ### Kihara R, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia 2014;28(8):1586-95 ### Erben P, et al. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. Ann Hematol 2014;93(1):81-8 ### Kristensen T, et al. Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis. Am J Hematol 2014;89(5):493-8 ### Agarwal R, et al. KIT D816V mutation detection: a comparative study using peripheral blood, bone marrow aspirate and bone marrow trephine samples for detection of KIT mutations in patients with systemic mastocytosis. Leuk Lymphoma 2014;55(9):2202-3 ### Furitsu T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993;92(4):1736-44 ### Kanakura Y, et al. Activating mutations of the c-kit proto-oncogene in a human mast cell leukemia cell line. Leukemia 1994;8 Suppl 1():S18-22 ### Nagata H, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 1995;92(23):10560-4 ### Beghini A, et al. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation. Blood Cells Mol Dis 1998;24(2):262-70 ### Pullarkat VA, et al. Mast cell disease associated with acute myeloid leukemia: detection of a new c-kit mutation Asp816His. Am J Hematol 2000;65(4):307-9 ### Frost MJ, et al. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 2002;1(12):1115-24 ### Zermati Y, et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 2003;22(5):660-4 ### Pullarkat VA, et al. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations. Am J Hematol 2003;73(1):12-7 ### Akin C, et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004;103(8):3222-5 ### Zhang LY, et al. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. Leuk Res 2006;30(4):373-8 ### Garcia-Montero AC, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006;108(7):2366-72 ### Corless CL, et al. Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia. J Mol Diagn 2006;8(5):604-12 ### Manara E, et al. Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002/01 trial: screening and prognostic impact of c-KIT mutations. Leukemia 2014;28(5):1132-4 ### Su L, et al. NPM1, FLT3-ITD, CEBPA, and c-kit mutations in 312 Chinese patients with de novo acute myeloid leukemia. Hematology 2014;19(6):324-8 ### Kim HJ, et al. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement. Ann Hematol 2013;92(2):163-71 ### 23181448 (review mastocytosis) ### 20425418 (review AML)"
KIT	exon(s) 11 any	Acute Myeloid Leukemia/Mast Cell Neoplasm	'AML'/'MAS'	" ### Kihara R, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia 2014;28(8):1586-95 ### Erben P, et al. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. Ann Hematol 2014;93(1):81-8 ### Kristensen T, et al. Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis. Am J Hematol 2014;89(5):493-8 ### Agarwal R, et al. KIT D816V mutation detection: a comparative study using peripheral blood, bone marrow aspirate and bone marrow trephine samples for detection of KIT mutations in patients with systemic mastocytosis. Leuk Lymphoma 2014;55(9):2202-3 ### Furitsu T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993;92(4):1736-44 ### Kanakura Y, et al. Activating mutations of the c-kit proto-oncogene in a human mast cell leukemia cell line. Leukemia 1994;8 Suppl 1():S18-22 ### Nagata H, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 1995;92(23):10560-4 ### Beghini A, et al. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation. Blood Cells Mol Dis 1998;24(2):262-70 ### Pullarkat VA, et al. Mast cell disease associated with acute myeloid leukemia: detection of a new c-kit mutation Asp816His. Am J Hematol 2000;65(4):307-9 ### Frost MJ, et al. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 2002;1(12):1115-24 ### Zermati Y, et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 2003;22(5):660-4 ### Pullarkat VA, et al. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations. Am J Hematol 2003;73(1):12-7 ### Akin C, et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004;103(8):3222-5 ### Zhang LY, et al. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. Leuk Res 2006;30(4):373-8 ### Garcia-Montero AC, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006;108(7):2366-72 ### Corless CL, et al. Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia. J Mol Diagn 2006;8(5):604-12 ### Manara E, et al. Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002/01 trial: screening and prognostic impact of c-KIT mutations. Leukemia 2014;28(5):1132-4 ### Su L, et al. NPM1, FLT3-ITD, CEBPA, and c-kit mutations in 312 Chinese patients with de novo acute myeloid leukemia. Hematology 2014;19(6):324-8 ### Kim HJ, et al. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement. Ann Hematol 2013;92(2):163-71 ### 23181448 (review mastocytosis) ### 20425418 (review AML)"
KIT	exon(s) 11 any	Gastrointestinal Stromal Tumor	'GIST'	" ### Barnett CM, Corless CL, Heinrich MC. Gastrointestinal stromal tumors: molecular markers and genetic subtypes. Hematol Oncol Clin North Am. 2013 Oct;27(5):871-88. doi: 10.1016/j.hoc.2013.07.003. Epub 2013 Aug 26. Review. ### Gajiwala KS, et al. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1542-7. doi: 10.1073/pnas.0812413106. Epub 2009 Jan 21. PubMed PMID: 19164557; PubMed Central PMCID: PMC2635778. PubMed PMID: 24093165. ### Ashman LK, Griffith R. Therapeutic targeting of c-KIT in cancer. Expert Opin Investig Drugs. 2013 Jan;22(1):103-15. doi:10.1517/13543784.2013.740010. Epub 2012 Nov 6. Review. PubMed PMID: 23127174. ### Lindblad O, Kazi JU, R√∂nnstrand L, Sun J. PI3 kinase is indispensable for oncogenic transformation by the V560D mutant of c-Kit in a kinase-independent manner. Cell Mol Life Sci. 2015 Jun 4. [Epub ahead of print] PubMed PMID: 26040420."
KIT	exon(s) 17 any	Acute Myeloid Leukemia/Mast Cell Neoplasm	'AML'/'MAS'	" ### Kihara R, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia 2014;28(8):1586-95 ### Erben P, et al. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. Ann Hematol 2014;93(1):81-8 ### Kristensen T, et al. Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis. Am J Hematol 2014;89(5):493-8 ### Agarwal R, et al. KIT D816V mutation detection: a comparative study using peripheral blood, bone marrow aspirate and bone marrow trephine samples for detection of KIT mutations in patients with systemic mastocytosis. Leuk Lymphoma 2014;55(9):2202-3 ### Furitsu T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993;92(4):1736-44 ### Kanakura Y, et al. Activating mutations of the c-kit proto-oncogene in a human mast cell leukemia cell line. Leukemia 1994;8 Suppl 1():S18-22 ### Nagata H, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 1995;92(23):10560-4 ### Beghini A, et al. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation. Blood Cells Mol Dis 1998;24(2):262-70 ### Pullarkat VA, et al. Mast cell disease associated with acute myeloid leukemia: detection of a new c-kit mutation Asp816His. Am J Hematol 2000;65(4):307-9 ### Frost MJ, et al. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 2002;1(12):1115-24 ### Zermati Y, et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 2003;22(5):660-4 ### Pullarkat VA, et al. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations. Am J Hematol 2003;73(1):12-7 ### Akin C, et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004;103(8):3222-5 ### Zhang LY, et al. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. Leuk Res 2006;30(4):373-8 ### Garcia-Montero AC, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006;108(7):2366-72 ### Corless CL, et al. Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia. J Mol Diagn 2006;8(5):604-12 ### Manara E, et al. Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002/01 trial: screening and prognostic impact of c-KIT mutations. Leukemia 2014;28(5):1132-4 ### Su L, et al. NPM1, FLT3-ITD, CEBPA, and c-kit mutations in 312 Chinese patients with de novo acute myeloid leukemia. Hematology 2014;19(6):324-8 ### Kim HJ, et al. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement. Ann Hematol 2013;92(2):163-71 ### 23181448 (review mastocytosis) ### 20425418 (review AML)"
KIT	exon(s) 17 any	Melanoma	'*M'	" ### Curtin et al., Somatic activation of KIT in distinct subtypes of melanoma J Clin Oncol. 2006 Sep 10;24(26):4340-6. Epub 2006 Aug 14. ### Beadling et al., KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res. 2008 Nov 1;14(21):6821-8. doi: 10.1158/1078-0432.CCR-08-0575. ### Torres-Cabala et al. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol. 2009 Nov;22(11):1446-56. doi: 10.1038/modpathol.2009.116. ### Guo et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol. 2011 Jul 20;29(21):2904-9. doi: 10.1200/JCO.2010.33.9275."
KIT	exon(s) 8 missense	Acute Myeloid Leukemia/Mast Cell Neoplasm	'AML'/'MAS'	" ### Kihara R, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia 2014;28(8):1586-95 ### Erben P, et al. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. Ann Hematol 2014;93(1):81-8 ### Kristensen T, et al. Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis. Am J Hematol 2014;89(5):493-8 ### Agarwal R, et al. KIT D816V mutation detection: a comparative study using peripheral blood, bone marrow aspirate and bone marrow trephine samples for detection of KIT mutations in patients with systemic mastocytosis. Leuk Lymphoma 2014;55(9):2202-3 ### Furitsu T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993;92(4):1736-44 ### Kanakura Y, et al. Activating mutations of the c-kit proto-oncogene in a human mast cell leukemia cell line. Leukemia 1994;8 Suppl 1():S18-22 ### Nagata H, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 1995;92(23):10560-4 ### Beghini A, et al. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation. Blood Cells Mol Dis 1998;24(2):262-70 ### Pullarkat VA, et al. Mast cell disease associated with acute myeloid leukemia: detection of a new c-kit mutation Asp816His. Am J Hematol 2000;65(4):307-9 ### Frost MJ, et al. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 2002;1(12):1115-24 ### Zermati Y, et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 2003;22(5):660-4 ### Pullarkat VA, et al. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations. Am J Hematol 2003;73(1):12-7 ### Akin C, et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004;103(8):3222-5 ### Zhang LY, et al. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. Leuk Res 2006;30(4):373-8 ### Garcia-Montero AC, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006;108(7):2366-72 ### Corless CL, et al. Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia. J Mol Diagn 2006;8(5):604-12 ### Manara E, et al. Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002/01 trial: screening and prognostic impact of c-KIT mutations. Leukemia 2014;28(5):1132-4 ### Su L, et al. NPM1, FLT3-ITD, CEBPA, and c-kit mutations in 312 Chinese patients with de novo acute myeloid leukemia. Hematology 2014;19(6):324-8 ### Kim HJ, et al. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement. Ann Hematol 2013;92(2):163-71 ### 23181448 (review mastocytosis) ### 20425418 (review AML)"
KIT	exon(s) 9 insertion	Gastrointestinal Stromal Tumor	'GIST'	" ### Nishida T, et al. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines. Gastric Cancer 2016;19(1):3-14 ### K√ºnstlinger H, et al. Gastrointestinal stromal tumors with KIT exon 9 mutations: Update on genotype-phenotype correlation and validation of a high-resolution melting assay for mutational testing. Am J Surg Pathol 2013;37(11):1648-59 ### Reshetnyak AV, et al. Structural basis for KIT receptor tyrosine kinase inhibition by antibodies targeting the D4 membrane-proximal region. Proc Natl Acad Sci U S A 2013;110(44):17832-7"
KIT	exon(s) 9 missense	Acute Myeloid Leukemia/Mast Cell Neoplasm	'AML'/'MAS'	" ### Kihara R, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia 2014;28(8):1586-95 ### Erben P, et al. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. Ann Hematol 2014;93(1):81-8 ### Kristensen T, et al. Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis. Am J Hematol 2014;89(5):493-8 ### Agarwal R, et al. KIT D816V mutation detection: a comparative study using peripheral blood, bone marrow aspirate and bone marrow trephine samples for detection of KIT mutations in patients with systemic mastocytosis. Leuk Lymphoma 2014;55(9):2202-3 ### Furitsu T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993;92(4):1736-44 ### Kanakura Y, et al. Activating mutations of the c-kit proto-oncogene in a human mast cell leukemia cell line. Leukemia 1994;8 Suppl 1():S18-22 ### Nagata H, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 1995;92(23):10560-4 ### Beghini A, et al. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation. Blood Cells Mol Dis 1998;24(2):262-70 ### Pullarkat VA, et al. Mast cell disease associated with acute myeloid leukemia: detection of a new c-kit mutation Asp816His. Am J Hematol 2000;65(4):307-9 ### Frost MJ, et al. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 2002;1(12):1115-24 ### Zermati Y, et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 2003;22(5):660-4 ### Pullarkat VA, et al. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations. Am J Hematol 2003;73(1):12-7 ### Akin C, et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004;103(8):3222-5 ### Zhang LY, et al. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. Leuk Res 2006;30(4):373-8 ### Garcia-Montero AC, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006;108(7):2366-72 ### Corless CL, et al. Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia. J Mol Diagn 2006;8(5):604-12 ### Manara E, et al. Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002/01 trial: screening and prognostic impact of c-KIT mutations. Leukemia 2014;28(5):1132-4 ### Su L, et al. NPM1, FLT3-ITD, CEBPA, and c-kit mutations in 312 Chinese patients with de novo acute myeloid leukemia. Hematology 2014;19(6):324-8 ### Kim HJ, et al. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement. Ann Hematol 2013;92(2):163-71 ### 23181448 (review mastocytosis) ### 20425418 (review AML)"
KIT	M541L	Gastrointestinal Stromal Tumor/Other Tumor Type	'GIST'/'CANCER'	" ### Rossi S et al 2010 The American journal of surgical pathology;34(10):1480-91. Molecular and Clinicopathologic Characterization of Gastrointestinal Stromal Tumors (GISTs) of Small Size. ### AIurlo et al. Identification of kitM541L somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in lowdose imatinib response. 2014 Oncotarget, Vol. 5, No. 13 ### Dufresne et al..Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis. Br J Cancer. 2010 Aug 10;103(4):482-5.. ### Grabellus et al. The prevalence of the c-kit exon 10 variant, M541L, in aggressive fibromatosis does not differ from the general population. J Clin Pathol. 2011 Nov;64(11):1021-4."
KIT	V559A	Melanoma	'*M'	" ### Curtin JA, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24(26):4340-6 ### Beadling C, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008;14(21):6821-8 ### Guo J, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011;29(21):2904-9"
KIT	V560D	Gastrointestinal Stromal Tumor	'GIST'	" ### Barnett CM, Corless CL, Heinrich MC. Gastrointestinal stromal tumors: molecular markers and genetic subtypes. Hematol Oncol Clin North Am. 2013 Oct;27(5):871-88. doi: 10.1016/j.hoc.2013.07.003. Epub 2013 Aug 26. Review. ### Gajiwala KS, et al. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1542-7. doi: 10.1073/pnas.0812413106. Epub 2009 Jan 21. PubMed PMID: 19164557; PubMed Central PMCID: PMC2635778. PubMed PMID: 24093165. ### Ashman LK, Griffith R. Therapeutic targeting of c-KIT in cancer. Expert Opin Investig Drugs. 2013 Jan;22(1):103-15. doi:10.1517/13543784.2013.740010. Epub 2012 Nov 6. Review. PubMed PMID: 23127174. ### Lindblad O, Kazi JU, R√∂nnstrand L, Sun J. PI3 kinase is indispensable for oncogenic transformation by the V560D mutant of c-Kit in a kinase-independent manner. Cell Mol Life Sci. 2015 Jun 4. [Epub ahead of print] PubMed PMID: 26040420."
KLF2	any frameshift	Marginal Zone B Cell Lymphoma	'*MZBL'	" ### Clipson A, et al. KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype. Leukemia 2015;29(5):1177-85"
KLF2	any missense	Marginal Zone B Cell Lymphoma	'*MZBL'	" ### Clipson A, et al. KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype. Leukemia 2015;29(5):1177-85"
KLF2	any nonsense	Marginal Zone B Cell Lymphoma	'*MZBL'	" ### Clipson A, et al. KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype. Leukemia 2015;29(5):1177-85"
KRAS	A11V	Adenocarcinoma/Carcinoma	'*AC2'/'*CA'	" ### Eser et al.. Oncogenic KRAS signalling in pancreatic cancer. British Journal of Cancer (2014) 111, 817‚Ä?22"
KRAS	A11V	Adenocarcinoma	'*AC2'	" ### Lievre A, et al.. KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab. J Clin Oncol 2008;26:374‚Ä?. ### Amado RG et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 2008;26:1626-1634. ### Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLosMed. 2005;2:e17 ### Querings et al..Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens. PLoS Onev.6(5); 2011. ### Janakiraman M, et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 2010;70(14):5901-11 ### Douillard JY, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369(11):1023-34"
KRAS	A146P	Adenocarcinoma/Carcinoma	'*AC2'/'*CA'	" ### Eser et al.. Oncogenic KRAS signalling in pancreatic cancer. British Journal of Cancer (2014) 111, 817‚Ä?22"
KRAS	A146P	Adenocarcinoma	'*AC2'	" ### Lievre A, et al.. KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab. J Clin Oncol 2008;26:374‚Ä?. ### Amado RG et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 2008;26:1626-1634. ### Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLosMed. 2005;2:e17 ### Querings et al..Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens. PLoS Onev.6(5); 2011. ### Janakiraman M, et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 2010;70(14):5901-11 ### Douillard JY, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369(11):1023-34"
KRAS	A146T	Adenocarcinoma/Carcinoma	'*AC2'/'*CA'	" ### Eser et al.. Oncogenic KRAS signalling in pancreatic cancer. British Journal of Cancer (2014) 111, 817‚Ä?22"
KRAS	A146T	Adenocarcinoma	'*AC2'	" ### Lievre A, et al.. KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab. J Clin Oncol 2008;26:374‚Ä?. ### Amado RG et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 2008;26:1626-1634. ### Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLosMed. 2005;2:e17 ### Querings et al..Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens. PLoS Onev.6(5); 2011. ### Janakiraman M, et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 2010;70(14):5901-11 ### Douillard JY, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369(11):1023-34"
KRAS	A146V	Adenocarcinoma/Carcinoma	'*AC2'/'*CA'	" ### Eser et al.. Oncogenic KRAS signalling in pancreatic cancer. British Journal of Cancer (2014) 111, 817‚Ä?22"
KRAS	A146V	Adenocarcinoma	'*AC2'	" ### Lievre A, et al.. KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab. J Clin Oncol 2008;26:374‚Ä?. ### Amado RG et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 2008;26:1626-1634. ### Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLosMed. 2005;2:e17 ### Querings et al..Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens. PLoS Onev.6(5); 2011. ### Janakiraman M, et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 2010;70(14):5901-11 ### Douillard JY, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369(11):1023-34"
KRAS	any mutation	Acute Myeloid Leukemia/Chronic Myelomonocytic Leukemia/Myelodysplastic Syndrome/B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma	'AML'/'*CMML'/'MDS'/'*BLL'/'LY'/'*TLL'/'LY'	" ### Trinquand A, et al. Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. J Clin Oncol 2013;31(34):4333-42 ### Park MJ, et al. Frequency of KRAS mutations in adult Korean patients with acute myeloid leukemia. Int J Hematol 2013;98(5):549-57 ### Itzykson R, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 2013;31(19):2428-36 ### Tyner JW, et al. High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Blood 2009;113(8):1749-55 ### Liang DC, et al. K-Ras mutations and N-Ras mutations in childhood acute leukemias with or without mixed-lineage leukemia gene rearrangements. Cancer 2006;106(4):950-6 ### Al-Kali A, et al. Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. Am J Hematol 2013;88(5):365-9 ### Gritsman K, et al. Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110Œ±. J Clin Invest 2014;124(4):1794-809"
KRAS	any mutation	Adenocarcinoma/Carcinoma	'*AC2'/'*CA'	" ### Zheng H, et al. TP53, PIK3CA, FBXW7 and KRAS Mutations in Esophageal Cancer Identified by Targeted Sequencing. Cancer Genomics Proteomics 2016;13(3):231-238 ### Bettstetter M, et al. Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome. Hum Pathol 2013;44(5):829-36 ### Li√®vre A, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26(3):374-9 ### Amado RG, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26(10):1626-34 ### Janakiraman M, et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 2010;70(14):5901-11 ### Douillard JY, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369(11):1023-34"
KRAS	any mutation	Adenocarcinoma/Cholangiocarcinoma	'*AC2'/'CH'	" ### Maroni L, et al. The significance of genetics for cholangiocarcinoma development. Ann Transl Med 2013;1(3):28 ### Churi CR, et al. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One 2014;9(12):e115383 ### Simbolo M, et al. Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. Oncotarget 2014;5(9):2839-52 ### Putra J, et al. Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing. Exp Mol Pathol 2015;99(2):240-4"
KRAS	any mutation	Adenocarcinoma	'*AC2'	" ### Cho NY, et al. BRAF and KRAS mutations in prostatic adenocarcinoma. Int J Cancer 2006;119(8):1858-62 ### Salmaninejad A, et al. Molecular Characterization of KRAS, BRAF, and EGFR Genes in Cases with Prostatic Adenocarcinoma; Reporting Bioinformatics Description and Recurrent Mutations. Clin Lab 2015;61(7):749-59 ### Wang XS, et al. Characterization of KRAS rearrangements in metastatic prostate cancer. Cancer Discov 2011;1(1):35-43"
KRAS	any mutation	Adenocarcinoma	'*AC2'	" ### Dimmler, et al. EGFR, KRAS, BRAF-mutations and microsatellite instability are absent in goblet cell carcinoids of the appendix. Pathol Res Pract 2014;210:274‚Ä?. ### Zauber P, et al. Ki-ras gene mutations are invariably present in low-grade mucinous tumors of the vermiform appendix. Scan J Gastroenterol 2011;46:869‚Ä?4 ### Shetty S, et al. Kras mutations and p53 overexpression in psedomyxoma peritonei: association with phenotype and prognosis. J Surg Res 2013;180:97‚Ä?03."
KRAS	any mutation	Adenocarcinoma	'*AC2'	" ### Xiong J, et al. Endometrial carcinomas with significant mucinous differentiation associated with higher frequency of k-ras mutations: a morphologic and molecular correlation study. Int J Gynecol Cancer 2013;23(7):1231-6 ### Garcia-Dios DA, et al. High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma. Gynecol Oncol 2013;128(2):327-34 ### Okuda T, et al. Genetics of endometrial cancers. Obstet Gynecol Int 2010;2010():984013 ### Cancer Genome Atlas Research Network, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497(7447):67-73 ### Birkeland E, et al. KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer. Br J Cancer 2012;107(12):1997-2004"
KRAS	any mutation	Mucinous Cystic Neoplasms of Pancreas	'*MCNP'	" ### Eser S, et al. Oncogenic KRAS signalling in pancreatic cancer. Br J Cancer 2014;111(5):817-22 ### Paini M, et al. Molecular pathology of intraductal papillary mucinous neoplasms of the pancreas. World J Gastroenterol 2014;20(29):10008-23 ### Z'graggen K, et al. Prevalence of activating K-ras mutations in the evolutionary stages of neoplasia in intraductal papillary mucinous tumors of the pancreas. Ann Surg 1997;226(4):491-8; discussion 498-500 ### Wu J, et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med 2011;3(92):92ra66 ### Jang JY, et al. Increased K-ras mutation and expression of S100A4 and MUC2 protein in the malignant intraductal papillary mucinous tumor of the pancreas. J Hepatobiliary Pancreat Surg 2009;16(5):668-74"
KRAS	any mutation	Papillary Carcinoma/Follicular Carcinoma	'THP'/'THF'	" ### Nikiforov YE Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med 2011;135(5):569-77 ### Nikiforov YE Molecular analysis of thyroid tumors. Mod Pathol 2011;24 Suppl 2():S34-43 ### Radkay LA, et al. Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics. Cancer Cytopathol 2014;122(12):873-82"
KRAS	any mutation	Squamous Cell Carcinoma	'SCC'	" ### Pan Y, Wang R, Ye T, Li C, Hu H, Yu Y, Zhang Y, Wang L, Luo X, Li H, Li Y, Shen L, Sun Y, Chen H. Comprehensive analysis of oncogenic mutations in lung squamous cell carcinoma with minor glandular component. Chest. 2014 Mar 1;145(3):473-9. doi: 10.1378/chest.12-2679. PubMed PMID: 24158231. ### Rothschild SI. Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK. Cancers (Basel). 2015 May 26;7(2):930-49. doi: 10.3390/cancers7020816. Review. PMID: 26018876."
KRAS	any mutation	Urothelial Carcinoma	'UTH'	" ### Ouerhani S, et al. The prevalence and prognostic significance of KRAS mutation in bladder cancer, chronic myeloid leukemia and colorectal cancer. Mol Biol Rep 2013;40(6):4109-14 ### Kompier LC, et al. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One 2010;5(11):e13821 ### Ouerhani S, et al. The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer. Cancer Biomark 2011-2012;10(6):259-66"
KRAS	any mutation	Urothelial Carcinoma	'UTH'	" ### Sfakianos JP, et al. Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur Urol 2015;68(6):970-7 ### Ouerhani S, et al. The prevalence and prognostic significance of KRAS mutation in bladder cancer, chronic myeloid leukemia and colorectal cancer. Mol Biol Rep 2013;40(6):4109-14 ### Kompier LC, et al. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One 2010;5(11):e13821 ### Ouerhani S, et al. The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer. Cancer Biomark 2011-2012;10(6):259-66"
KRAS	" codon(s) 12, 13, 61, 117, 146 any"	Acute Myeloid Leukemia/Chronic Myelomonocytic Leukemia/Myelodysplastic Syndrome/B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma	'AML'/'*CMML'/'MDS'/'*BLL'/'LY'/'*TLL'/'LY'	" ### Trinquand A, et al. Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. J Clin Oncol 2013;31(34):4333-42 ### Park MJ, et al. Frequency of KRAS mutations in adult Korean patients with acute myeloid leukemia. Int J Hematol 2013;98(5):549-57 ### Itzykson R, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 2013;31(19):2428-36 ### Tyner JW, et al. High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Blood 2009;113(8):1749-55 ### Liang DC, et al. K-Ras mutations and N-Ras mutations in childhood acute leukemias with or without mixed-lineage leukemia gene rearrangements. Cancer 2006;106(4):950-6 ### Al-Kali A, et al. Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. Am J Hematol 2013;88(5):365-9 ### Gritsman K, et al. Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110Œ±. J Clin Invest 2014;124(4):1794-809"
KRAS	" codon(s) 12, 13, 61, 117, 146 any"	Adenocarcinoma/Carcinoma	'*AC2'/'*CA'	" ### Eser et al.. Oncogenic KRAS signalling in pancreatic cancer. British Journal of Cancer (2014) 111, 817‚Ä?22"
KRAS	" codon(s) 12, 13, 61, 117, 146 any"	Adenocarcinoma	'*AC2'	" ### Lievre A, et al.. KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab. J Clin Oncol 2008;26:374‚Ä?. ### Amado RG et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 2008;26:1626-1634. ### Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLosMed. 2005;2:e17 ### Querings et al..Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens. PLoS Onev.6(5); 2011. ### Janakiraman M, et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 2010;70(14):5901-11 ### Douillard JY, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369(11):1023-34"
KRAS	" codon(s) 12, 13, 61, 117, 146 any"	Adenocarcinoma/Pleomorphic Carcinoma	'*AC2'/'*PMC'	### Rothschild SI. Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK. Cancers (Basel). 2015 May 26;7(2):930-49. doi: 10.3390/cancers7020816. Review. PMID: 26018876.
KRAS	" codon(s) 12, 13, 61, 117, 146 any"	Squamous Cell Carcinoma	'SCC'	" ### Pan Y, Wang R, Ye T, Li C, Hu H, Yu Y, Zhang Y, Wang L, Luo X, Li H, Li Y, Shen L, Sun Y, Chen H. Comprehensive analysis of oncogenic mutations in lung squamous cell carcinoma with minor glandular component. Chest. 2014 Mar 1;145(3):473-9. doi: 10.1378/chest.12-2679. PubMed PMID: 24158231. ### Rothschild SI. Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK. Cancers (Basel). 2015 May 26;7(2):930-49. doi: 10.3390/cancers7020816. Review. PMID: 26018876."
KRAS	codon(s) 12 any	Adenocarcinoma	'*AC2'	" ### Javle M et al. Molecular Characterization of Gallbladder Cancer using Somatic Mutation Profiling. Human pathology. 2014;45(4):701-708. doi:10.1016/j.humpath.2013.11.001. ### Churi CR, et al. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One 2014;9(12):e115383"
KRAS	G12A	Adenocarcinoma/Carcinoma	'*AC2'/'*CA'	" ### Eser et al.. Oncogenic KRAS signalling in pancreatic cancer. British Journal of Cancer (2014) 111, 817‚Ä?22"
KRAS	G12A	Adenocarcinoma	'*AC2'	" ### Lievre A, et al.. KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab. J Clin Oncol 2008;26:374‚Ä?. ### Amado RG et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 2008;26:1626-1634. ### Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLosMed. 2005;2:e17 ### Querings et al..Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens. PLoS Onev.6(5); 2011. ### Janakiraman M, et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 2010;70(14):5901-11 ### Douillard JY, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369(11):1023-34"
KRAS	G12A	Adenocarcinoma/Pleomorphic Carcinoma	'*AC2'/'*PMC'	### Rothschild SI. Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK. Cancers (Basel). 2015 May 26;7(2):930-49. doi: 10.3390/cancers7020816. Review. PMID: 26018876.
KRAS	G12A	Adenocarcinoma	'*AC2'	" ### Tsang YT, et al. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma. J Pathol 2013;231(4):449-56 ### Grisham RN, et al. BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer 2013;119(3):548-54 ### Gershenson DM, et al. Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum. Br J Cancer 2015;113(9):1254-8"
KRAS	G12A	Squamous Cell Carcinoma	'SCC'	" ### Pan Y, Wang R, Ye T, Li C, Hu H, Yu Y, Zhang Y, Wang L, Luo X, Li H, Li Y, Shen L, Sun Y, Chen H. Comprehensive analysis of oncogenic mutations in lung squamous cell carcinoma with minor glandular component. Chest. 2014 Mar 1;145(3):473-9. doi: 10.1378/chest.12-2679. PubMed PMID: 24158231. ### Rothschild SI. Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK. Cancers (Basel). 2015 May 26;7(2):930-49. doi: 10.3390/cancers7020816. Review. PMID: 26018876."
KRAS	G12C	Adenocarcinoma/Carcinoma	'*AC2'/'*CA'	" ### Eser et al.. Oncogenic KRAS signalling in pancreatic cancer. British Journal of Cancer (2014) 111, 817‚Ä?22"
KRAS	G12C	Adenocarcinoma	'*AC2'	" ### Lievre A, et al.. KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab. J Clin Oncol 2008;26:374‚Ä?. ### Amado RG et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 2008;26:1626-1634. ### Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLosMed. 2005;2:e17 ### Querings et al..Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens. PLoS Onev.6(5); 2011. ### Janakiraman M, et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 2010;70(14):5901-11 ### Douillard JY, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369(11):1023-34"
KRAS	G12C	Adenocarcinoma/Pleomorphic Carcinoma	'*AC2'/'*PMC'	### Rothschild SI. Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK. Cancers (Basel). 2015 May 26;7(2):930-49. doi: 10.3390/cancers7020816. Review. PMID: 26018876.
KRAS	G12C	Squamous Cell Carcinoma	'SCC'	" ### Pan Y, Wang R, Ye T, Li C, Hu H, Yu Y, Zhang Y, Wang L, Luo X, Li H, Li Y, Shen L, Sun Y, Chen H. Comprehensive analysis of oncogenic mutations in lung squamous cell carcinoma with minor glandular component. Chest. 2014 Mar 1;145(3):473-9. doi: 10.1378/chest.12-2679. PubMed PMID: 24158231. ### Rothschild SI. Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK. Cancers (Basel). 2015 May 26;7(2):930-49. doi: 10.3390/cancers7020816. Review. PMID: 26018876."
KRAS	G12D	Adenocarcinoma/Carcinoma	'*AC2'/'*CA'	" ### Eser et al.. Oncogenic KRAS signalling in pancreatic cancer. British Journal of Cancer (2014) 111, 817‚Ä?22"
KRAS	G12D	Adenocarcinoma	'*AC2'	" ### Javle M et al. Molecular Characterization of Gallbladder Cancer using Somatic Mutation Profiling. Human pathology. 2014;45(4):701-708. doi:10.1016/j.humpath.2013.11.001. ### Churi CR, et al. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One 2014;9(12):e115383"
KRAS	G12D	Adenocarcinoma	'*AC2'	" ### Lievre A, et al.. KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab. J Clin Oncol 2008;26:374‚Ä?. ### Amado RG et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 2008;26:1626-1634. ### Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLosMed. 2005;2:e17 ### Querings et al..Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens. PLoS Onev.6(5); 2011. ### Janakiraman M, et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 2010;70(14):5901-11 ### Douillard JY, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369(11):1023-34"
KRAS	G12D	Adenocarcinoma/Pleomorphic Carcinoma	'*AC2'/'*PMC'	### Rothschild SI. Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK. Cancers (Basel). 2015 May 26;7(2):930-49. doi: 10.3390/cancers7020816. Review. PMID: 26018876.
KRAS	G12D	Adenocarcinoma	'*AC2'	" ### Tsang YT, et al. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma. J Pathol 2013;231(4):449-56 ### Grisham RN, et al. BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer 2013;119(3):548-54 ### Gershenson DM, et al. Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum. Br J Cancer 2015;113(9):1254-8"
KRAS	G12D	Squamous Cell Carcinoma	'SCC'	" ### Pan Y, Wang R, Ye T, Li C, Hu H, Yu Y, Zhang Y, Wang L, Luo X, Li H, Li Y, Shen L, Sun Y, Chen H. Comprehensive analysis of oncogenic mutations in lung squamous cell carcinoma with minor glandular component. Chest. 2014 Mar 1;145(3):473-9. doi: 10.1378/chest.12-2679. PubMed PMID: 24158231. ### Rothschild SI. Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK. Cancers (Basel). 2015 May 26;7(2):930-49. doi: 10.3390/cancers7020816. Review. PMID: 26018876."
KRAS	G12R	Adenocarcinoma/Carcinoma	'*AC2'/'*CA'	" ### Eser et al.. Oncogenic KRAS signalling in pancreatic cancer. British Journal of Cancer (2014) 111, 817‚Ä?22"
KRAS	G12R	Adenocarcinoma	'*AC2'	" ### Lievre A, et al.. KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab. J Clin Oncol 2008;26:374‚Ä?. ### Amado RG et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 2008;26:1626-1634. ### Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLosMed. 2005;2:e17 ### Querings et al..Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens. PLoS Onev.6(5); 2011. ### Janakiraman M, et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 2010;70(14):5901-11 ### Douillard JY, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369(11):1023-34"
KRAS	G12R	Adenocarcinoma/Pleomorphic Carcinoma	'*AC2'/'*PMC'	### Rothschild SI. Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK. Cancers (Basel). 2015 May 26;7(2):930-49. doi: 10.3390/cancers7020816. Review. PMID: 26018876.
KRAS	G12R	Adenocarcinoma	'*AC2'	" ### Tsang YT, et al. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma. J Pathol 2013;231(4):449-56 ### Grisham RN, et al. BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer 2013;119(3):548-54 ### Gershenson DM, et al. Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum. Br J Cancer 2015;113(9):1254-8"
KRAS	G12R	Squamous Cell Carcinoma	'SCC'	" ### Pan Y, Wang R, Ye T, Li C, Hu H, Yu Y, Zhang Y, Wang L, Luo X, Li H, Li Y, Shen L, Sun Y, Chen H. Comprehensive analysis of oncogenic mutations in lung squamous cell carcinoma with minor glandular component. Chest. 2014 Mar 1;145(3):473-9. doi: 10.1378/chest.12-2679. PubMed PMID: 24158231. ### Rothschild SI. Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK. Cancers (Basel). 2015 May 26;7(2):930-49. doi: 10.3390/cancers7020816. Review. PMID: 26018876."
KRAS	G12S	Adenocarcinoma/Carcinoma	'*AC2'/'*CA'	" ### Eser et al.. Oncogenic KRAS signalling in pancreatic cancer. British Journal of Cancer (2014) 111, 817‚Ä?22"
KRAS	G12S	Adenocarcinoma	'*AC2'	" ### Lievre A, et al.. KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab. J Clin Oncol 2008;26:374‚Ä?. ### Amado RG et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 2008;26:1626-1634. ### Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLosMed. 2005;2:e17 ### Querings et al..Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens. PLoS Onev.6(5); 2011. ### Janakiraman M, et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 2010;70(14):5901-11 ### Douillard JY, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369(11):1023-34"
KRAS	G12S	Adenocarcinoma/Pleomorphic Carcinoma	'*AC2'/'*PMC'	### Rothschild SI. Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK. Cancers (Basel). 2015 May 26;7(2):930-49. doi: 10.3390/cancers7020816. Review. PMID: 26018876.
KRAS	G12S	Adenocarcinoma	'*AC2'	" ### Tsang YT, et al. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma. J Pathol 2013;231(4):449-56 ### Grisham RN, et al. BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer 2013;119(3):548-54 ### Gershenson DM, et al. Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum. Br J Cancer 2015;113(9):1254-8"
KRAS	G12S	Squamous Cell Carcinoma	'SCC'	" ### Pan Y, Wang R, Ye T, Li C, Hu H, Yu Y, Zhang Y, Wang L, Luo X, Li H, Li Y, Shen L, Sun Y, Chen H. Comprehensive analysis of oncogenic mutations in lung squamous cell carcinoma with minor glandular component. Chest. 2014 Mar 1;145(3):473-9. doi: 10.1378/chest.12-2679. PubMed PMID: 24158231. ### Rothschild SI. Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK. Cancers (Basel). 2015 May 26;7(2):930-49. doi: 10.3390/cancers7020816. Review. PMID: 26018876."
KRAS	G12V	Adenocarcinoma/Carcinoma	'*AC2'/'*CA'	" ### Eser et al.. Oncogenic KRAS signalling in pancreatic cancer. British Journal of Cancer (2014) 111, 817‚Ä?22"
KRAS	G12V	Adenocarcinoma	'*AC2'	" ### Lievre A, et al.. KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab. J Clin Oncol 2008;26:374‚Ä?. ### Amado RG et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 2008;26:1626-1634. ### Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLosMed. 2005;2:e17 ### Querings et al..Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens. PLoS Onev.6(5); 2011. ### Janakiraman M, et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 2010;70(14):5901-11 ### Douillard JY, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369(11):1023-34"
KRAS	G12V	Adenocarcinoma/Pleomorphic Carcinoma	'*AC2'/'*PMC'	### Rothschild SI. Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK. Cancers (Basel). 2015 May 26;7(2):930-49. doi: 10.3390/cancers7020816. Review. PMID: 26018876.
KRAS	G12V	Adenocarcinoma	'*AC2'	" ### Tsang YT, et al. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma. J Pathol 2013;231(4):449-56 ### Grisham RN, et al. BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer 2013;119(3):548-54 ### Gershenson DM, et al. Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum. Br J Cancer 2015;113(9):1254-8"
KRAS	G12V	Squamous Cell Carcinoma	'SCC'	" ### Pan Y, Wang R, Ye T, Li C, Hu H, Yu Y, Zhang Y, Wang L, Luo X, Li H, Li Y, Shen L, Sun Y, Chen H. Comprehensive analysis of oncogenic mutations in lung squamous cell carcinoma with minor glandular component. Chest. 2014 Mar 1;145(3):473-9. doi: 10.1378/chest.12-2679. PubMed PMID: 24158231. ### Rothschild SI. Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK. Cancers (Basel). 2015 May 26;7(2):930-49. doi: 10.3390/cancers7020816. Review. PMID: 26018876."
KRAS	G13C	Adenocarcinoma/Carcinoma	'*AC2'/'*CA'	" ### Eser et al.. Oncogenic KRAS signalling in pancreatic cancer. British Journal of Cancer (2014) 111, 817‚Ä?22"
KRAS	G13C	Adenocarcinoma	'*AC2'	" ### Lievre A, et al.. KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab. J Clin Oncol 2008;26:374‚Ä?. ### Amado RG et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 2008;26:1626-1634. ### Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLosMed. 2005;2:e17 ### Querings et al..Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens. PLoS Onev.6(5); 2011. ### Janakiraman M, et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 2010;70(14):5901-11 ### Douillard JY, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369(11):1023-34"
KRAS	G13C	Adenocarcinoma/Pleomorphic Carcinoma	'*AC2'/'*PMC'	### Rothschild SI. Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK. Cancers (Basel). 2015 May 26;7(2):930-49. doi: 10.3390/cancers7020816. Review. PMID: 26018876.
KRAS	G13C	Squamous Cell Carcinoma	'SCC'	" ### Pan Y, Wang R, Ye T, Li C, Hu H, Yu Y, Zhang Y, Wang L, Luo X, Li H, Li Y, Shen L, Sun Y, Chen H. Comprehensive analysis of oncogenic mutations in lung squamous cell carcinoma with minor glandular component. Chest. 2014 Mar 1;145(3):473-9. doi: 10.1378/chest.12-2679. PubMed PMID: 24158231. ### Rothschild SI. Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK. Cancers (Basel). 2015 May 26;7(2):930-49. doi: 10.3390/cancers7020816. Review. PMID: 26018876."
KRAS	G13R	Adenocarcinoma/Carcinoma	'*AC2'/'*CA'	" ### Eser et al.. Oncogenic KRAS signalling in pancreatic cancer. British Journal of Cancer (2014) 111, 817‚Ä?22"
KRAS	G13R	Adenocarcinoma	'*AC2'	" ### Lievre A, et al.. KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab. J Clin Oncol 2008;26:374‚Ä?. ### Amado RG et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 2008;26:1626-1634. ### Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLosMed. 2005;2:e17 ### Querings et al..Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens. PLoS Onev.6(5); 2011. ### Janakiraman M, et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 2010;70(14):5901-11 ### Douillard JY, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369(11):1023-34"
KRAS	G13R	Adenocarcinoma/Pleomorphic Carcinoma	'*AC2'/'*PMC'	### Rothschild SI. Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK. Cancers (Basel). 2015 May 26;7(2):930-49. doi: 10.3390/cancers7020816. Review. PMID: 26018876.
KRAS	G13R	Squamous Cell Carcinoma	'SCC'	" ### Pan Y, Wang R, Ye T, Li C, Hu H, Yu Y, Zhang Y, Wang L, Luo X, Li H, Li Y, Shen L, Sun Y, Chen H. Comprehensive analysis of oncogenic mutations in lung squamous cell carcinoma with minor glandular component. Chest. 2014 Mar 1;145(3):473-9. doi: 10.1378/chest.12-2679. PubMed PMID: 24158231. ### Rothschild SI. Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK. Cancers (Basel). 2015 May 26;7(2):930-49. doi: 10.3390/cancers7020816. Review. PMID: 26018876."
KRAS	G13S	Adenocarcinoma/Carcinoma	'*AC2'/'*CA'	" ### Eser et al.. Oncogenic KRAS signalling in pancreatic cancer. British Journal of Cancer (2014) 111, 817‚Ä?22"
KRAS	G13S	Adenocarcinoma	'*AC2'	" ### Lievre A, et al.. KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab. J Clin Oncol 2008;26:374‚Ä?. ### Amado RG et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 2008;26:1626-1634. ### Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLosMed. 2005;2:e17 ### Querings et al..Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens. PLoS Onev.6(5); 2011. ### Janakiraman M, et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 2010;70(14):5901-11 ### Douillard JY, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369(11):1023-34"
KRAS	G13S	Adenocarcinoma/Pleomorphic Carcinoma	'*AC2'/'*PMC'	### Rothschild SI. Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK. Cancers (Basel). 2015 May 26;7(2):930-49. doi: 10.3390/cancers7020816. Review. PMID: 26018876.
KRAS	G13S	Squamous Cell Carcinoma	'SCC'	" ### Pan Y, Wang R, Ye T, Li C, Hu H, Yu Y, Zhang Y, Wang L, Luo X, Li H, Li Y, Shen L, Sun Y, Chen H. Comprehensive analysis of oncogenic mutations in lung squamous cell carcinoma with minor glandular component. Chest. 2014 Mar 1;145(3):473-9. doi: 10.1378/chest.12-2679. PubMed PMID: 24158231. ### Rothschild SI. Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK. Cancers (Basel). 2015 May 26;7(2):930-49. doi: 10.3390/cancers7020816. Review. PMID: 26018876."
KRAS	Q22K	Adenocarcinoma	'*AC2'	" ### Rothschild SI Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK. Cancers (Basel) 2015;7(2):930-49 ### Azzato EM, et al. Rare Complex Mutational Profile in an ALK Inhibitor-resistant Non-small Cell Lung Cancer. Anticancer Res 2015;35(5):3007-12 ### Metro G, et al. Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: a case report. Ecancermedicalscience 2015;9():559 ### Zenker M, et al. Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations. J Med Genet 2007;44(2):131-5"
KRAS	Q61H	Adenocarcinoma/Carcinoma	'*AC2'/'*CA'	" ### Eser et al.. Oncogenic KRAS signalling in pancreatic cancer. British Journal of Cancer (2014) 111, 817‚Ä?22"
KRAS	Q61H	Adenocarcinoma	'*AC2'	" ### Lievre A, et al.. KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab. J Clin Oncol 2008;26:374‚Ä?. ### Amado RG et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 2008;26:1626-1634. ### Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLosMed. 2005;2:e17 ### Querings et al..Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens. PLoS Onev.6(5); 2011. ### Janakiraman M, et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 2010;70(14):5901-11 ### Douillard JY, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369(11):1023-34"
KRAS	Q61H	Adenocarcinoma/Pleomorphic Carcinoma	'*AC2'/'*PMC'	### Rothschild SI. Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK. Cancers (Basel). 2015 May 26;7(2):930-49. doi: 10.3390/cancers7020816. Review. PMID: 26018876.
KRAS	Q61H	Squamous Cell Carcinoma	'SCC'	" ### Pan Y, Wang R, Ye T, Li C, Hu H, Yu Y, Zhang Y, Wang L, Luo X, Li H, Li Y, Shen L, Sun Y, Chen H. Comprehensive analysis of oncogenic mutations in lung squamous cell carcinoma with minor glandular component. Chest. 2014 Mar 1;145(3):473-9. doi: 10.1378/chest.12-2679. PubMed PMID: 24158231. ### Rothschild SI. Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK. Cancers (Basel). 2015 May 26;7(2):930-49. doi: 10.3390/cancers7020816. Review. PMID: 26018876."
KRAS	Q61K	Adenocarcinoma/Carcinoma	'*AC2'/'*CA'	" ### Eser et al.. Oncogenic KRAS signalling in pancreatic cancer. British Journal of Cancer (2014) 111, 817‚Ä?22"
KRAS	Q61K	Adenocarcinoma	'*AC2'	" ### Lievre A, et al.. KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab. J Clin Oncol 2008;26:374‚Ä?. ### Amado RG et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 2008;26:1626-1634. ### Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLosMed. 2005;2:e17 ### Querings et al..Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens. PLoS Onev.6(5); 2011. ### Janakiraman M, et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 2010;70(14):5901-11 ### Douillard JY, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369(11):1023-34"
KRAS	Q61K	Adenocarcinoma/Pleomorphic Carcinoma	'*AC2'/'*PMC'	### Rothschild SI. Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK. Cancers (Basel). 2015 May 26;7(2):930-49. doi: 10.3390/cancers7020816. Review. PMID: 26018876.
KRAS	Q61K	Squamous Cell Carcinoma	'SCC'	" ### Pan Y, Wang R, Ye T, Li C, Hu H, Yu Y, Zhang Y, Wang L, Luo X, Li H, Li Y, Shen L, Sun Y, Chen H. Comprehensive analysis of oncogenic mutations in lung squamous cell carcinoma with minor glandular component. Chest. 2014 Mar 1;145(3):473-9. doi: 10.1378/chest.12-2679. PubMed PMID: 24158231. ### Rothschild SI. Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK. Cancers (Basel). 2015 May 26;7(2):930-49. doi: 10.3390/cancers7020816. Review. PMID: 26018876."
KRAS	Q61L	Adenocarcinoma/Carcinoma	'*AC2'/'*CA'	" ### Eser et al.. Oncogenic KRAS signalling in pancreatic cancer. British Journal of Cancer (2014) 111, 817‚Ä?22"
KRAS	Q61L	Adenocarcinoma	'*AC2'	" ### Lievre A, et al.. KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab. J Clin Oncol 2008;26:374‚Ä?. ### Amado RG et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 2008;26:1626-1634. ### Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLosMed. 2005;2:e17 ### Querings et al..Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens. PLoS Onev.6(5); 2011. ### Janakiraman M, et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 2010;70(14):5901-11 ### Douillard JY, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369(11):1023-34"
KRAS	Q61L	Adenocarcinoma/Pleomorphic Carcinoma	'*AC2'/'*PMC'	### Rothschild SI. Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK. Cancers (Basel). 2015 May 26;7(2):930-49. doi: 10.3390/cancers7020816. Review. PMID: 26018876.
KRAS	Q61L	Squamous Cell Carcinoma	'SCC'	" ### Pan Y, Wang R, Ye T, Li C, Hu H, Yu Y, Zhang Y, Wang L, Luo X, Li H, Li Y, Shen L, Sun Y, Chen H. Comprehensive analysis of oncogenic mutations in lung squamous cell carcinoma with minor glandular component. Chest. 2014 Mar 1;145(3):473-9. doi: 10.1378/chest.12-2679. PubMed PMID: 24158231. ### Rothschild SI. Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK. Cancers (Basel). 2015 May 26;7(2):930-49. doi: 10.3390/cancers7020816. Review. PMID: 26018876."
KRAS	Q61R	Adenocarcinoma/Carcinoma	'*AC2'/'*CA'	" ### Eser et al.. Oncogenic KRAS signalling in pancreatic cancer. British Journal of Cancer (2014) 111, 817‚Ä?22"
KRAS	Q61R	Adenocarcinoma	'*AC2'	" ### Lievre A, et al.. KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab. J Clin Oncol 2008;26:374‚Ä?. ### Amado RG et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 2008;26:1626-1634. ### Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLosMed. 2005;2:e17 ### Querings et al..Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens. PLoS Onev.6(5); 2011. ### Janakiraman M, et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 2010;70(14):5901-11 ### Douillard JY, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369(11):1023-34"
KRAS	Q61R	Adenocarcinoma/Pleomorphic Carcinoma	'*AC2'/'*PMC'	### Rothschild SI. Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK. Cancers (Basel). 2015 May 26;7(2):930-49. doi: 10.3390/cancers7020816. Review. PMID: 26018876.
KRAS	Q61R	Squamous Cell Carcinoma	'SCC'	" ### Pan Y, Wang R, Ye T, Li C, Hu H, Yu Y, Zhang Y, Wang L, Luo X, Li H, Li Y, Shen L, Sun Y, Chen H. Comprehensive analysis of oncogenic mutations in lung squamous cell carcinoma with minor glandular component. Chest. 2014 Mar 1;145(3):473-9. doi: 10.1378/chest.12-2679. PubMed PMID: 24158231. ### Rothschild SI. Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK. Cancers (Basel). 2015 May 26;7(2):930-49. doi: 10.3390/cancers7020816. Review. PMID: 26018876."
KRAS	V14I	Adenocarcinoma	'*AC2'	" ### Li√®vre A, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26(3):374-9 ### Amado RG, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26(10):1626-34 ### Alvi MA, et al. Comprehensive molecular pathology analysis of small bowel adenocarcinoma reveals novel targets with potential for clinical utility. Oncotarget 2015;6(25):20863-74 ### Vaughn CP, et al. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer 2011;50(5):307-12 ### Hern√°ndez-Porras I, et al. K-Ras(V14I) -induced Noonan syndrome predisposes to tumour development in mice. J Pathol 2016;239(2):206-17 ### Gremer L, et al. Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders. Hum Mutat 2011;32(1):33-43 ### Tyner JW, et al. High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Blood 2009;113(8):1749-55"
LUC7L2	any mutation	Acute Myeloid Leukemia/Myelodysplastic Syndrome	'AML'/'MDS'	" ### Haferlach T, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014;28(2):241-7 ### Singh H, et al. Putative RNA-splicing gene LUC7L2 on 7q34 represents a candidate gene in pathogenesis of myeloid malignancies. Blood Cancer J 2013;3():e117 ### Makishima H, et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood 2012;119(14):3203-10"
MAP2K1	any mutation	Hairy Cell Leukemia	'HCL'	" ### Waterfall JJ, et al. High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias. Nat Genet 2014;46(1):8-10"
MDM2	copy number gain	Urothelial Carcinoma	'UTH'	" ### Bill KL, et al. SAR405838: A novel and potent inhibitor of the MDM2:p53 axis for the treatment of dedifferentiated liposarcoma. Clin Cancer Res 2015;(): ### Binh MB, et al. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol 2005;29(10):1340-7 ### Weaver J, et al. Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms. Mod Pathol 2008;21(8):943-9 ### Jour G, et al. Prognostic relevance of F√©d√©ration Nationale des Centres de Lutte Contre le Cancer grade and MDM2 amplification levels in dedifferentiated liposarcoma: a study of 50 cases. Mod Pathol 2015;28(1):37-47 ### Italiano A, et al. Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas. Clin Cancer Res 2009;15(18):5696-703 ### Lee S, et al. CDK4 amplification predicts recurrence of well-differentiated liposarcoma of the abdomen. PLoS One 2014;9(8):e99452 ### Simon R, et al. Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer. Oncogene 2002;21(16):2476-83 ### Chekaluk Y, et al. Identification of nine genomic regions of amplification in urothelial carcinoma, correlation with stage, and potential prognostic and therapeutic value. PLoS One 2013;8(4):e60927"
MEF2B	any mutation	Mantle Cell Lymphoma/Diffuse Large B Cell Lymphoma/Follicular Lymphoma	'MCL'/'DLBCL'/'FL'	" ### Be√† S, et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci U S A 2013;110(45):18250-5 ### Lohr JG, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A 2012;109(10):3879-84 ### Morin RD, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011;476(7360):298-303"
MET	E168D	Adenocarcinoma/Carcinoma	'*AC2'/'*CA'	" ### Kumar A, et al. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med 2016;22(4):369-78 ### Barbieri CE, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012;44(6):685-9 ### Varkaris A, et al. The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin Investig Drugs 2011;20(12):1677-84"
MET	E168D	Adenocarcinoma	'*AC2'	" ### Krishnaswamy et al Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer.Clin Cancer Res 2009;15(18) September 15, 2009"
MET	E168D	Adenocarcinoma	'*AC2'	" ### Krishnaswamy et al Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer.Clin Cancer Res 2009;15(18) September 15, 2009 ### Monica Kong-Beltran et al . Somatic Mutations Lead to an Oncogenic Deletion of MET in Lung Cancer. Cancer Res 2006; 66(1): 283-9 ### Detection and Therapeutic Implications of c-Met Mutations in Small Cell Lung Cancer and Neuroendocrine Tumors. Voortman J et al 2012 Current pharmaceutical design ### Neklason et al. BMC Cancer 2011, 11:424 Activating mutation in MET oncogene in familial colorectal cancer ### https://pct.mdanderson.org/genes/alterations?type=Germline&geneName=MET"
MET	E168D	Melanoma	'*M'	" ### Krishnaswamy S, et al. Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res 2009;15(18):5714-23 ### Hodis E, et al. A landscape of driver mutations in melanoma. Cell 2012;150(2):251-63 ### Berger MF, et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 2012;485(7399):502-6"
MET	E168D	Papillary Carcinoma	'THP'	" ### Costa V, et al. New somatic mutations and WNK1-B4GALNT3 gene fusion in papillary thyroid carcinoma. Oncotarget 2015;6(13):11242-11251 ### Krishnaswamy S, et al. Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res 2009;15(18):5714-5723"
MET	H1112Y	Adenocarcinoma	'*AC2'	" ### Krishnaswamy et al Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer.Clin Cancer Res 2009;15(18) September 15, 2009 ### Monica Kong-Beltran et al . Somatic Mutations Lead to an Oncogenic Deletion of MET in Lung Cancer. Cancer Res 2006; 66(1): 283-9 ### Detection and Therapeutic Implications of c-Met Mutations in Small Cell Lung Cancer and Neuroendocrine Tumors. Voortman J et al 2012 Current pharmaceutical design ### Neklason et al. BMC Cancer 2011, 11:424 Activating mutation in MET oncogene in familial colorectal cancer ### https://pct.mdanderson.org/genes/alterations?type=Germline&geneName=MET"
MET	L1195V	Papillary Renal Cell Carcinoma	'RPC'	" ### Neklason DW, et al. Activating mutation in MET oncogene in familial colorectal cancer. BMC Cancer 2011;11():424 ### Cancer Genome Atlas Research Network, et al. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med 2016;374(2):135-45"
MET	L1213F	Papillary Renal Cell Carcinoma	'RPC'	" ### Neklason DW, et al. Activating mutation in MET oncogene in familial colorectal cancer. BMC Cancer 2011;11():424 ### Cancer Genome Atlas Research Network, et al. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med 2016;374(2):135-45"
MET	M1131T	Papillary Renal Cell Carcinoma	'RPC'	" ### Neklason DW, et al. Activating mutation in MET oncogene in familial colorectal cancer. BMC Cancer 2011;11():424 ### Cancer Genome Atlas Research Network, et al. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med 2016;374(2):135-45"
MET	M1149T	Papillary Renal Cell Carcinoma	'RPC'	" ### Neklason DW, et al. Activating mutation in MET oncogene in familial colorectal cancer. BMC Cancer 2011;11():424 ### Cancer Genome Atlas Research Network, et al. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med 2016;374(2):135-45"
MET	V1188L	Papillary Renal Cell Carcinoma	'RPC'	" ### Neklason DW, et al. Activating mutation in MET oncogene in familial colorectal cancer. BMC Cancer 2011;11():424 ### Cancer Genome Atlas Research Network, et al. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med 2016;374(2):135-45"
MET	V12201	Papillary Renal Cell Carcinoma	'RPC'	" ### Neklason DW, et al. Activating mutation in MET oncogene in familial colorectal cancer. BMC Cancer 2011;11():424 ### Cancer Genome Atlas Research Network, et al. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med 2016;374(2):135-45"
MLH1	V384D	Adenocarcinoma/Carcinoma	'*AC2'/'*CA'	" ### Chiu CH, et al. MLH1 V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients with EGFR L858R-positive lung adenocarcinoma. Oncotarget 2015;6(10):8407-17 ### Ohsawa T, et al. Colorectal cancer susceptibility associated with the hMLH1 V384D variant. Mol Med Rep 2009;2(6):887-91"
MLH1	V384D	Papillary Carcinoma	'THP'	" ### Kunstman JW, et al. Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. Hum Mol Genet 2015;24(8):2318-29 ### Chiu CH, et al. MLH1 V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients with EGFR L858R-positive lung adenocarcinoma. Oncotarget 2015;6(10):8407-17 ### Ohsawa T, et al. Colorectal cancer susceptibility associated with the hMLH1 V384D variant. Mol Med Rep 2009;2(6):887-91"
MPL	codon(s) 515 missense	Myeloproliferative Neoplasm/Essential Thrombocythemia/Primary Myelofibrosis	'*MPN2'/'*ET'/'MY'	" ### Pikman Y, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3(7):e270 ### Ding J, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 2004;103(11):4198-200 ### Pardanani AD, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006;108(10):3472-6 ### Hussein K, et al. MPLW515L mutation in acute megakaryoblastic leukaemia. Leukemia 2009;23(5):852-5"
MPL	W515K	Myeloproliferative Neoplasm/Essential Thrombocythemia/Primary Myelofibrosis	'*MPN2'/'*ET'/'MY'	" ### Pikman Y, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3(7):e270 ### Ding J, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 2004;103(11):4198-200 ### Pardanani AD, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006;108(10):3472-6 ### Hussein K, et al. MPLW515L mutation in acute megakaryoblastic leukaemia. Leukemia 2009;23(5):852-5"
MPL	W515L	Myeloproliferative Neoplasm/Essential Thrombocythemia/Primary Myelofibrosis	'*MPN2'/'*ET'/'MY'	" ### Pikman Y, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3(7):e270 ### Ding J, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 2004;103(11):4198-200 ### Pardanani AD, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006;108(10):3472-6 ### Hussein K, et al. MPLW515L mutation in acute megakaryoblastic leukaemia. Leukemia 2009;23(5):852-5"
MYD88	any mutation	Lymphoplasmacytic Lymphoma	'LPL'	" ### Ngo VN, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011;470(7332):115-9 ### Treon SP, et al. MYD88 L265P somatic mutation in Waldenstr√∂m's macroglobulinemia. N Engl J Med 2012;367(9):826-33 ### Puente XS, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011;475(7354):101-5 ### Willenbacher W, et al. Improved accuracy of discrimination between IgM multiple myeloma and Waldenstr√∂m macroglobulinaemia by testing for MYD88 L265P mutations. Br J Haematol 2013;161(6):902-4 ### Mori N, et al. L265P mutation of the MYD88 gene is frequent in Waldenstr√∂m's macroglobulinemia and its absence in myeloma. PLoS One 2013;8(11):e80088 ### Landgren O, et al. MYD88 L265P somatic mutation in IgM MGUS. N Engl J Med 2012;367(23):2255-6; author reply 2256-7 ### Wang L, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011;365(26):2497-506 ### Jeelall YS, et al. Oncogenic MYD88 mutation drives Toll pathway to lymphoma. Immunol Cell Biol 2011;89(6):659-60 ### Je EM, et al. Absence of MYD88 gene mutation in acute leukemias and multiple myelomas. Eur J Haematol 2012;88(3):273-4 ### McIlwain H Biochemistry and neurochemistry in the 1800s: their origins in comparative animal chemistry. Essays Biochem 1990;25():197-224 ### Kim Y, et al. CD79B and MYD88 mutations in diffuse large B-cell lymphoma. Hum Pathol 2014;45(3):556-64 ### Mart√≠nez-Trillos A, et al. Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. Blood 2014;123(24):3790-6 ### Treon SP, et al. Ibrutinib in previously treated Waldenstr√∂m's macroglobulinemia. N Engl J Med 2015;372(15):1430-40"
NCOA2	any missense	Adenocarcinoma	'*AC2'	" ### Taylor BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18(1):11-22 ### Barbieri CE, et al. The mutational landscape of prostate cancer. Eur Urol 2013;64(4):567-76 ### Silva MP, et al. NCOA2 is a candidate target gene of 8q gain associated with clinically aggressive prostate cancer. Genes Chromosomes Cancer 2016;():"
NCOA2	copy number gain	Adenocarcinoma	'*AC2'	" ### Taylor BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18(1):11-22 ### Barbieri CE, et al. The mutational landscape of prostate cancer. Eur Urol 2013;64(4):567-76 ### Silva MP, et al. NCOA2 is a candidate target gene of 8q gain associated with clinically aggressive prostate cancer. Genes Chromosomes Cancer 2016;():"
NKX2-1	copy number gain	Adenocarcinoma	'*AC2'	" ### Weir BA, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007;450(7171):893-8 ### Yamaguchi T, et al. NKX2-1/TTF-1: an enigmatic oncogene that functions as a double-edged sword for cancer cell survival and progression. Cancer Cell 2013;23(6):718-23 ### Winslow MM, et al. Suppression of lung adenocarcinoma progression by Nkx2-1. Nature 2011;473(7345):101-4"
NOTCH1	exon(s) 26 deletion	T Lymphoblastic Leukemia/Lymphoma	'*TLL'/'LY'	" ### Weng AP, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004;306(5694):269-71 ### Stilgenbauer S, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014;123(21):3247-54 ### Weissmann S, et al. Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients. Leukemia 2013;27(12):2393-6 ### Puente XS, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011;475(7354):101-5 ### Stilgenbauer S, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014;123(21):3247-54 ### Baliakas P, et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia 2015;29(2):329-36"
NOTCH1	exon(s) 26 insertion	T Lymphoblastic Leukemia/Lymphoma	'*TLL'/'LY'	" ### Weng AP, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004;306(5694):269-71 ### Stilgenbauer S, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014;123(21):3247-54 ### Weissmann S, et al. Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients. Leukemia 2013;27(12):2393-6 ### Puente XS, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011;475(7354):101-5 ### Stilgenbauer S, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014;123(21):3247-54 ### Baliakas P, et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia 2015;29(2):329-36"
NOTCH1	exon(s) 26 missense	T Lymphoblastic Leukemia/Lymphoma	'*TLL'/'LY'	" ### Weng AP, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004;306(5694):269-71 ### Stilgenbauer S, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014;123(21):3247-54 ### Weissmann S, et al. Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients. Leukemia 2013;27(12):2393-6 ### Puente XS, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011;475(7354):101-5 ### Stilgenbauer S, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014;123(21):3247-54 ### Baliakas P, et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia 2015;29(2):329-36"
NOTCH1	exon(s) 27 deletion	T Lymphoblastic Leukemia/Lymphoma	'*TLL'/'LY'	" ### Weng AP, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004;306(5694):269-71 ### Stilgenbauer S, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014;123(21):3247-54 ### Weissmann S, et al. Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients. Leukemia 2013;27(12):2393-6 ### Puente XS, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011;475(7354):101-5 ### Stilgenbauer S, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014;123(21):3247-54 ### Baliakas P, et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia 2015;29(2):329-36"
NOTCH1	exon(s) 27 insertion	T Lymphoblastic Leukemia/Lymphoma	'*TLL'/'LY'	" ### Weng AP, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004;306(5694):269-71 ### Stilgenbauer S, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014;123(21):3247-54 ### Weissmann S, et al. Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients. Leukemia 2013;27(12):2393-6 ### Puente XS, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011;475(7354):101-5 ### Stilgenbauer S, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014;123(21):3247-54 ### Baliakas P, et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia 2015;29(2):329-36"
NOTCH1	exon(s) 27 missense	T Lymphoblastic Leukemia/Lymphoma	'*TLL'/'LY'	" ### Weng AP, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004;306(5694):269-71 ### Stilgenbauer S, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014;123(21):3247-54 ### Weissmann S, et al. Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients. Leukemia 2013;27(12):2393-6 ### Puente XS, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011;475(7354):101-5 ### Stilgenbauer S, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014;123(21):3247-54 ### Baliakas P, et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia 2015;29(2):329-36"
NOTCH1	exon(s) 34 frameshift	Chronic Lymphocytic Leukemia	'CLL'	" ### Weng AP, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004;306(5694):269-71 ### Stilgenbauer S, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014;123(21):3247-54 ### Weissmann S, et al. Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients. Leukemia 2013;27(12):2393-6 ### Puente XS, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011;475(7354):101-5 ### Stilgenbauer S, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014;123(21):3247-54 ### Baliakas P, et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia 2015;29(2):329-36"
NOTCH1	exon(s) 34 frameshift	T Lymphoblastic Leukemia/Lymphoma	'*TLL'/'LY'	" ### Weng AP, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004;306(5694):269-71 ### Stilgenbauer S, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014;123(21):3247-54 ### Weissmann S, et al. Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients. Leukemia 2013;27(12):2393-6 ### Puente XS, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011;475(7354):101-5 ### Stilgenbauer S, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014;123(21):3247-54 ### Baliakas P, et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia 2015;29(2):329-36"
NOTCH1	exon(s) 34 missense	Chronic Lymphocytic Leukemia	'CLL'	" ### Weng AP, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004;306(5694):269-71 ### Stilgenbauer S, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014;123(21):3247-54 ### Weissmann S, et al. Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients. Leukemia 2013;27(12):2393-6 ### Puente XS, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011;475(7354):101-5 ### Stilgenbauer S, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014;123(21):3247-54 ### Baliakas P, et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia 2015;29(2):329-36"
NOTCH1	exon(s) 34 missense	T Lymphoblastic Leukemia/Lymphoma	'*TLL'/'LY'	" ### Weng AP, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004;306(5694):269-71 ### Stilgenbauer S, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014;123(21):3247-54 ### Weissmann S, et al. Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients. Leukemia 2013;27(12):2393-6 ### Puente XS, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011;475(7354):101-5 ### Stilgenbauer S, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014;123(21):3247-54 ### Baliakas P, et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia 2015;29(2):329-36"
NOTCH1	exon(s) 34 nonsense	Chronic Lymphocytic Leukemia	'CLL'	" ### Weng AP, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004;306(5694):269-71 ### Stilgenbauer S, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014;123(21):3247-54 ### Weissmann S, et al. Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients. Leukemia 2013;27(12):2393-6 ### Puente XS, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011;475(7354):101-5 ### Stilgenbauer S, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014;123(21):3247-54 ### Baliakas P, et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia 2015;29(2):329-36"
NOTCH1	exon(s) 34 nonsense	T Lymphoblastic Leukemia/Lymphoma	'*TLL'/'LY'	" ### Weng AP, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004;306(5694):269-71 ### Stilgenbauer S, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014;123(21):3247-54 ### Weissmann S, et al. Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients. Leukemia 2013;27(12):2393-6 ### Puente XS, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011;475(7354):101-5 ### Stilgenbauer S, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014;123(21):3247-54 ### Baliakas P, et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia 2015;29(2):329-36"
NOTCH2	any mutation	Marginal Zone B Cell Lymphoma/Diffuse Large B Cell Lymphoma	'*MZBL'/'DLBCL'	" ### Lee SY, et al. Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma. Cancer Sci 2009;100(5):920-6 ### Kiel MJ, et al. Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J Exp Med 2012;209(9):1553-65"
NOTCH2	exon(s) 34 frameshift	Marginal Zone B Cell Lymphoma/Diffuse Large B Cell Lymphoma	'*MZBL'/'DLBCL'	" ### Lee SY, et al. Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma. Cancer Sci 2009;100(5):920-6 ### Kiel MJ, et al. Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J Exp Med 2012;209(9):1553-65"
NOTCH2	exon(s) 34 frameshift	Marginal Zone B Cell Lymphoma	'*MZBL'	" ### Kiel MJ, et al. Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J Exp Med 2012;209(9):1553-65 ### Lee SY, et al. Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma. Cancer Sci 2009;100(5):920-6"
NOTCH2	I2304fs	Marginal Zone B Cell Lymphoma/Diffuse Large B Cell Lymphoma	'*MZBL'/'DLBCL'	" ### Lee SY, et al. Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma. Cancer Sci 2009;100(5):920-6 ### Kiel MJ, et al. Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J Exp Med 2012;209(9):1553-65"
NOTCH2	I2304fs	Marginal Zone B Cell Lymphoma	'*MZBL'	" ### Kiel MJ, et al. Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J Exp Med 2012;209(9):1553-65 ### Lee SY, et al. Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma. Cancer Sci 2009;100(5):920-6"
NPM1	codon(s) 288 frameshift	Acute Myeloid Leukemia	'AML'	" ### Falini B, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005;352(3):254-66 ### Suzuki T, et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood 2005;106(8):2854-61 ### Kihara R, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia 2014;28(8):1586-95 ### Patel JP, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012;366(12):1079-89"
NPM1	codon(s) 290 frameshift	Acute Myeloid Leukemia	'AML'	" ### Falini B, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005;352(3):254-66 ### Suzuki T, et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood 2005;106(8):2854-61 ### Kihara R, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia 2014;28(8):1586-95 ### Patel JP, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012;366(12):1079-89"
NRAS	any mutation	Acute Myeloid Leukemia/Chronic Myelomonocytic Leukemia/Myelodysplastic Syndrome/B Lymphoblastic Leukemia/Lymphoma/MDS/MPN	'AML'/'*CMML'/'MDS'/'*BLL'/'LY'/'MDS'/'MPN'	" ### Jain N, et al. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res 2014;20(2):490-8 ### Murphy DM, et al. NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes. Leukemia 2013;27(10):2077-81 ### Bejar R, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011;364(26):2496-506 ### Bacher U, et al. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica 2007;92(6):744-52 ### Dicker F, et al. Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML. Leukemia 2010;24(8):1528-32 ### Ricci C, et al. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant. Clin Cancer Res 2010;16(8):2246-56 ### Tyner JW, et al. High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Blood 2009;113(8):1749-55 ### Al-Kali A, et al. Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. Am J Hematol 2013;88(5):365-9 ### Zhang J, et al. Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2011;118(11):3080-7"
NRAS	" codon(s) 12, 13, 61, 146 any"	Adenocarcinoma	'*AC2'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	" codon(s) 12, 13, 61, 146 any"	Adenocarcinoma/Non-Small Cell Lung Carcinoma	'*AC2'/'NSCLC'	" ### Ohashi et al. Characteristics of lung cancers harboring NRAS mutations. Clinical Cancer Research 19.9 (2013): 2584-2591. ### Vujic I et al. Mutant NRASQ61 shares signaling similarities across various cancer types ‚Ä?potential implications for future therapies. Oncotarget. 2014;5(17):7936-7944. ### Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler K, Franklin WA, Iafrate AJ, Ladanyi M, Kris MG, Johnson BE, Bunn PA, Minna JD, Kwiatkowski DJ; LCMC Investigators. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2015 May;10(5):768-77. doi: 10.1097/JTO.0000000000000516. PubMed PMID: 25738220; PubMed Central PMCID: PMC4410843. ### Araujo LH, Lammers PE, Matthews-Smith V, Eisenberg R, Gonzalez A, Schwartz AG, Timmers C, Shilo K, Zhao W, Natarajan TG, Zhang J, Yilmaz AS, Liu T, Coombes K, Carbone DP. Somatic Mutation Spectrum of Non-Small-Cell Lung Cancer in African Americans: A Pooled Analysis. J Thorac Oncol. 2015 Oct;10(10):1430-6. doi: 10.1097/JTO.0000000000000650. PubMed PMID: 26301800; PubMed Central PMCID: PMC4618391."
NRAS	" codon(s) 12, 13, 61, 146 any"	Follicular Carcinoma/Papillary Carcinoma	'THF'/'THP'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	" codon(s) 12, 13, 61, 146 any"	Melanoma	'*M'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	" codon(s) 12, 13, 61, 146 any"	Other Tumor Type	'CANCER'	" ### Keutgen et al...Molecular diagnosis for indeterminate thyroid nodules on fine needle aspiration: advances and limitations. Expert Rev. Mol. Diagn. 13(6), 613‚Ä?23 (2013) ### Zhu Z et al.... Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J. Clin. Endocrinol. Metab. 91(9), 3603‚Ä?610 (2006)."
NRAS	" codon(s) 12, 13, 61, 146 any"	Urothelial Carcinoma	'UTH'	" ### Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One. 2010 Nov 3;5(11):e13821. doi: 10.1371/journal.pone.0013821. PubMed PMID: 21072204; PubMed Central PMCID: PMC2972209. ### Calderaro J, Rebouissou S, de Koning L, Masmoudi A, H√©rault A, Dubois T, Maille P, Soyeux P, Sibony M, de la Taille A, Vordos D, Lebret T, Radvanyi F, Allory Y. PI3K/AKT pathway activation in bladder carcinogenesis. Int J Cancer. 2014 Apr 15;134(8):1776-84. doi: 10.1002/ijc.28518. Epub 2013 Oct 24. PubMed PMID: 24122582."
NRAS	G12A	Adenocarcinoma	'*AC2'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	G12A	Adenocarcinoma/Non-Small Cell Lung Carcinoma	'*AC2'/'NSCLC'	" ### Ohashi et al. Characteristics of lung cancers harboring NRAS mutations. Clinical Cancer Research 19.9 (2013): 2584-2591. ### Vujic I et al. Mutant NRASQ61 shares signaling similarities across various cancer types ‚Ä?potential implications for future therapies. Oncotarget. 2014;5(17):7936-7944. ### Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler K, Franklin WA, Iafrate AJ, Ladanyi M, Kris MG, Johnson BE, Bunn PA, Minna JD, Kwiatkowski DJ; LCMC Investigators. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2015 May;10(5):768-77. doi: 10.1097/JTO.0000000000000516. PubMed PMID: 25738220; PubMed Central PMCID: PMC4410843. ### Araujo LH, Lammers PE, Matthews-Smith V, Eisenberg R, Gonzalez A, Schwartz AG, Timmers C, Shilo K, Zhao W, Natarajan TG, Zhang J, Yilmaz AS, Liu T, Coombes K, Carbone DP. Somatic Mutation Spectrum of Non-Small-Cell Lung Cancer in African Americans: A Pooled Analysis. J Thorac Oncol. 2015 Oct;10(10):1430-6. doi: 10.1097/JTO.0000000000000650. PubMed PMID: 26301800; PubMed Central PMCID: PMC4618391."
NRAS	G12A	Follicular Carcinoma/Papillary Carcinoma	'THF'/'THP'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	G12A	Melanoma	'*M'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	G12A	Other Tumor Type	'CANCER'	" ### Keutgen et al...Molecular diagnosis for indeterminate thyroid nodules on fine needle aspiration: advances and limitations. Expert Rev. Mol. Diagn. 13(6), 613‚Ä?23 (2013) ### Zhu Z et al.... Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J. Clin. Endocrinol. Metab. 91(9), 3603‚Ä?610 (2006)."
NRAS	G12A	Urothelial Carcinoma	'UTH'	" ### Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One. 2010 Nov 3;5(11):e13821. doi: 10.1371/journal.pone.0013821. PubMed PMID: 21072204; PubMed Central PMCID: PMC2972209. ### Calderaro J, Rebouissou S, de Koning L, Masmoudi A, H√©rault A, Dubois T, Maille P, Soyeux P, Sibony M, de la Taille A, Vordos D, Lebret T, Radvanyi F, Allory Y. PI3K/AKT pathway activation in bladder carcinogenesis. Int J Cancer. 2014 Apr 15;134(8):1776-84. doi: 10.1002/ijc.28518. Epub 2013 Oct 24. PubMed PMID: 24122582."
NRAS	G12D	Adenocarcinoma	'*AC2'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	G12D	Adenocarcinoma/Non-Small Cell Lung Carcinoma	'*AC2'/'NSCLC'	" ### Ohashi et al. Characteristics of lung cancers harboring NRAS mutations. Clinical Cancer Research 19.9 (2013): 2584-2591. ### Vujic I et al. Mutant NRASQ61 shares signaling similarities across various cancer types ‚Ä?potential implications for future therapies. Oncotarget. 2014;5(17):7936-7944. ### Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler K, Franklin WA, Iafrate AJ, Ladanyi M, Kris MG, Johnson BE, Bunn PA, Minna JD, Kwiatkowski DJ; LCMC Investigators. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2015 May;10(5):768-77. doi: 10.1097/JTO.0000000000000516. PubMed PMID: 25738220; PubMed Central PMCID: PMC4410843. ### Araujo LH, Lammers PE, Matthews-Smith V, Eisenberg R, Gonzalez A, Schwartz AG, Timmers C, Shilo K, Zhao W, Natarajan TG, Zhang J, Yilmaz AS, Liu T, Coombes K, Carbone DP. Somatic Mutation Spectrum of Non-Small-Cell Lung Cancer in African Americans: A Pooled Analysis. J Thorac Oncol. 2015 Oct;10(10):1430-6. doi: 10.1097/JTO.0000000000000650. PubMed PMID: 26301800; PubMed Central PMCID: PMC4618391."
NRAS	G12D	Cholangiocarcinoma	'CH'	" ### Voss, Jesse S., et al. ""Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions."" Human pathology 44.7 (2013): 1216-1222. ### Deshpande, Vikram, et al. ""Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma."" BMC cancer 11.1 (2011): 60. ### Putra J, de Abreu FB, Peterson JD, Pipas JM, Mody K, Amos CI, Tsongalis GJ, Suriawinata AA. Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing. Exp Mol Pathol. 2015 Oct;99(2):240-4. doi:0.1016/j.yexmp.2015.07.005. Epub 2015 Jul 17. PubMed PMID: 26189129; PubMed Central PMCID: PMC4591249. ### Zhu AX, Borger DR, Kim Y, Cosgrove D, Ejaz A, Alexandrescu S, Groeschl RT, Deshpande V, Lindberg JM, Ferrone C, Sempoux C, Yau T, Poon R, Popescu I, Bauer TW, Gamblin TC, Gigot JF, Anders RA, Pawlik TM. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets. Ann Surg Oncol. 2014 Nov;21(12):3827-34. doi: 10.1245/s10434-014-3828-x. Epub 2014 Jun 3. PubMed PMID: 24889489; PubMed Central PMCID: PMC4324507."
NRAS	G12D	Follicular Carcinoma/Papillary Carcinoma	'THF'/'THP'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	G12D	Melanoma	'*M'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	G12D	Other Tumor Type	'CANCER'	" ### Keutgen et al...Molecular diagnosis for indeterminate thyroid nodules on fine needle aspiration: advances and limitations. Expert Rev. Mol. Diagn. 13(6), 613‚Ä?23 (2013) ### Zhu Z et al.... Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J. Clin. Endocrinol. Metab. 91(9), 3603‚Ä?610 (2006)."
NRAS	G12D	Urothelial Carcinoma	'UTH'	" ### Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One. 2010 Nov 3;5(11):e13821. doi: 10.1371/journal.pone.0013821. PubMed PMID: 21072204; PubMed Central PMCID: PMC2972209. ### Calderaro J, Rebouissou S, de Koning L, Masmoudi A, H√©rault A, Dubois T, Maille P, Soyeux P, Sibony M, de la Taille A, Vordos D, Lebret T, Radvanyi F, Allory Y. PI3K/AKT pathway activation in bladder carcinogenesis. Int J Cancer. 2014 Apr 15;134(8):1776-84. doi: 10.1002/ijc.28518. Epub 2013 Oct 24. PubMed PMID: 24122582."
NRAS	G12R	Adenocarcinoma	'*AC2'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	G12R	Adenocarcinoma/Non-Small Cell Lung Carcinoma	'*AC2'/'NSCLC'	" ### Ohashi et al. Characteristics of lung cancers harboring NRAS mutations. Clinical Cancer Research 19.9 (2013): 2584-2591. ### Vujic I et al. Mutant NRASQ61 shares signaling similarities across various cancer types ‚Ä?potential implications for future therapies. Oncotarget. 2014;5(17):7936-7944. ### Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler K, Franklin WA, Iafrate AJ, Ladanyi M, Kris MG, Johnson BE, Bunn PA, Minna JD, Kwiatkowski DJ; LCMC Investigators. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2015 May;10(5):768-77. doi: 10.1097/JTO.0000000000000516. PubMed PMID: 25738220; PubMed Central PMCID: PMC4410843. ### Araujo LH, Lammers PE, Matthews-Smith V, Eisenberg R, Gonzalez A, Schwartz AG, Timmers C, Shilo K, Zhao W, Natarajan TG, Zhang J, Yilmaz AS, Liu T, Coombes K, Carbone DP. Somatic Mutation Spectrum of Non-Small-Cell Lung Cancer in African Americans: A Pooled Analysis. J Thorac Oncol. 2015 Oct;10(10):1430-6. doi: 10.1097/JTO.0000000000000650. PubMed PMID: 26301800; PubMed Central PMCID: PMC4618391."
NRAS	G12R	Follicular Carcinoma/Papillary Carcinoma	'THF'/'THP'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	G12R	Melanoma	'*M'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	G12R	Other Tumor Type	'CANCER'	" ### Keutgen et al...Molecular diagnosis for indeterminate thyroid nodules on fine needle aspiration: advances and limitations. Expert Rev. Mol. Diagn. 13(6), 613‚Ä?23 (2013) ### Zhu Z et al.... Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J. Clin. Endocrinol. Metab. 91(9), 3603‚Ä?610 (2006)."
NRAS	G12R	Urothelial Carcinoma	'UTH'	" ### Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One. 2010 Nov 3;5(11):e13821. doi: 10.1371/journal.pone.0013821. PubMed PMID: 21072204; PubMed Central PMCID: PMC2972209. ### Calderaro J, Rebouissou S, de Koning L, Masmoudi A, H√©rault A, Dubois T, Maille P, Soyeux P, Sibony M, de la Taille A, Vordos D, Lebret T, Radvanyi F, Allory Y. PI3K/AKT pathway activation in bladder carcinogenesis. Int J Cancer. 2014 Apr 15;134(8):1776-84. doi: 10.1002/ijc.28518. Epub 2013 Oct 24. PubMed PMID: 24122582."
NRAS	G12S	Adenocarcinoma	'*AC2'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	G12S	Adenocarcinoma/Non-Small Cell Lung Carcinoma	'*AC2'/'NSCLC'	" ### Ohashi et al. Characteristics of lung cancers harboring NRAS mutations. Clinical Cancer Research 19.9 (2013): 2584-2591. ### Vujic I et al. Mutant NRASQ61 shares signaling similarities across various cancer types ‚Ä?potential implications for future therapies. Oncotarget. 2014;5(17):7936-7944. ### Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler K, Franklin WA, Iafrate AJ, Ladanyi M, Kris MG, Johnson BE, Bunn PA, Minna JD, Kwiatkowski DJ; LCMC Investigators. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2015 May;10(5):768-77. doi: 10.1097/JTO.0000000000000516. PubMed PMID: 25738220; PubMed Central PMCID: PMC4410843. ### Araujo LH, Lammers PE, Matthews-Smith V, Eisenberg R, Gonzalez A, Schwartz AG, Timmers C, Shilo K, Zhao W, Natarajan TG, Zhang J, Yilmaz AS, Liu T, Coombes K, Carbone DP. Somatic Mutation Spectrum of Non-Small-Cell Lung Cancer in African Americans: A Pooled Analysis. J Thorac Oncol. 2015 Oct;10(10):1430-6. doi: 10.1097/JTO.0000000000000650. PubMed PMID: 26301800; PubMed Central PMCID: PMC4618391."
NRAS	G12S	Follicular Carcinoma/Papillary Carcinoma	'THF'/'THP'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	G12S	Melanoma	'*M'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	G12S	Other Tumor Type	'CANCER'	" ### Keutgen et al...Molecular diagnosis for indeterminate thyroid nodules on fine needle aspiration: advances and limitations. Expert Rev. Mol. Diagn. 13(6), 613‚Ä?23 (2013) ### Zhu Z et al.... Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J. Clin. Endocrinol. Metab. 91(9), 3603‚Ä?610 (2006)."
NRAS	G12S	Urothelial Carcinoma	'UTH'	" ### Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One. 2010 Nov 3;5(11):e13821. doi: 10.1371/journal.pone.0013821. PubMed PMID: 21072204; PubMed Central PMCID: PMC2972209. ### Calderaro J, Rebouissou S, de Koning L, Masmoudi A, H√©rault A, Dubois T, Maille P, Soyeux P, Sibony M, de la Taille A, Vordos D, Lebret T, Radvanyi F, Allory Y. PI3K/AKT pathway activation in bladder carcinogenesis. Int J Cancer. 2014 Apr 15;134(8):1776-84. doi: 10.1002/ijc.28518. Epub 2013 Oct 24. PubMed PMID: 24122582."
NRAS	G12V	Adenocarcinoma	'*AC2'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	G12V	Adenocarcinoma/Non-Small Cell Lung Carcinoma	'*AC2'/'NSCLC'	" ### Ohashi et al. Characteristics of lung cancers harboring NRAS mutations. Clinical Cancer Research 19.9 (2013): 2584-2591. ### Vujic I et al. Mutant NRASQ61 shares signaling similarities across various cancer types ‚Ä?potential implications for future therapies. Oncotarget. 2014;5(17):7936-7944. ### Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler K, Franklin WA, Iafrate AJ, Ladanyi M, Kris MG, Johnson BE, Bunn PA, Minna JD, Kwiatkowski DJ; LCMC Investigators. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2015 May;10(5):768-77. doi: 10.1097/JTO.0000000000000516. PubMed PMID: 25738220; PubMed Central PMCID: PMC4410843. ### Araujo LH, Lammers PE, Matthews-Smith V, Eisenberg R, Gonzalez A, Schwartz AG, Timmers C, Shilo K, Zhao W, Natarajan TG, Zhang J, Yilmaz AS, Liu T, Coombes K, Carbone DP. Somatic Mutation Spectrum of Non-Small-Cell Lung Cancer in African Americans: A Pooled Analysis. J Thorac Oncol. 2015 Oct;10(10):1430-6. doi: 10.1097/JTO.0000000000000650. PubMed PMID: 26301800; PubMed Central PMCID: PMC4618391."
NRAS	G12V	Follicular Carcinoma/Papillary Carcinoma	'THF'/'THP'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	G12V	Melanoma	'*M'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	G12V	Other Tumor Type	'CANCER'	" ### Keutgen et al...Molecular diagnosis for indeterminate thyroid nodules on fine needle aspiration: advances and limitations. Expert Rev. Mol. Diagn. 13(6), 613‚Ä?23 (2013) ### Zhu Z et al.... Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J. Clin. Endocrinol. Metab. 91(9), 3603‚Ä?610 (2006)."
NRAS	G12V	Urothelial Carcinoma	'UTH'	" ### Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One. 2010 Nov 3;5(11):e13821. doi: 10.1371/journal.pone.0013821. PubMed PMID: 21072204; PubMed Central PMCID: PMC2972209. ### Calderaro J, Rebouissou S, de Koning L, Masmoudi A, H√©rault A, Dubois T, Maille P, Soyeux P, Sibony M, de la Taille A, Vordos D, Lebret T, Radvanyi F, Allory Y. PI3K/AKT pathway activation in bladder carcinogenesis. Int J Cancer. 2014 Apr 15;134(8):1776-84. doi: 10.1002/ijc.28518. Epub 2013 Oct 24. PubMed PMID: 24122582."
NRAS	G13A	Adenocarcinoma	'*AC2'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	G13A	Adenocarcinoma/Non-Small Cell Lung Carcinoma	'*AC2'/'NSCLC'	" ### Ohashi et al. Characteristics of lung cancers harboring NRAS mutations. Clinical Cancer Research 19.9 (2013): 2584-2591. ### Vujic I et al. Mutant NRASQ61 shares signaling similarities across various cancer types ‚Ä?potential implications for future therapies. Oncotarget. 2014;5(17):7936-7944. ### Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler K, Franklin WA, Iafrate AJ, Ladanyi M, Kris MG, Johnson BE, Bunn PA, Minna JD, Kwiatkowski DJ; LCMC Investigators. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2015 May;10(5):768-77. doi: 10.1097/JTO.0000000000000516. PubMed PMID: 25738220; PubMed Central PMCID: PMC4410843. ### Araujo LH, Lammers PE, Matthews-Smith V, Eisenberg R, Gonzalez A, Schwartz AG, Timmers C, Shilo K, Zhao W, Natarajan TG, Zhang J, Yilmaz AS, Liu T, Coombes K, Carbone DP. Somatic Mutation Spectrum of Non-Small-Cell Lung Cancer in African Americans: A Pooled Analysis. J Thorac Oncol. 2015 Oct;10(10):1430-6. doi: 10.1097/JTO.0000000000000650. PubMed PMID: 26301800; PubMed Central PMCID: PMC4618391."
NRAS	G13A	Follicular Carcinoma/Papillary Carcinoma	'THF'/'THP'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	G13A	Melanoma	'*M'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	G13A	Other Tumor Type	'CANCER'	" ### Keutgen et al...Molecular diagnosis for indeterminate thyroid nodules on fine needle aspiration: advances and limitations. Expert Rev. Mol. Diagn. 13(6), 613‚Ä?23 (2013) ### Zhu Z et al.... Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J. Clin. Endocrinol. Metab. 91(9), 3603‚Ä?610 (2006)."
NRAS	G13A	Urothelial Carcinoma	'UTH'	" ### Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One. 2010 Nov 3;5(11):e13821. doi: 10.1371/journal.pone.0013821. PubMed PMID: 21072204; PubMed Central PMCID: PMC2972209. ### Calderaro J, Rebouissou S, de Koning L, Masmoudi A, H√©rault A, Dubois T, Maille P, Soyeux P, Sibony M, de la Taille A, Vordos D, Lebret T, Radvanyi F, Allory Y. PI3K/AKT pathway activation in bladder carcinogenesis. Int J Cancer. 2014 Apr 15;134(8):1776-84. doi: 10.1002/ijc.28518. Epub 2013 Oct 24. PubMed PMID: 24122582."
NRAS	G13C	Adenocarcinoma	'*AC2'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	G13C	Adenocarcinoma/Non-Small Cell Lung Carcinoma	'*AC2'/'NSCLC'	" ### Ohashi et al. Characteristics of lung cancers harboring NRAS mutations. Clinical Cancer Research 19.9 (2013): 2584-2591. ### Vujic I et al. Mutant NRASQ61 shares signaling similarities across various cancer types ‚Ä?potential implications for future therapies. Oncotarget. 2014;5(17):7936-7944. ### Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler K, Franklin WA, Iafrate AJ, Ladanyi M, Kris MG, Johnson BE, Bunn PA, Minna JD, Kwiatkowski DJ; LCMC Investigators. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2015 May;10(5):768-77. doi: 10.1097/JTO.0000000000000516. PubMed PMID: 25738220; PubMed Central PMCID: PMC4410843. ### Araujo LH, Lammers PE, Matthews-Smith V, Eisenberg R, Gonzalez A, Schwartz AG, Timmers C, Shilo K, Zhao W, Natarajan TG, Zhang J, Yilmaz AS, Liu T, Coombes K, Carbone DP. Somatic Mutation Spectrum of Non-Small-Cell Lung Cancer in African Americans: A Pooled Analysis. J Thorac Oncol. 2015 Oct;10(10):1430-6. doi: 10.1097/JTO.0000000000000650. PubMed PMID: 26301800; PubMed Central PMCID: PMC4618391."
NRAS	G13C	Follicular Carcinoma/Papillary Carcinoma	'THF'/'THP'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	G13C	Melanoma	'*M'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	G13C	Other Tumor Type	'CANCER'	" ### Keutgen et al...Molecular diagnosis for indeterminate thyroid nodules on fine needle aspiration: advances and limitations. Expert Rev. Mol. Diagn. 13(6), 613‚Ä?23 (2013) ### Zhu Z et al.... Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J. Clin. Endocrinol. Metab. 91(9), 3603‚Ä?610 (2006)."
NRAS	G13C	Urothelial Carcinoma	'UTH'	" ### Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One. 2010 Nov 3;5(11):e13821. doi: 10.1371/journal.pone.0013821. PubMed PMID: 21072204; PubMed Central PMCID: PMC2972209. ### Calderaro J, Rebouissou S, de Koning L, Masmoudi A, H√©rault A, Dubois T, Maille P, Soyeux P, Sibony M, de la Taille A, Vordos D, Lebret T, Radvanyi F, Allory Y. PI3K/AKT pathway activation in bladder carcinogenesis. Int J Cancer. 2014 Apr 15;134(8):1776-84. doi: 10.1002/ijc.28518. Epub 2013 Oct 24. PubMed PMID: 24122582."
NRAS	G13D	Adenocarcinoma	'*AC2'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	G13D	Adenocarcinoma/Non-Small Cell Lung Carcinoma	'*AC2'/'NSCLC'	" ### Ohashi et al. Characteristics of lung cancers harboring NRAS mutations. Clinical Cancer Research 19.9 (2013): 2584-2591. ### Vujic I et al. Mutant NRASQ61 shares signaling similarities across various cancer types ‚Ä?potential implications for future therapies. Oncotarget. 2014;5(17):7936-7944. ### Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler K, Franklin WA, Iafrate AJ, Ladanyi M, Kris MG, Johnson BE, Bunn PA, Minna JD, Kwiatkowski DJ; LCMC Investigators. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2015 May;10(5):768-77. doi: 10.1097/JTO.0000000000000516. PubMed PMID: 25738220; PubMed Central PMCID: PMC4410843. ### Araujo LH, Lammers PE, Matthews-Smith V, Eisenberg R, Gonzalez A, Schwartz AG, Timmers C, Shilo K, Zhao W, Natarajan TG, Zhang J, Yilmaz AS, Liu T, Coombes K, Carbone DP. Somatic Mutation Spectrum of Non-Small-Cell Lung Cancer in African Americans: A Pooled Analysis. J Thorac Oncol. 2015 Oct;10(10):1430-6. doi: 10.1097/JTO.0000000000000650. PubMed PMID: 26301800; PubMed Central PMCID: PMC4618391."
NRAS	G13D	Follicular Carcinoma/Papillary Carcinoma	'THF'/'THP'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	G13D	Melanoma	'*M'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	G13D	Other Tumor Type	'CANCER'	" ### Keutgen et al...Molecular diagnosis for indeterminate thyroid nodules on fine needle aspiration: advances and limitations. Expert Rev. Mol. Diagn. 13(6), 613‚Ä?23 (2013) ### Zhu Z et al.... Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J. Clin. Endocrinol. Metab. 91(9), 3603‚Ä?610 (2006)."
NRAS	G13D	Urothelial Carcinoma	'UTH'	" ### Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One. 2010 Nov 3;5(11):e13821. doi: 10.1371/journal.pone.0013821. PubMed PMID: 21072204; PubMed Central PMCID: PMC2972209. ### Calderaro J, Rebouissou S, de Koning L, Masmoudi A, H√©rault A, Dubois T, Maille P, Soyeux P, Sibony M, de la Taille A, Vordos D, Lebret T, Radvanyi F, Allory Y. PI3K/AKT pathway activation in bladder carcinogenesis. Int J Cancer. 2014 Apr 15;134(8):1776-84. doi: 10.1002/ijc.28518. Epub 2013 Oct 24. PubMed PMID: 24122582."
NRAS	G13R	Adenocarcinoma	'*AC2'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	G13R	Adenocarcinoma/Non-Small Cell Lung Carcinoma	'*AC2'/'NSCLC'	" ### Ohashi et al. Characteristics of lung cancers harboring NRAS mutations. Clinical Cancer Research 19.9 (2013): 2584-2591. ### Vujic I et al. Mutant NRASQ61 shares signaling similarities across various cancer types ‚Ä?potential implications for future therapies. Oncotarget. 2014;5(17):7936-7944. ### Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler K, Franklin WA, Iafrate AJ, Ladanyi M, Kris MG, Johnson BE, Bunn PA, Minna JD, Kwiatkowski DJ; LCMC Investigators. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2015 May;10(5):768-77. doi: 10.1097/JTO.0000000000000516. PubMed PMID: 25738220; PubMed Central PMCID: PMC4410843. ### Araujo LH, Lammers PE, Matthews-Smith V, Eisenberg R, Gonzalez A, Schwartz AG, Timmers C, Shilo K, Zhao W, Natarajan TG, Zhang J, Yilmaz AS, Liu T, Coombes K, Carbone DP. Somatic Mutation Spectrum of Non-Small-Cell Lung Cancer in African Americans: A Pooled Analysis. J Thorac Oncol. 2015 Oct;10(10):1430-6. doi: 10.1097/JTO.0000000000000650. PubMed PMID: 26301800; PubMed Central PMCID: PMC4618391."
NRAS	G13R	Follicular Carcinoma/Papillary Carcinoma	'THF'/'THP'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	G13R	Melanoma	'*M'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	G13R	Other Tumor Type	'CANCER'	" ### Keutgen et al...Molecular diagnosis for indeterminate thyroid nodules on fine needle aspiration: advances and limitations. Expert Rev. Mol. Diagn. 13(6), 613‚Ä?23 (2013) ### Zhu Z et al.... Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J. Clin. Endocrinol. Metab. 91(9), 3603‚Ä?610 (2006)."
NRAS	G13R	Urothelial Carcinoma	'UTH'	" ### Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One. 2010 Nov 3;5(11):e13821. doi: 10.1371/journal.pone.0013821. PubMed PMID: 21072204; PubMed Central PMCID: PMC2972209. ### Calderaro J, Rebouissou S, de Koning L, Masmoudi A, H√©rault A, Dubois T, Maille P, Soyeux P, Sibony M, de la Taille A, Vordos D, Lebret T, Radvanyi F, Allory Y. PI3K/AKT pathway activation in bladder carcinogenesis. Int J Cancer. 2014 Apr 15;134(8):1776-84. doi: 10.1002/ijc.28518. Epub 2013 Oct 24. PubMed PMID: 24122582."
NRAS	G13S	Adenocarcinoma	'*AC2'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	G13S	Adenocarcinoma/Non-Small Cell Lung Carcinoma	'*AC2'/'NSCLC'	" ### Ohashi et al. Characteristics of lung cancers harboring NRAS mutations. Clinical Cancer Research 19.9 (2013): 2584-2591. ### Vujic I et al. Mutant NRASQ61 shares signaling similarities across various cancer types ‚Ä?potential implications for future therapies. Oncotarget. 2014;5(17):7936-7944. ### Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler K, Franklin WA, Iafrate AJ, Ladanyi M, Kris MG, Johnson BE, Bunn PA, Minna JD, Kwiatkowski DJ; LCMC Investigators. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2015 May;10(5):768-77. doi: 10.1097/JTO.0000000000000516. PubMed PMID: 25738220; PubMed Central PMCID: PMC4410843. ### Araujo LH, Lammers PE, Matthews-Smith V, Eisenberg R, Gonzalez A, Schwartz AG, Timmers C, Shilo K, Zhao W, Natarajan TG, Zhang J, Yilmaz AS, Liu T, Coombes K, Carbone DP. Somatic Mutation Spectrum of Non-Small-Cell Lung Cancer in African Americans: A Pooled Analysis. J Thorac Oncol. 2015 Oct;10(10):1430-6. doi: 10.1097/JTO.0000000000000650. PubMed PMID: 26301800; PubMed Central PMCID: PMC4618391."
NRAS	G13S	Follicular Carcinoma/Papillary Carcinoma	'THF'/'THP'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	G13S	Melanoma	'*M'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	G13S	Other Tumor Type	'CANCER'	" ### Keutgen et al...Molecular diagnosis for indeterminate thyroid nodules on fine needle aspiration: advances and limitations. Expert Rev. Mol. Diagn. 13(6), 613‚Ä?23 (2013) ### Zhu Z et al.... Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J. Clin. Endocrinol. Metab. 91(9), 3603‚Ä?610 (2006)."
NRAS	G13S	Urothelial Carcinoma	'UTH'	" ### Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One. 2010 Nov 3;5(11):e13821. doi: 10.1371/journal.pone.0013821. PubMed PMID: 21072204; PubMed Central PMCID: PMC2972209. ### Calderaro J, Rebouissou S, de Koning L, Masmoudi A, H√©rault A, Dubois T, Maille P, Soyeux P, Sibony M, de la Taille A, Vordos D, Lebret T, Radvanyi F, Allory Y. PI3K/AKT pathway activation in bladder carcinogenesis. Int J Cancer. 2014 Apr 15;134(8):1776-84. doi: 10.1002/ijc.28518. Epub 2013 Oct 24. PubMed PMID: 24122582."
NRAS	G13V	Adenocarcinoma	'*AC2'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	G13V	Adenocarcinoma/Non-Small Cell Lung Carcinoma	'*AC2'/'NSCLC'	" ### Ohashi et al. Characteristics of lung cancers harboring NRAS mutations. Clinical Cancer Research 19.9 (2013): 2584-2591. ### Vujic I et al. Mutant NRASQ61 shares signaling similarities across various cancer types ‚Ä?potential implications for future therapies. Oncotarget. 2014;5(17):7936-7944. ### Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler K, Franklin WA, Iafrate AJ, Ladanyi M, Kris MG, Johnson BE, Bunn PA, Minna JD, Kwiatkowski DJ; LCMC Investigators. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2015 May;10(5):768-77. doi: 10.1097/JTO.0000000000000516. PubMed PMID: 25738220; PubMed Central PMCID: PMC4410843. ### Araujo LH, Lammers PE, Matthews-Smith V, Eisenberg R, Gonzalez A, Schwartz AG, Timmers C, Shilo K, Zhao W, Natarajan TG, Zhang J, Yilmaz AS, Liu T, Coombes K, Carbone DP. Somatic Mutation Spectrum of Non-Small-Cell Lung Cancer in African Americans: A Pooled Analysis. J Thorac Oncol. 2015 Oct;10(10):1430-6. doi: 10.1097/JTO.0000000000000650. PubMed PMID: 26301800; PubMed Central PMCID: PMC4618391."
NRAS	G13V	Follicular Carcinoma/Papillary Carcinoma	'THF'/'THP'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	G13V	Melanoma	'*M'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	G13V	Other Tumor Type	'CANCER'	" ### Keutgen et al...Molecular diagnosis for indeterminate thyroid nodules on fine needle aspiration: advances and limitations. Expert Rev. Mol. Diagn. 13(6), 613‚Ä?23 (2013) ### Zhu Z et al.... Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J. Clin. Endocrinol. Metab. 91(9), 3603‚Ä?610 (2006)."
NRAS	G13V	Urothelial Carcinoma	'UTH'	" ### Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One. 2010 Nov 3;5(11):e13821. doi: 10.1371/journal.pone.0013821. PubMed PMID: 21072204; PubMed Central PMCID: PMC2972209. ### Calderaro J, Rebouissou S, de Koning L, Masmoudi A, H√©rault A, Dubois T, Maille P, Soyeux P, Sibony M, de la Taille A, Vordos D, Lebret T, Radvanyi F, Allory Y. PI3K/AKT pathway activation in bladder carcinogenesis. Int J Cancer. 2014 Apr 15;134(8):1776-84. doi: 10.1002/ijc.28518. Epub 2013 Oct 24. PubMed PMID: 24122582."
NRAS	Q61H	Adenocarcinoma	'*AC2'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	Q61H	Adenocarcinoma/Non-Small Cell Lung Carcinoma	'*AC2'/'NSCLC'	" ### Ohashi et al. Characteristics of lung cancers harboring NRAS mutations. Clinical Cancer Research 19.9 (2013): 2584-2591. ### Vujic I et al. Mutant NRASQ61 shares signaling similarities across various cancer types ‚Ä?potential implications for future therapies. Oncotarget. 2014;5(17):7936-7944. ### Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler K, Franklin WA, Iafrate AJ, Ladanyi M, Kris MG, Johnson BE, Bunn PA, Minna JD, Kwiatkowski DJ; LCMC Investigators. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2015 May;10(5):768-77. doi: 10.1097/JTO.0000000000000516. PubMed PMID: 25738220; PubMed Central PMCID: PMC4410843. ### Araujo LH, Lammers PE, Matthews-Smith V, Eisenberg R, Gonzalez A, Schwartz AG, Timmers C, Shilo K, Zhao W, Natarajan TG, Zhang J, Yilmaz AS, Liu T, Coombes K, Carbone DP. Somatic Mutation Spectrum of Non-Small-Cell Lung Cancer in African Americans: A Pooled Analysis. J Thorac Oncol. 2015 Oct;10(10):1430-6. doi: 10.1097/JTO.0000000000000650. PubMed PMID: 26301800; PubMed Central PMCID: PMC4618391."
NRAS	Q61H	Follicular Carcinoma/Papillary Carcinoma	'THF'/'THP'	" ### Nikiforov YE Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med 2011;135(5):569-77 ### Bae JS, et al. Impact of NRAS Mutations on the Diagnosis of Follicular Neoplasm of the Thyroid. Int J Endocrinol 2014;2014():289834 ### Fern√°ndez-Medarde A, et al. Ras in cancer and developmental diseases. Genes Cancer 2011;2(3):344-58 ### Radkay LA, et al. Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics. Cancer Cytopathol 2014;122(12):873-82"
NRAS	Q61H	Melanoma	'*M'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	Q61H	Other Tumor Type	'CANCER'	" ### Keutgen et al...Molecular diagnosis for indeterminate thyroid nodules on fine needle aspiration: advances and limitations. Expert Rev. Mol. Diagn. 13(6), 613‚Ä?23 (2013) ### Zhu Z et al.... Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J. Clin. Endocrinol. Metab. 91(9), 3603‚Ä?610 (2006)."
NRAS	Q61H	Urothelial Carcinoma	'UTH'	" ### Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One. 2010 Nov 3;5(11):e13821. doi: 10.1371/journal.pone.0013821. PubMed PMID: 21072204; PubMed Central PMCID: PMC2972209. ### Calderaro J, Rebouissou S, de Koning L, Masmoudi A, H√©rault A, Dubois T, Maille P, Soyeux P, Sibony M, de la Taille A, Vordos D, Lebret T, Radvanyi F, Allory Y. PI3K/AKT pathway activation in bladder carcinogenesis. Int J Cancer. 2014 Apr 15;134(8):1776-84. doi: 10.1002/ijc.28518. Epub 2013 Oct 24. PubMed PMID: 24122582."
NRAS	Q61K	Adenocarcinoma	'*AC2'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	Q61K	Adenocarcinoma/Non-Small Cell Lung Carcinoma	'*AC2'/'NSCLC'	" ### Ohashi et al. Characteristics of lung cancers harboring NRAS mutations. Clinical Cancer Research 19.9 (2013): 2584-2591. ### Vujic I et al. Mutant NRASQ61 shares signaling similarities across various cancer types ‚Ä?potential implications for future therapies. Oncotarget. 2014;5(17):7936-7944. ### Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler K, Franklin WA, Iafrate AJ, Ladanyi M, Kris MG, Johnson BE, Bunn PA, Minna JD, Kwiatkowski DJ; LCMC Investigators. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2015 May;10(5):768-77. doi: 10.1097/JTO.0000000000000516. PubMed PMID: 25738220; PubMed Central PMCID: PMC4410843. ### Araujo LH, Lammers PE, Matthews-Smith V, Eisenberg R, Gonzalez A, Schwartz AG, Timmers C, Shilo K, Zhao W, Natarajan TG, Zhang J, Yilmaz AS, Liu T, Coombes K, Carbone DP. Somatic Mutation Spectrum of Non-Small-Cell Lung Cancer in African Americans: A Pooled Analysis. J Thorac Oncol. 2015 Oct;10(10):1430-6. doi: 10.1097/JTO.0000000000000650. PubMed PMID: 26301800; PubMed Central PMCID: PMC4618391."
NRAS	Q61K	Follicular Carcinoma/Papillary Carcinoma	'THF'/'THP'	" ### Nikiforov YE Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med 2011;135(5):569-77 ### Bae JS, et al. Impact of NRAS Mutations on the Diagnosis of Follicular Neoplasm of the Thyroid. Int J Endocrinol 2014;2014():289834 ### Fern√°ndez-Medarde A, et al. Ras in cancer and developmental diseases. Genes Cancer 2011;2(3):344-58 ### Radkay LA, et al. Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics. Cancer Cytopathol 2014;122(12):873-82"
NRAS	Q61K	Melanoma	'*M'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	Q61K	Other Tumor Type	'CANCER'	" ### Keutgen et al...Molecular diagnosis for indeterminate thyroid nodules on fine needle aspiration: advances and limitations. Expert Rev. Mol. Diagn. 13(6), 613‚Ä?23 (2013) ### Zhu Z et al.... Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J. Clin. Endocrinol. Metab. 91(9), 3603‚Ä?610 (2006)."
NRAS	Q61K	Urothelial Carcinoma	'UTH'	" ### Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One. 2010 Nov 3;5(11):e13821. doi: 10.1371/journal.pone.0013821. PubMed PMID: 21072204; PubMed Central PMCID: PMC2972209. ### Calderaro J, Rebouissou S, de Koning L, Masmoudi A, H√©rault A, Dubois T, Maille P, Soyeux P, Sibony M, de la Taille A, Vordos D, Lebret T, Radvanyi F, Allory Y. PI3K/AKT pathway activation in bladder carcinogenesis. Int J Cancer. 2014 Apr 15;134(8):1776-84. doi: 10.1002/ijc.28518. Epub 2013 Oct 24. PubMed PMID: 24122582."
NRAS	Q61L	Adenocarcinoma	'*AC2'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	Q61L	Adenocarcinoma/Non-Small Cell Lung Carcinoma	'*AC2'/'NSCLC'	" ### Ohashi et al. Characteristics of lung cancers harboring NRAS mutations. Clinical Cancer Research 19.9 (2013): 2584-2591. ### Vujic I et al. Mutant NRASQ61 shares signaling similarities across various cancer types ‚Ä?potential implications for future therapies. Oncotarget. 2014;5(17):7936-7944. ### Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler K, Franklin WA, Iafrate AJ, Ladanyi M, Kris MG, Johnson BE, Bunn PA, Minna JD, Kwiatkowski DJ; LCMC Investigators. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2015 May;10(5):768-77. doi: 10.1097/JTO.0000000000000516. PubMed PMID: 25738220; PubMed Central PMCID: PMC4410843. ### Araujo LH, Lammers PE, Matthews-Smith V, Eisenberg R, Gonzalez A, Schwartz AG, Timmers C, Shilo K, Zhao W, Natarajan TG, Zhang J, Yilmaz AS, Liu T, Coombes K, Carbone DP. Somatic Mutation Spectrum of Non-Small-Cell Lung Cancer in African Americans: A Pooled Analysis. J Thorac Oncol. 2015 Oct;10(10):1430-6. doi: 10.1097/JTO.0000000000000650. PubMed PMID: 26301800; PubMed Central PMCID: PMC4618391."
NRAS	Q61L	Follicular Carcinoma/Papillary Carcinoma	'THF'/'THP'	" ### Nikiforov YE Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med 2011;135(5):569-77 ### Bae JS, et al. Impact of NRAS Mutations on the Diagnosis of Follicular Neoplasm of the Thyroid. Int J Endocrinol 2014;2014():289834 ### Fern√°ndez-Medarde A, et al. Ras in cancer and developmental diseases. Genes Cancer 2011;2(3):344-58 ### Radkay LA, et al. Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics. Cancer Cytopathol 2014;122(12):873-82"
NRAS	Q61L	Melanoma	'*M'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	Q61L	Other Tumor Type	'CANCER'	" ### Keutgen et al...Molecular diagnosis for indeterminate thyroid nodules on fine needle aspiration: advances and limitations. Expert Rev. Mol. Diagn. 13(6), 613‚Ä?23 (2013) ### Zhu Z et al.... Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J. Clin. Endocrinol. Metab. 91(9), 3603‚Ä?610 (2006)."
NRAS	Q61L	Urothelial Carcinoma	'UTH'	" ### Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One. 2010 Nov 3;5(11):e13821. doi: 10.1371/journal.pone.0013821. PubMed PMID: 21072204; PubMed Central PMCID: PMC2972209. ### Calderaro J, Rebouissou S, de Koning L, Masmoudi A, H√©rault A, Dubois T, Maille P, Soyeux P, Sibony M, de la Taille A, Vordos D, Lebret T, Radvanyi F, Allory Y. PI3K/AKT pathway activation in bladder carcinogenesis. Int J Cancer. 2014 Apr 15;134(8):1776-84. doi: 10.1002/ijc.28518. Epub 2013 Oct 24. PubMed PMID: 24122582."
NRAS	Q61R	Adenocarcinoma	'*AC2'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	Q61R	Adenocarcinoma/Non-Small Cell Lung Carcinoma	'*AC2'/'NSCLC'	" ### Ohashi et al. Characteristics of lung cancers harboring NRAS mutations. Clinical Cancer Research 19.9 (2013): 2584-2591. ### Vujic I et al. Mutant NRASQ61 shares signaling similarities across various cancer types ‚Ä?potential implications for future therapies. Oncotarget. 2014;5(17):7936-7944. ### Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler K, Franklin WA, Iafrate AJ, Ladanyi M, Kris MG, Johnson BE, Bunn PA, Minna JD, Kwiatkowski DJ; LCMC Investigators. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2015 May;10(5):768-77. doi: 10.1097/JTO.0000000000000516. PubMed PMID: 25738220; PubMed Central PMCID: PMC4410843. ### Araujo LH, Lammers PE, Matthews-Smith V, Eisenberg R, Gonzalez A, Schwartz AG, Timmers C, Shilo K, Zhao W, Natarajan TG, Zhang J, Yilmaz AS, Liu T, Coombes K, Carbone DP. Somatic Mutation Spectrum of Non-Small-Cell Lung Cancer in African Americans: A Pooled Analysis. J Thorac Oncol. 2015 Oct;10(10):1430-6. doi: 10.1097/JTO.0000000000000650. PubMed PMID: 26301800; PubMed Central PMCID: PMC4618391."
NRAS	Q61R	Cholangiocarcinoma	'CH'	" ### Voss, Jesse S., et al. ""Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions."" Human pathology 44.7 (2013): 1216-1222. ### Deshpande, Vikram, et al. ""Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma."" BMC cancer 11.1 (2011): 60. ### Putra J, de Abreu FB, Peterson JD, Pipas JM, Mody K, Amos CI, Tsongalis GJ, Suriawinata AA. Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing. Exp Mol Pathol. 2015 Oct;99(2):240-4. doi:0.1016/j.yexmp.2015.07.005. Epub 2015 Jul 17. PubMed PMID: 26189129; PubMed Central PMCID: PMC4591249. ### Zhu AX, Borger DR, Kim Y, Cosgrove D, Ejaz A, Alexandrescu S, Groeschl RT, Deshpande V, Lindberg JM, Ferrone C, Sempoux C, Yau T, Poon R, Popescu I, Bauer TW, Gamblin TC, Gigot JF, Anders RA, Pawlik TM. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets. Ann Surg Oncol. 2014 Nov;21(12):3827-34. doi: 10.1245/s10434-014-3828-x. Epub 2014 Jun 3. PubMed PMID: 24889489; PubMed Central PMCID: PMC4324507."
NRAS	Q61R	Follicular Carcinoma/Papillary Carcinoma	'THF'/'THP'	" ### Nikiforov YE Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med 2011;135(5):569-77 ### Bae JS, et al. Impact of NRAS Mutations on the Diagnosis of Follicular Neoplasm of the Thyroid. Int J Endocrinol 2014;2014():289834 ### Fern√°ndez-Medarde A, et al. Ras in cancer and developmental diseases. Genes Cancer 2011;2(3):344-58 ### Radkay LA, et al. Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics. Cancer Cytopathol 2014;122(12):873-82"
NRAS	Q61R	Melanoma	'*M'	" ### Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71 ### JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517 ### De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62 ### Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77 ### Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47"
NRAS	Q61R	Other Tumor Type	'CANCER'	" ### Keutgen et al...Molecular diagnosis for indeterminate thyroid nodules on fine needle aspiration: advances and limitations. Expert Rev. Mol. Diagn. 13(6), 613‚Ä?23 (2013) ### Zhu Z et al.... Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J. Clin. Endocrinol. Metab. 91(9), 3603‚Ä?610 (2006)."
NRAS	Q61R	Urothelial Carcinoma	'UTH'	" ### Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One. 2010 Nov 3;5(11):e13821. doi: 10.1371/journal.pone.0013821. PubMed PMID: 21072204; PubMed Central PMCID: PMC2972209. ### Calderaro J, Rebouissou S, de Koning L, Masmoudi A, H√©rault A, Dubois T, Maille P, Soyeux P, Sibony M, de la Taille A, Vordos D, Lebret T, Radvanyi F, Allory Y. PI3K/AKT pathway activation in bladder carcinogenesis. Int J Cancer. 2014 Apr 15;134(8):1776-84. doi: 10.1002/ijc.28518. Epub 2013 Oct 24. PubMed PMID: 24122582."
NT5C2	any mutation	B Lymphoblastic Leukemia/Lymphoma/T Lymphoblastic Leukemia/Lymphoma	'*BLL'/'LY'/'*TLL'/'LY'	" ### Tzoneva G, et al. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nat Med 2013;19(3):368-71 ### Meyer JA, et al. Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat Genet 2013;45(3):290-4"
PAX5	any mutation	B Lymphoblastic Leukemia/Lymphoma	'*BLL'/'LY'	" ### Shah S, et al. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat Genet 2013;45(10):1226-31 ### Liu GJ, et al. Pax5 loss imposes a reversible differentiation block in B-progenitor acute lymphoblastic leukemia. Genes Dev 2014;28(12):1337-50"
PBRM1	any mutation	Clear Cell Renal Cell Carcinoma/Renal Cell Carcinoma	'RCCC'/'R'	" ### Hakimi AA, et al. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol 2013;63(5):848-54 ### Gossage L, et al. Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma. Genes Chromosomes Cancer 2014;53(1):38-51 ### Liao L, et al. The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer. Cancer Genet 2015;208(5):206-14 ### Randall JM, et al. Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art. Cancer Metastasis Rev 2014;33(4):1109-24"
PDGFA	Y273F	Ductal Carcinoma	'*DC'	" ### Heinrich MC, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008;26(33):5360-7 ### Sihto H, et al. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. J Clin Oncol 2005;23(1):49-57"
PDGFRA	codon(s) 842 any	Gastrointestinal Stromal Tumor	'GIST'	" ### Corless et al.. PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to Imatinib. 2005 J Clin Oncol 23:5357-5364."
PDGFRA	H650Q	Myeloproliferative Neoplasm	'*MPN2'	" ### Velghe AI, et al. PDGFRA alterations in cancer: characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutations. Oncogene 2014;33(20):2568-76 ### Hochhaus A, et al. Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study. J Cancer Res Clin Oncol 2013;139(12):1985-93 ### Elling C, et al. Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. Blood 2011;117(10):2935-43 ### Cools J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348(13):1201-14 ### Lierman E, et al. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood 2006;108(4):1374-6 ### Lierman E, et al. Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases. Leukemia 2012;26(7):1693-5"
PDGFRA	N659S	Myeloproliferative Neoplasm	'*MPN2'	" ### Velghe AI, et al. PDGFRA alterations in cancer: characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutations. Oncogene 2014;33(20):2568-76 ### Hochhaus A, et al. Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study. J Cancer Res Clin Oncol 2013;139(12):1985-93 ### Elling C, et al. Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. Blood 2011;117(10):2935-43 ### Cools J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348(13):1201-14 ### Lierman E, et al. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood 2006;108(4):1374-6 ### Lierman E, et al. Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases. Leukemia 2012;26(7):1693-5"
PDGFRA	Y849S	Myeloproliferative Neoplasm	'*MPN2'	" ### Velghe AI, et al. PDGFRA alterations in cancer: characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutations. Oncogene 2014;33(20):2568-76 ### Hochhaus A, et al. Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study. J Cancer Res Clin Oncol 2013;139(12):1985-93 ### Elling C, et al. Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. Blood 2011;117(10):2935-43 ### Cools J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348(13):1201-14 ### Lierman E, et al. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood 2006;108(4):1374-6 ### Lierman E, et al. Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases. Leukemia 2012;26(7):1693-5"
PDS5B	any mutation	Myelodysplastic Syndrome	'MDS'	" ### Kon A, et al. Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat Genet 2013;45(10):1232-7"
PHF6	any mutation	T Lymphoblastic Leukemia/Lymphoma/Acute Myeloid Leukemia	'*TLL'/'LY'/'AML'	" ### Huh HJ, et al. Gene mutation profiles and prognostic implications in Korean patients with T-lymphoblastic leukemia. Ann Hematol 2013;92(5):635-44 ### Li X, et al. Somatic mutations of PHF6 in patients with chronic myeloid leukemia in blast crisis. Leuk Lymphoma 2013;54(3):671-2 ### Patel JP, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012;366(12):1079-89 ### Wang Q, et al. Mutations of PHF6 are associated with mutations of NOTCH1, JAK1 and rearrangement of SET-NUP214 in T-cell acute lymphoblastic leukemia. Haematologica 2011;96(12):1808-14 ### Yoo NJ, et al. Somatic mutation of PHF6 gene in T-cell acute lymphoblatic leukemia, acute myelogenous leukemia and hepatocellular carcinoma. Acta Oncol 2012;51(1):107-11 ### Van Vlierberghe P, et al. PHF6 mutations in adult acute myeloid leukemia. Leukemia 2011;25(1):130-4 ### Van Vlierberghe P, et al. PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet 2010;42(4):338-42"
PIGA	any mutation	Other Tumor Type	'CANCER'	" ### Madkaikar M, et al. Paroxysmal nocturnal haemoglobinuria: diagnostic tests, advantages, &amp;amp; limitations. Eur J Haematol 2009;83(6):503-11 ### http://omim.org/entry/311770"
PIK3CA	any mutation	Adenocarcinoma/Carcinoma	'*AC2'/'*CA'	" ### Samuels Y, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304(5670):554 ### Taylor BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18(1):11-22 ### Barbieri CE, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012;44(6):685-9"
PIK3CA	any mutation	Hepatocellular Carcinoma/Adenocarcinoma/Cholangiocarcinoma	'*HCC'/'*AC2'/'CH'	" ### Karakas B, et al. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 2006;94(4):455-9 ### Lee JW, et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005;24(8):1477-80 ### Velho S, et al. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 2005;41(11):1649-54 ### Jiao Y, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet 2013;45(12):1470-3 ### Witkiewicz AK, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun 2015;6():6744"
PIK3CA	any mutation	Medulloblastoma	'MB'	" ### Robinson G, et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 2012;488(7409):43-8 ### Hartmann C, et al. PIK3CA mutations in glioblastoma multiforme. Acta Neuropathol 2005;109(6):639-42 ### Gallia GL, et al. PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res 2006;4(10):709-14 ### Broderick DK, et al. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res 2004;64(15):5048-50 ### Theeler BJ, et al. Adult brainstem gliomas: Correlation of clinical and molecular features. J Neurol Sci 2015;353(1-2):92-7 ### Gessi M, et al. FGFR1 mutations in Rosette-forming glioneuronal tumors of the fourth ventricle. J Neuropathol Exp Neurol 2014;73(6):580-4"
PIK3CA	any mutation	Squamous Cell Carcinoma	'SCC'	" ### Stransky N, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011;333(6046):1157-60 ### Cancer Genome Atlas Network Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015;517(7536):576-82 ### Cacheux W, et al. Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resection. Br J Cancer 2016;114(12):1387-94 ### Smaglo BG, et al. Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas. Oncotarget 2015;6(41):43594-604 ### Zhang P, et al. Molecular heterogeneity of head and neck squamous cell carcinoma defined by next-generation sequencing. Am J Pathol 2014;184(5):1323-30"
PIK3CA	any mutation	Urothelial Carcinoma	'UTH'	" ### Knowles, Margaret, et al. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nature Reviews Cancer 15.1 (2015): 25-41. ### Chaux, Alcides, et al. PIK3CA Mutational Analysis in Formalin-Fixed, Paraffin-Embedded Archival Tissues of Urothelial Carcinoma of Urinary Bladder. bioRxiv (2015): 020263. ### Netto, George J. Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?. Nature Reviews Urology 9.1 (2012): 41-51. ### Qian, Chao-Nan, et al. Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models. Cancer research 69.21 (2009): 8256-8264."
PIK3CA	" codon(s) 542, 545, 1047 any"	Adenocarcinoma	'*AC2'	" ### DeRoock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations of the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol. 2010;11:753-762. ### Prenan H, DeSchutter J, Jacobs B, et al. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res.2009;15:3184-3188 ### Stephens PJ et al. The landscape of cancer genes and mutational processes in breast cancer. 2012 Nature;486(7403):400-4 ### K111N"
PIK3CA	" codon(s) 542, 545, 1047 any"	Diffuse Large B Cell Lymphoma/Chronic Lymphocytic Leukemia	'DLBCL'/'CLL'	" ### Abubaker J, et al. PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma. Leukemia 2007;21(11):2368-70 ### Marincevic M, et al. Infrequent occurrence of PIK3CA mutations in chronic lymphocytic leukemia. Leuk Lymphoma 2009;50(5):829-30 ### Hummerdal P, et al. Absence of hot spot mutations of the PIK3CA gene in acute myeloid leukaemia. Eur J Haematol 2006;77(1):86-7 ### Kalender Atak Z, et al. High accuracy mutation detection in leukemia on a selected panel of cancer genes. PLoS One 2012;7(6):e38463 ### Janku F, et al. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep 2014;6(2):377-87 ### M√ºller CI, et al. Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene. Leuk Res 2007;31(1):27-32"
PIK3CA	" codon(s) 542, 545, 1047 any"	Hepatocellular Carcinoma/Adenocarcinoma/Cholangiocarcinoma	'*HCC'/'*AC2'/'CH'	" ### Karakas B, et al. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 2006;94(4):455-9 ### Lee JW, et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005;24(8):1477-80 ### Velho S, et al. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 2005;41(11):1649-54 ### Jiao Y, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet 2013;45(12):1470-3 ### Witkiewicz AK, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun 2015;6():6744"
PIK3CA	" codon(s) 542, 545, 1047 any"	Squamous Cell Carcinoma	'SCC'	" ### Stransky N, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011;333(6046):1157-60 ### Cancer Genome Atlas Network Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015;517(7536):576-82 ### Cacheux W, et al. Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resection. Br J Cancer 2016;114(12):1387-94 ### Smaglo BG, et al. Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas. Oncotarget 2015;6(41):43594-604 ### Zhang P, et al. Molecular heterogeneity of head and neck squamous cell carcinoma defined by next-generation sequencing. Am J Pathol 2014;184(5):1323-30"
PIK3CA	E542K	Adenocarcinoma	'*AC2'	" ### DeRoock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations of the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol. 2010;11:753-762. ### Prenan H, DeSchutter J, Jacobs B, et al. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res.2009;15:3184-3188 ### Stephens PJ et al. The landscape of cancer genes and mutational processes in breast cancer. 2012 Nature;486(7403):400-4 ### K111N"
PIK3CA	E542K	Diffuse Large B Cell Lymphoma/Chronic Lymphocytic Leukemia	'DLBCL'/'CLL'	" ### Abubaker J, et al. PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma. Leukemia 2007;21(11):2368-70 ### Marincevic M, et al. Infrequent occurrence of PIK3CA mutations in chronic lymphocytic leukemia. Leuk Lymphoma 2009;50(5):829-30 ### Hummerdal P, et al. Absence of hot spot mutations of the PIK3CA gene in acute myeloid leukaemia. Eur J Haematol 2006;77(1):86-7 ### Kalender Atak Z, et al. High accuracy mutation detection in leukemia on a selected panel of cancer genes. PLoS One 2012;7(6):e38463 ### Janku F, et al. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep 2014;6(2):377-87 ### M√ºller CI, et al. Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene. Leuk Res 2007;31(1):27-32"
PIK3CA	E542K	Hepatocellular Carcinoma/Adenocarcinoma/Cholangiocarcinoma	'*HCC'/'*AC2'/'CH'	" ### Karakas B, et al. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 2006;94(4):455-9 ### Lee JW, et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005;24(8):1477-80 ### Velho S, et al. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 2005;41(11):1649-54 ### Jiao Y, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet 2013;45(12):1470-3 ### Witkiewicz AK, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun 2015;6():6744"
PIK3CA	E542K	Squamous Cell Carcinoma	'SCC'	" ### Stransky N, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011;333(6046):1157-60 ### Cancer Genome Atlas Network Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015;517(7536):576-82 ### Cacheux W, et al. Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resection. Br J Cancer 2016;114(12):1387-94 ### Smaglo BG, et al. Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas. Oncotarget 2015;6(41):43594-604 ### Zhang P, et al. Molecular heterogeneity of head and neck squamous cell carcinoma defined by next-generation sequencing. Am J Pathol 2014;184(5):1323-30"
PIK3CA	E545K	Adenocarcinoma	'*AC2'	" ### DeRoock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations of the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol. 2010;11:753-762. ### Prenan H, DeSchutter J, Jacobs B, et al. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res.2009;15:3184-3188 ### Stephens PJ et al. The landscape of cancer genes and mutational processes in breast cancer. 2012 Nature;486(7403):400-4 ### K111N"
PIK3CA	E545K	Adenocarcinoma	'*AC2'	" ### Samuels Y, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304(5670):554 ### Therkildsen C, et al. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Acta Oncol 2014;53(7):852-64 ### Liao RG, et al. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res 2013;73(16):5195-205 ### Ogino S, et al. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. Oncogene 2014;33(23):2949-55"
PIK3CA	E545K	Diffuse Large B Cell Lymphoma/Chronic Lymphocytic Leukemia	'DLBCL'/'CLL'	" ### Abubaker J, et al. PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma. Leukemia 2007;21(11):2368-70 ### Marincevic M, et al. Infrequent occurrence of PIK3CA mutations in chronic lymphocytic leukemia. Leuk Lymphoma 2009;50(5):829-30 ### Hummerdal P, et al. Absence of hot spot mutations of the PIK3CA gene in acute myeloid leukaemia. Eur J Haematol 2006;77(1):86-7 ### Kalender Atak Z, et al. High accuracy mutation detection in leukemia on a selected panel of cancer genes. PLoS One 2012;7(6):e38463 ### Janku F, et al. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep 2014;6(2):377-87 ### M√ºller CI, et al. Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene. Leuk Res 2007;31(1):27-32"
PIK3CA	E545K	Hepatocellular Carcinoma/Adenocarcinoma/Cholangiocarcinoma	'*HCC'/'*AC2'/'CH'	" ### Karakas B, et al. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 2006;94(4):455-9 ### Lee JW, et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005;24(8):1477-80 ### Velho S, et al. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 2005;41(11):1649-54 ### Jiao Y, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet 2013;45(12):1470-3 ### Witkiewicz AK, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun 2015;6():6744"
PIK3CA	E545K	Squamous Cell Carcinoma	'SCC'	" ### Stransky N, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011;333(6046):1157-60 ### Cancer Genome Atlas Network Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015;517(7536):576-82 ### Cacheux W, et al. Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resection. Br J Cancer 2016;114(12):1387-94 ### Smaglo BG, et al. Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas. Oncotarget 2015;6(41):43594-604 ### Zhang P, et al. Molecular heterogeneity of head and neck squamous cell carcinoma defined by next-generation sequencing. Am J Pathol 2014;184(5):1323-30"
PIK3CA	" exon(s) 10, 20, 21 any"	Adenocarcinoma	'*AC2'	" ### Liao X et al. Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review. Clinical Cancer Research 2012;18(8):2257-68 ### Samuels et al High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004 Apr 23;304(5670):554. ### Ogino et al..Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. Oncogene (2014) 33, 2949‚Ä?955"
PIK3CA	" exon(s) 10, 20, 21 any"	Adenocarcinoma/Squamous Cell Carcinoma	'*AC2'/'SCC'	" ### Sequist L et al.. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011 Mar 23;3(75):75ra26. ### Kawano O, et al. PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer 2006;54(2):209-15"
PIK3CA	" exon(s) 10, 20, 21 any"	Diffuse Large B Cell Lymphoma/Chronic Lymphocytic Leukemia	'DLBCL'/'CLL'	" ### Abubaker J, et al. PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma. Leukemia 2007;21(11):2368-70 ### Marincevic M, et al. Infrequent occurrence of PIK3CA mutations in chronic lymphocytic leukemia. Leuk Lymphoma 2009;50(5):829-30 ### Hummerdal P, et al. Absence of hot spot mutations of the PIK3CA gene in acute myeloid leukaemia. Eur J Haematol 2006;77(1):86-7 ### Kalender Atak Z, et al. High accuracy mutation detection in leukemia on a selected panel of cancer genes. PLoS One 2012;7(6):e38463 ### Janku F, et al. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep 2014;6(2):377-87 ### M√ºller CI, et al. Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene. Leuk Res 2007;31(1):27-32"
PIK3CA	" exon(s) 10, 20, 21 any"	Glial Neoplasm	'*GN''	" ### Hartmann et al PIK3CA mutations in glioblastoma multiforme.Acta Neuropathol (2005) 109: 639‚Ä?42 ### Gallia et al. PIK3CA Gene Mutations in Pediatric and Adult Glioblastoma Multiforme. Mol Cancer Res 2006;4(10):709‚Ä?4) ### Broderick DK, Di C, Parrett TJ, Samuels YR, Cummins JM, McLendon RE, Fults DW, Velculescu VE, Bigner DD, Yan H. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res. 2004 Aug 1;64(15):5048-50. PubMed PMID: 15289301. ### Theeler BJ, Ellezam B, Melguizo-Gavilanes I, de Groot JF, Mahajan A, Aldape KD, Bruner JM, Puduvalli VK. Adult brainstem gliomas: Correlation of clinical and molecular features. J Neurol Sci. 2015 Jun 15;353(1-2):92-7. doi: 10.1016/j.jns.2015.04.014. Epub 2015 Apr 18. PubMed PMID: 25934342. ### Gessi M, Moneim YA, Hammes J, Goschzik T, Scholz M, Denkhaus D, Waha A, Pietsch T. FGFR1 mutations in Rosette-forming glioneuronal tumors of the fourth ventricle. J Neuropathol Exp Neurol. 2014 Jun;73(6):580-4. doi: 10.1097/NEN.0000000000000080. PubMed PMID: 24806303."
PIK3CA	" exon(s) 10, 20, 21 any"	Papillary Carcinoma/Carcinoma	'THP'/'*CA'	" ### Nikiforova et al. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrin Metab 2013 Nov;98(11):E1852-60 ### Garcia-Rostan et al Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res. 2005 Nov15;65(22):10199-207 ### Ricarte-Filho JC et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 2009 Jun 1;69(11):4885-93. doi: 10.1158/0008-5472.CAN-09-0727. ### Hou P et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin. Cancer Res. 2007;13:1161‚Ä?170 ### Vu-Phan et al. Genetics and epigenetics of sporadic thyroid cancer. Molecular and cellular endocrinology 386, no. 1 (2014): 55-66."
PIK3CA	H1047R	Adenocarcinoma	'*AC2'	" ### DeRoock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations of the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol. 2010;11:753-762. ### Prenan H, DeSchutter J, Jacobs B, et al. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res.2009;15:3184-3188 ### Stephens PJ et al. The landscape of cancer genes and mutational processes in breast cancer. 2012 Nature;486(7403):400-4 ### K111N"
PIK3CA	H1047R	Diffuse Large B Cell Lymphoma/Chronic Lymphocytic Leukemia	'DLBCL'/'CLL'	" ### Abubaker J, et al. PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma. Leukemia 2007;21(11):2368-70 ### Marincevic M, et al. Infrequent occurrence of PIK3CA mutations in chronic lymphocytic leukemia. Leuk Lymphoma 2009;50(5):829-30 ### Hummerdal P, et al. Absence of hot spot mutations of the PIK3CA gene in acute myeloid leukaemia. Eur J Haematol 2006;77(1):86-7 ### Kalender Atak Z, et al. High accuracy mutation detection in leukemia on a selected panel of cancer genes. PLoS One 2012;7(6):e38463 ### Janku F, et al. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep 2014;6(2):377-87 ### M√ºller CI, et al. Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene. Leuk Res 2007;31(1):27-32"
PIK3CA	H1047R	Hepatocellular Carcinoma/Adenocarcinoma/Cholangiocarcinoma	'*HCC'/'*AC2'/'CH'	" ### Karakas B, et al. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 2006;94(4):455-9 ### Lee JW, et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005;24(8):1477-80 ### Velho S, et al. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 2005;41(11):1649-54 ### Jiao Y, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet 2013;45(12):1470-3 ### Witkiewicz AK, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun 2015;6():6744"
PIK3CA	H1047R	Squamous Cell Carcinoma	'SCC'	" ### Stransky N, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011;333(6046):1157-60 ### Cancer Genome Atlas Network Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015;517(7536):576-82 ### Cacheux W, et al. Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resection. Br J Cancer 2016;114(12):1387-94 ### Smaglo BG, et al. Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas. Oncotarget 2015;6(41):43594-604 ### Zhang P, et al. Molecular heterogeneity of head and neck squamous cell carcinoma defined by next-generation sequencing. Am J Pathol 2014;184(5):1323-30"
PIM1	any mutation	Acute Myeloid Leukemia/Myelodysplastic Syndrome	'AML'/'MDS'	" ### Fathi AT, et al. A potential therapeutic target for FLT3-ITD AML: PIM1 kinase. Leuk Res 2012;36(2):224-31 ### Chen LS, et al. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. Blood 2011;118(3):693-702"
PRPF40B	any mutation	Myeloproliferative Neoplasm/Acute Myeloid Leukemia/Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia	'*MPN2'/'AML'/'MDS'/'*CMML'	" ### Yoshida K, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011;478(7367):64-9"
PRPF8	any mutation	Myelodysplastic Syndrome/Acute Myeloid Leukemia	'MDS'/'AML'	" ### Haferlach T, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014;28(2):241-7 ### Makishima H, et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood 2012;119(14):3203-10"
PTEN	any deletion	Adenocarcinoma	'*AC2'	" ### Alphy Rose-James et al. Molecular Markers with Predictive and Prognostic Relevance in Lung Cancer. Lung Cancer International, vol. 2012, Article ID 729532, 12 pages, 2012. doi:10.1155/2012/729532 ### Martin L. Sos et al. PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR. Cancer research 69.8 (2009): 3256‚Ä?261. PMC. Web. 27 Aug. 2015. ### Hollander MC et al. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer. 2011 Apr;11(4):289-301. doi: 10.1038/nrc3037."
PTEN	any deletion	Adenocarcinoma	'*AC2'	" ### Barbieri CE, et al. Reprint of: The prostate cancer genome: Perspectives and potential. Urol Oncol 2015;33(2):95-102 ### Cancer Genome Atlas Research Network. Electronic address: schultz@cbio.mskcc.org, et al. The Molecular Taxonomy of Primary Prostate Cancer. Cell 2015;163(4):1011-25 ### Robinson D, et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015;161(5):1215-28"
PTEN	any deletion	Adenocarcinoma	'*AC2'	" ### DeRoock et al‚Ä?2011. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 2011 Jun;12(6):594-603. ### Laurent-Puig et al‚Ä?009. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol. 2009 Dec 10;27(35):5924-30"
PTEN	any deletion	Adenocarcinoma	'*AC2'	" ### Keniry M, et al. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 2008;27(41):5477-85 ### Kang YH, et al. Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Invest 2002;82(3):285-91 ### Pilarski R, et al. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. J Natl Cancer Inst 2013;105(21):1607-16 ### Matsuoka T, et al. The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma. Cancers (Basel) 2014;6(3):1441-63 ### Wen YG, et al. Mutation analysis of tumor suppressor gene PTEN in patients with gastric carcinomas and its impact on PI3K/AKT pathway. Oncol Rep 2010;24(1):89-95"
PTEN	any deletion	Follicular Carcinoma/Papillary Carcinoma	'THF'/'THP'	" ### Yip L Molecular markers for thyroid cancer diagnosis, prognosis, and targeted therapy. J Surg Oncol 2015;111(1):43-50 ### Xing M Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 2013;13(3):184-99 ### Gustafson S, et al. Cowden syndrome. Semin Oncol 2007;34(5):428-34 ### Keniry M, et al. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 2008;27(41):5477-85 ### Landa I, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest 2016;126(3):1052-66"
PTEN	any deletion	Glioblastoma/Glial Neoplasm	'GB'/'*GN''	" ### Arslantas A, et al. The importance of genomic copy number changes in the prognosis of glioblastoma multiforme. Neurosurg Rev 2004;27(1):58-64 ### Keniry M, et al. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 2008;27(41):5477-85 ### De Luca A, et al. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets 2012;16 Suppl 2():S17-27"
PTEN	any deletion	Invasive Ductal Carcinoma/Adenocarcinoma	'*IDC'/'*AC2'	" ### Keniry M, et al. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 2008;27(41):5477-85 ### De Luca A, et al. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets 2012;16 Suppl 2():S17-27 ### Saal LH, et al. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet 2008;40(1):102-7 ### Saal LH, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A 2007;104(18):7564-9 ### Tan MH, et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012;18(2):400-7"
PTEN	any frameshift	Adenocarcinoma	'*AC2'	" ### Alphy Rose-James et al. Molecular Markers with Predictive and Prognostic Relevance in Lung Cancer. Lung Cancer International, vol. 2012, Article ID 729532, 12 pages, 2012. doi:10.1155/2012/729532 ### Martin L. Sos et al. PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR. Cancer research 69.8 (2009): 3256‚Ä?261. PMC. Web. 27 Aug. 2015. ### Hollander MC et al. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer. 2011 Apr;11(4):289-301. doi: 10.1038/nrc3037."
PTEN	any frameshift	Adenocarcinoma	'*AC2'	" ### Keniry M, et al. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 2008;27(41):5477-85 ### Kang YH, et al. Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Invest 2002;82(3):285-91 ### Pilarski R, et al. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. J Natl Cancer Inst 2013;105(21):1607-16 ### Matsuoka T, et al. The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma. Cancers (Basel) 2014;6(3):1441-63 ### Wen YG, et al. Mutation analysis of tumor suppressor gene PTEN in patients with gastric carcinomas and its impact on PI3K/AKT pathway. Oncol Rep 2010;24(1):89-95"
PTEN	any frameshift	Follicular Carcinoma/Papillary Carcinoma	'THF'/'THP'	" ### Yip L Molecular markers for thyroid cancer diagnosis, prognosis, and targeted therapy. J Surg Oncol 2015;111(1):43-50 ### Xing M Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 2013;13(3):184-99 ### Gustafson S, et al. Cowden syndrome. Semin Oncol 2007;34(5):428-34 ### Keniry M, et al. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 2008;27(41):5477-85 ### Landa I, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest 2016;126(3):1052-66"
PTEN	any frameshift	Invasive Ductal Carcinoma/Adenocarcinoma	'*IDC'/'*AC2'	" ### Keniry M, et al. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 2008;27(41):5477-85 ### De Luca A, et al. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets 2012;16 Suppl 2():S17-27 ### Saal LH, et al. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet 2008;40(1):102-7 ### Saal LH, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A 2007;104(18):7564-9 ### Tan MH, et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012;18(2):400-7"
PTEN	any missense	Adenocarcinoma	'*AC2'	" ### Barbieri CE, et al. Reprint of: The prostate cancer genome: Perspectives and potential. Urol Oncol 2015;33(2):95-102 ### Cancer Genome Atlas Research Network. Electronic address: schultz@cbio.mskcc.org, et al. The Molecular Taxonomy of Primary Prostate Cancer. Cell 2015;163(4):1011-25 ### Robinson D, et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015;161(5):1215-28"
PTEN	any missense	Adenocarcinoma	'*AC2'	" ### Keniry M, et al. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 2008;27(41):5477-85 ### Kang YH, et al. Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Invest 2002;82(3):285-91 ### Pilarski R, et al. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. J Natl Cancer Inst 2013;105(21):1607-16 ### Matsuoka T, et al. The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma. Cancers (Basel) 2014;6(3):1441-63 ### Wen YG, et al. Mutation analysis of tumor suppressor gene PTEN in patients with gastric carcinomas and its impact on PI3K/AKT pathway. Oncol Rep 2010;24(1):89-95"
PTEN	any missense	Invasive Ductal Carcinoma/Adenocarcinoma	'*IDC'/'*AC2'	" ### Keniry M, et al. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 2008;27(41):5477-85 ### De Luca A, et al. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets 2012;16 Suppl 2():S17-27 ### Saal LH, et al. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet 2008;40(1):102-7 ### Saal LH, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A 2007;104(18):7564-9 ### Tan MH, et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012;18(2):400-7"
PTEN	any mutation	Adenocarcinoma	'*AC2'	" ### Djordjevic B, et al. Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing. Mod Pathol 2012;25(5):699-708 ### Lacey JV Jr, et al. PTEN expression in endometrial biopsies as a marker of progression to endometrial carcinoma. Cancer Res 2008;68(14):6014-20"
PTEN	any mutation	Adenocarcinoma	'*AC2'	" ### Keniry M, et al. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 2008;27(41):5477-85 ### Kang YH, et al. Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Invest 2002;82(3):285-91 ### Pilarski R, et al. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. J Natl Cancer Inst 2013;105(21):1607-16 ### Matsuoka T, et al. The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma. Cancers (Basel) 2014;6(3):1441-63 ### Wen YG, et al. Mutation analysis of tumor suppressor gene PTEN in patients with gastric carcinomas and its impact on PI3K/AKT pathway. Oncol Rep 2010;24(1):89-95"
PTEN	any mutation	Carcinoma	'*CA'	" ### McCoy KL, et al. The clinical importance of parathyroid atypia: is long-term surveillance necessary? Surgery 2015;158(4):929-35; discussion 935-6 ### Han SY, et al. Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay. Cancer Res 2000;60(12):3147-51 ### Yip L, et al. Loss of heterozygosity of selected tumor suppressor genes in parathyroid carcinoma. Surgery 2008;144(6):949-55; discussion 954-5 ### Kasaian K, et al. Complete genomic landscape of a recurring sporadic parathyroid carcinoma. J Pathol 2013;230(3):249-60 ### McCoy KL, et al. The clinical importance of parathyroid atypia: is long-term surveillance necessary? Surgery 2015;158(4):929-35; discussion 935-6"
PTEN	any mutation	Clear Cell Renal Cell Carcinoma/Renal Cell Carcinoma	'RCCC'/'R'	" ### Lee HJ, et al. Prognostic significance of biallelic loss of PTEN in clear cell renal cell carcinoma. J Urol 2014;192(3):940-6 ### Brugarolas J Molecular genetics of clear-cell renal cell carcinoma. J Clin Oncol 2014;32(18):1968-76"
PTEN	any mutation	Follicular Carcinoma/Papillary Carcinoma	'THF'/'THP'	" ### Yip L Molecular markers for thyroid cancer diagnosis, prognosis, and targeted therapy. J Surg Oncol 2015;111(1):43-50 ### Xing M Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 2013;13(3):184-99 ### Gustafson S, et al. Cowden syndrome. Semin Oncol 2007;34(5):428-34 ### Keniry M, et al. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 2008;27(41):5477-85 ### Landa I, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest 2016;126(3):1052-66"
PTEN	any mutation	Glioblastoma/Glial Neoplasm	'GB'/'*GN''	" ### Arslantas A, et al. The importance of genomic copy number changes in the prognosis of glioblastoma multiforme. Neurosurg Rev 2004;27(1):58-64 ### Keniry M, et al. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 2008;27(41):5477-85 ### De Luca A, et al. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets 2012;16 Suppl 2():S17-27"
PTEN	any mutation	Invasive Ductal Carcinoma/Adenocarcinoma	'*IDC'/'*AC2'	" ### Keniry M, et al. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 2008;27(41):5477-85 ### De Luca A, et al. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets 2012;16 Suppl 2():S17-27 ### Saal LH, et al. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet 2008;40(1):102-7 ### Saal LH, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A 2007;104(18):7564-9 ### Tan MH, et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012;18(2):400-7"
PTEN	any mutation	Melanoma	'*M'	" ### Keniry M, et al. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 2008;27(41):5477-85 ### Hill VK, et al. The genetics of melanoma: recent advances. Annu Rev Genomics Hum Genet 2013;14():257-79 ### Chin L, et al. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 2006;20(16):2149-82"
PTEN	any mutation	T Lymphoblastic Leukemia/Lymphoma	'*TLL'/'LY'	" ### Trinquand A, et al. Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. J Clin Oncol 2013;31(34):4333-42 ### Zuurbier L, et al. The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia. Haematologica 2012;97(9):1405-13"
PTEN	G165R	Carcinoma	'*CA'	" ### McCoy KL, et al. The clinical importance of parathyroid atypia: is long-term surveillance necessary? Surgery 2015;158(4):929-35; discussion 935-6 ### Han SY, et al. Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay. Cancer Res 2000;60(12):3147-51 ### Yip L, et al. Loss of heterozygosity of selected tumor suppressor genes in parathyroid carcinoma. Surgery 2008;144(6):949-55; discussion 954-5 ### Kasaian K, et al. Complete genomic landscape of a recurring sporadic parathyroid carcinoma. J Pathol 2013;230(3):249-60 ### McCoy KL, et al. The clinical importance of parathyroid atypia: is long-term surveillance necessary? Surgery 2015;158(4):929-35; discussion 935-6"
PTEN	Y68H	Adenocarcinoma	'*AC2'	" ### Marsh DJ, et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet 1998;7(3):507-15 ### Han SY, et al. Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay. Cancer Res 2000;60(12):3147-51 ### He X, et al. Naturally occurring germline and tumor-associated mutations within the ATP-binding motifs of PTEN lead to oxidative damage of DNA associated with decreased nuclear p53. Hum Mol Genet 2011;20(1):80-9"
PTPN11	any mutation	Acute Myeloid Leukemia/Myelodysplastic Syndrome/B Lymphoblastic Leukemia/Lymphoma	'AML'/'MDS'/'*BLL'/'LY'	" ### Tartaglia M, et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 2003;34(2):148-50 ### Yu B, et al. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies. Mol Cancer Ther 2013;12(9):1738-48 ### Barbosa TC, et al. Impact of mutations in FLT3, PTPN11 and RAS genes on the overall survival of pediatric B cell precursor acute lymphoblastic leukemia in Brazil. Leuk Lymphoma 2014;55(7):1501-9 ### Molteni CG, et al. PTPN11 mutations in childhood acute lymphoblastic leukemia occur as a secondary event associated with high hyperdiploidy. Leukemia 2010;24(1):232-5 ### Christiansen DH, et al. Mutations of the PTPN11 gene in therapy-related MDS and AML with rare balanced chromosome translocations. Genes Chromosomes Cancer 2007;46(6):517-21 ### Goemans BF, et al. Differences in the prevalence of PTPN11 mutations in FAB M5 paediatric acute myeloid leukaemia. Br J Haematol 2005;130(5):801-3 ### Hugues L, et al. Mutations of PTPN11 are rare in adult myeloid malignancies. Haematologica 2005;90(6):853-4 ### Nomded√©u J, et al. Low frequency of exon 3 PTPN11 mutations in adult de novo acute myeloid leukemia. Analysis of a consecutive series of 173 patients. Haematologica 2005;90(3):412-3 ### Loh ML, et al. Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Res 2005;29(4):459-62 ### Johan MF, et al. Mutations in PTPN11 are uncommon in adult myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 2004;124(6):843-4 ### Zhang J, et al. Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2011;118(11):3080-7"
PTPN11	any mutation	Adenocarcinoma/Squamous Cell Carcinoma/Non-Small Cell Lung Carcinoma	'*AC2'/'SCC'/'NSCLC'	" ### Martinelli S, et al. Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors. Cancer Genet Cytogenet 2006;166(2):124-9 ### Rizvi NA, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348(6230):124-8 ### Qu CK The SHP-2 tyrosine phosphatase: signaling mechanisms and biological functions. Cell Res 2000;10(4):279-88 ### Tartaglia M, et al. Germ-line and somatic PTPN11 mutations in human disease. Eur J Med Genet 2005;48(2):81-96 ### Grosskopf S, et al. Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in‚ÄÖvitro and in‚ÄÖvivo. ChemMedChem 2015;10(5):815-26 ### Yu B, et al. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies. Mol Cancer Ther 2013;12(9):1738-48 ### Bentires-Alj M, et al. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res 2004;64(24):8816-20"
PTPN11	any mutation	Glioblastoma/Glial Neoplasm	'GB'/'*GN''	" ### Martinelli S, et al. Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors. Cancer Genet Cytogenet 2006;166(2):124-9 ### Qu CK The SHP-2 tyrosine phosphatase: signaling mechanisms and biological functions. Cell Res 2000;10(4):279-88 ### Tartaglia M, et al. Germ-line and somatic PTPN11 mutations in human disease. Eur J Med Genet 2005;48(2):81-96 ### Grosskopf S, et al. Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in‚ÄÖvitro and in‚ÄÖvivo. ChemMedChem 2015;10(5):815-26 ### Yu B, et al. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies. Mol Cancer Ther 2013;12(9):1738-48"
RAD21	any mutation	Acute Myeloid Leukemia/Myelodysplastic Syndrome/Chronic Myeloid Leukemia	'AML'/'MDS'/'CML'	" ### Thol F, et al. Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. Blood 2014;123(6):914-20 ### Kon A, et al. Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat Genet 2013;45(10):1232-7"
RB1	any mutation	Glioblastoma	'GB'	" ### Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455(7216):1061-8 ### Brennan CW, et al. The somatic genomic landscape of glioblastoma. Cell 2013;155(2):462-77 ### Schr√∂der LB, et al. CDK4/6 Inhibitor PD0332991 in Glioblastoma Treatment: Does It Have a Future? Front Oncol 2015;5():259"
RB1	any mutation	Retinoblastoma	'RB'	" ### DiFiore et al.. RB1 in Cancer: Different Mechanisms of RB1 Inactivation and Alterations of pRb Pathway in Tumorigenesis. J. Cell. Physiol. 228: 1676‚Ä?687, 2013"
RIT1	any mutation	Acute Myeloid Leukemia/Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia	'AML'/'MDS'/'*CMML'	" ### G√≥mez-Segu√≠ I, et al. Novel recurrent mutations in the RAS-like GTP-binding gene RIT1 in myeloid malignancies. Leukemia 2013;27(9):1943-6"
RPL10	any mutation	T Lymphoblastic Leukemia/Lymphoma	'*TLL'/'LY'	" ### De Keersmaecker K, et al. Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. Nat Genet 2013;45(2):186-90"
RUNX1	any mutation	Myelodysplastic Syndrome/Acute Myeloid Leukemia/Chronic Myelomonocytic Leukemia/T Lymphoblastic Leukemia/Lymphoma	'MDS'/'AML'/'*CMML'/'*TLL'/'LY'	" ### Bejar R, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011;364(26):2496-506 ### Mangan JK, et al. RUNX1 mutations in clonal myeloid disorders: from conventional cytogenetics to next generation sequencing, a story 40 years in the making. Crit Rev Oncog 2011;16(1-2):77-91 ### Kihara R, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia 2014;28(8):1586-95 ### Haferlach T, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014;28(2):241-7 ### Ichikawa M, et al. A role for RUNX1 in hematopoiesis and myeloid leukemia. Int J Hematol 2013;97(6):726-34 ### Cazzola M, et al. The genetic basis of myelodysplasia and its clinical relevance. Blood 2013;122(25):4021-34 ### Mok MM, et al. RUNX1 point mutations potentially identify a subset of early immature T-cell acute lymphoblastic leukaemia that may originate from differentiated T-cells. Gene 2014;545(1):111-6 ### Zhang J, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012;481(7380):157-63"
SETBP1	any mutation	Atypical Chronic Myeloid Leukemia/Chronic Neutrophilic Leukemia/MDS/MPN/Acute Myeloid Leukemia/Chronic Myelomonocytic Leukemia	'ACML'/'CNL'/'MDS'/'MPN'/'AML'/'*CMML'	" ### Piazza R, et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet 2013;45(1):18-24 ### Damm F, et al. SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. Leukemia 2013;27(6):1401-3 ### Makishima H, et al. Somatic SETBP1 mutations in myeloid malignancies. Nat Genet 2013;45(8):942-6"
SETD2	any frameshift	Acute Myeloid Leukemia/T Lymphoblastic Leukemia/Lymphoma	'AML'/'*TLL'/'LY'	" ### Zhu X, et al. Identification of functional cooperative mutations of SETD2 in human acute leukemia. Nat Genet 2014;46(3):287-93 ### Mar BG, et al. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nat Commun 2014;5():3469 ### Zhang J, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012;481(7380):157-63"
SETD2	any missense	Acute Myeloid Leukemia/T Lymphoblastic Leukemia/Lymphoma	'AML'/'*TLL'/'LY'	" ### Zhu X, et al. Identification of functional cooperative mutations of SETD2 in human acute leukemia. Nat Genet 2014;46(3):287-93 ### Mar BG, et al. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nat Commun 2014;5():3469 ### Zhang J, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012;481(7380):157-63"
SETD2	any mutation	Clear Cell Renal Cell Carcinoma/Renal Cell Carcinoma	'RCCC'/'R'	" ### Hakimi AA, et al. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol 2013;63(5):848-54 ### Gossage L, et al. Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma. Genes Chromosomes Cancer 2014;53(1):38-51 ### Liao L, et al. The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer. Cancer Genet 2015;208(5):206-14 ### Randall JM, et al. Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art. Cancer Metastasis Rev 2014;33(4):1109-24 ### Cancer Genome Atlas Research Network Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013;499(7456):43-9 ### Sato Y, et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet 2013;45(8):860-7"
SETD2	any nonsense	Acute Myeloid Leukemia/T Lymphoblastic Leukemia/Lymphoma	'AML'/'*TLL'/'LY'	" ### Zhu X, et al. Identification of functional cooperative mutations of SETD2 in human acute leukemia. Nat Genet 2014;46(3):287-93 ### Mar BG, et al. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nat Commun 2014;5():3469 ### Zhang J, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012;481(7380):157-63"
SF1	any mutation	Myeloproliferative Neoplasm/Acute Myeloid Leukemia/Myelodysplastic Syndrome	'*MPN2'/'AML'/'MDS'	" ### Yoshida K, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011;478(7367):64-9"
SF3A1	any mutation	Chronic Myelomonocytic Leukemia/Acute Myeloid Leukemia/Myelodysplastic Syndrome	'*CMML'/'AML'/'MDS'	" ### Larsson CA, et al. The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome. Mol Cancer Res 2013;11(8):815-27 ### Yoshida K, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011;478(7367):64-9"
SF3B1	" codon(s) 700, 666, 662, 625, 622 missense"	Myeloproliferative Neoplasm/Chronic Lymphocytic Leukemia/MDS with Ring Sideroblasts/Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia/Acute Myeloid Leukemia/Primary Myelofibrosis/Essential Thrombocythemia	'*MPN2'/'CLL'/'*MDS-RAS'/'MDS'/'*CMML'/'AML'/'MY'/'*ET'	" ### Jeromin S, et al. SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. Leukemia 2014;28(1):108-17 ### Yoshida K, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011;478(7367):64-9 ### Damm F, et al. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood 2012;119(14):3211-8 ### Wang L, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011;365(26):2497-506 ### Lasho TL, et al. SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients. Leukemia 2012;26(5):1135-7 ### Papaemmanuil E, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011;365(15):1384-95 ### Stilgenbauer S, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014;123(21):3247-54 ### Baliakas P, et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia 2015;29(2):329-36 ### Visconte V, et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia 2012;26(3):542-5 ### Damm F, et al. SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications. Leukemia 2012;26(5):1137-40"
SF3B1	exon(s) 13, 14, 15, 16 missense	Myeloproliferative Neoplasm/Chronic Lymphocytic Leukemia/MDS with Ring Sideroblasts/Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia/Acute Myeloid Leukemia/Primary Myelofibrosis/Essential Thrombocythemia	'*MPN2'/'CLL'/'*MDS-RAS'/'MDS'/'*CMML'/'AML'/'MY'/'*ET'	" ### Jeromin S, et al. SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. Leukemia 2014;28(1):108-17 ### Yoshida K, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011;478(7367):64-9 ### Damm F, et al. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood 2012;119(14):3211-8 ### Wang L, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011;365(26):2497-506 ### Lasho TL, et al. SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients. Leukemia 2012;26(5):1135-7 ### Papaemmanuil E, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011;365(15):1384-95 ### Stilgenbauer S, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014;123(21):3247-54 ### Baliakas P, et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia 2015;29(2):329-36 ### Visconte V, et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia 2012;26(3):542-5 ### Damm F, et al. SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications. Leukemia 2012;26(5):1137-40"
SH2B3	any mutation	Myeloproliferative Neoplasm/T Lymphoblastic Leukemia/Lymphoma/B Lymphoblastic Leukemia/Lymphoma	'*MPN2'/'*TLL'/'LY'/'*BLL'/'LY'	" ### Lesteven E, et al. Association of a single-nucleotide polymorphism in the SH2B3 gene with JAK2V617F-positive myeloproliferative neoplasms. Blood 2014;123(5):794-6 ### Perez-Garcia A, et al. Genetic loss of SH2B3 in acute lymphoblastic leukemia. Blood 2013;122(14):2425-32 ### Roberts KG, et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 2012;22(2):153-66 ### Zhang J, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012;481(7380):157-63 ### Oh ST, et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 2010;116(6):988-92 ### Pardanani A, et al. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia 2010;24(10):1713-8"
SMAD4	any mutation	Adenocarcinoma/Carcinoma	'*AC2'/'*CA'	" ### Wang LH, et al. Inactivation of SMAD4 tumor suppressor gene during gastric carcinoma progression. Clin Cancer Res 2007;13(1):102-10 ### Cancer Genome Atlas Research Network Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513(7517):202-9 ### Park JW, et al. Cooperativity of E-cadherin and Smad4 loss to promote diffuse-type gastric adenocarcinoma and metastasis. Mol Cancer Res 2014;12(8):1088-99 ### cbioportal.org"
SMAD4	any mutation	Adenocarcinoma	'*AC2'	" ### Chen et al..SMAD4 Loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells. . BMC Cancer 2014, 14:181"
SMAD4	any mutation	Adenocarcinoma	'*AC2'	" ### C. Kandoth, M. D. McLellan et al, Mutational landscape and significance across 12 major cancer types. Nature. 502, 2013 ### SM Haeger, JJ Tompson et al, Smad4 loss promotes lung cancer formation but increases sensitivity to DNA topoisomerase inhibitors. Oncogene. 1-10, 2015 ### C. Bian, Z. Li et al, Clinical outcome and expression of mutant P53, P16, and Smad4 in lung adenocarcinoma: a prospective study. World Journal of Surgical Oncology. 13:128, 2015"
SMAD4	any mutation	Adenocarcinoma	'*AC2'	" ### Fleming et al‚Ä?. SMAD2, SMAD3 and SMAD4 Mutations in Colorectal Cancer. Cancer Res January 15, 2013 73; 725"
SMAD4	any mutation	Adenocarcinoma	'*AC2'	" ### Liu N, et al. SMAD4 expression in breast ductal carcinoma correlates with prognosis. Oncol Lett 2015;10(3):1709-1715 ### Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature 2012;490(7418):61-70 ### Deckers M, et al. The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res 2006;66(4):2202-9 ### Lee JY, et al. Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer. Oncotarget 2015;6(41):43731-42 ### Stephens PJ, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012;486(7403):400-4 ### Zhong D, et al. Homozygous deletion of SMAD4 in breast cancer cell lines and invasive ductal carcinomas. Cancer Biol Ther 2006;5(6):601-7 ### Ciriello G, et al. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell 2015;163(2):506-19"
SMAD4	any mutation	Papillary Carcinoma/Follicular Carcinoma	'THP'/'THF'	" ### D'Inzeo S, et al. Effects of the Smad4 C324Y mutation on thyroid cell proliferation. Int J Oncol 2013;42(6):1890-6 ### Nikolic A, et al. SMAD4 gene promoter mutations in patients with thyroid tumors. Exp Mol Pathol 2015;99(1):100-3 ### D'Inzeo S, et al. Role of reduced expression of SMAD4 in papillary thyroid carcinoma. J Mol Endocrinol 2010;45(4):229-44"
SMAD4	C324Y	Papillary Carcinoma/Follicular Carcinoma	'THP'/'THF'	" ### D'Inzeo S, et al. Effects of the Smad4 C324Y mutation on thyroid cell proliferation. Int J Oncol 2013;42(6):1890-6 ### Nikolic A, et al. SMAD4 gene promoter mutations in patients with thyroid tumors. Exp Mol Pathol 2015;99(1):100-3 ### D'Inzeo S, et al. Role of reduced expression of SMAD4 in papillary thyroid carcinoma. J Mol Endocrinol 2010;45(4):229-44"
SMAD4	R361H	Adenocarcinoma/Carcinoma	'*AC2'/'*CA'	" ### Wang LH, et al. Inactivation of SMAD4 tumor suppressor gene during gastric carcinoma progression. Clin Cancer Res 2007;13(1):102-10 ### Cancer Genome Atlas Research Network Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513(7517):202-9 ### Park JW, et al. Cooperativity of E-cadherin and Smad4 loss to promote diffuse-type gastric adenocarcinoma and metastasis. Mol Cancer Res 2014;12(8):1088-99 ### cbioportal.org"
SMC1A	any mutation	Acute Myeloid Leukemia/Chronic Myeloid Leukemia	'AML'/'CML'	" ### Thol F, et al. Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. Blood 2014;123(6):914-20 ### Kon A, et al. Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat Genet 2013;45(10):1232-7"
SMC3	any mutation	Acute Myeloid Leukemia/Myelodysplastic Syndrome	'AML'/'MDS'	" ### Thol F, et al. Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. Blood 2014;123(6):914-20 ### Kon A, et al. Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat Genet 2013;45(10):1232-7"
SMO	any mutation	Basal Cell Carcinoma	'BCC'	" ### Bonilla X, et al. Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma. Nat Genet 2016;48(4):398-406 ### Danial C, et al. An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib. Clin Cancer Res 2016;22(6):1325-9"
SPOP	any mutation	Adenocarcinoma	'*AC2'	" ### Cancer Genome Atlas Research Network. Electronic address: schultz@cbio.mskcc.org, et al. The Molecular Taxonomy of Primary Prostate Cancer. Cell 2015;163(4):1011-25 ### Barbieri CE, et al. Reprint of: The prostate cancer genome: Perspectives and potential. Urol Oncol 2015;33(2):95-102 ### Barbieri CE, et al. The mutational landscape of prostate cancer. Eur Urol 2013;64(4):567-76 ### Tomlins SA, et al. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 2008;13(6):519-28 ### Ateeq B, et al. Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med 2011;3(72):72ra17 ### Barbieri CE, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012;44(6):685-9"
SRSF2	codon(s) 95 missense	Chronic Myelomonocytic Leukemia/Myelodysplastic Syndrome/Acute Myeloid Leukemia/Primary Myelofibrosis	'*CMML'/'MDS'/'AML'/'MY'	" ### Guglielmelli P, et al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia 2014;28(9):1804-10 ### Vannucchi AM, et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013;27(9):1861-9 ### Haferlach T, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014;28(2):241-7 ### Taskesen E, et al. Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling. Blood 2014;123(21):3327-35 ### Patnaik MM, et al. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance. Am J Hematol 2013;88(3):201-6 ### Thol F, et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 2012;119(15):3578-84"
STAG2	any mutation	Myeloproliferative Neoplasm/Chronic Myelomonocytic Leukemia/Myelodysplastic Syndrome/Acute Myeloid Leukemia/Chronic Myeloid Leukemia	'*MPN2'/'*CMML'/'MDS'/'AML'/'CML'	" ### Thol F, et al. Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. Blood 2014;123(6):914-20 ### Kon A, et al. Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat Genet 2013;45(10):1232-7 ### Solomon DA, et al. Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science 2011;333(6045):1039-43"
STAT3	any mutation	T-Cell LGL Leukemia/T Cell Lymphoproliferative Disorder/NK Cell Lymphoproliferative Disorder	'*TLGL'/'*TLPD'/'*NCLD'	" ### Munoz J, et al. STAT3 inhibitors: finding a home in lymphoma and leukemia. Oncologist 2014;19(5):536-44 ### Koskela HL, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012;366(20):1905-13 ### Jerez A, et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood 2012;120(15):3048-57 ### Jerez A, et al. STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. Blood 2013;122(14):2453-9"
TET2	any mutation	Myeloproliferative Neoplasm/Mast Cell Neoplasm/Acute Myeloid Leukemia/Primary Myelofibrosis/Myelodysplastic Syndrome/Angioimmunoblastic T-Cell Lymphoma/Chronic Myelomonocytic Leukemia	'*MPN2'/'MAS'/'AML'/'MY'/'MDS'/'*ATL'/'*CMML'	" ### 24220273(good review) ### Tefferi A, et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009;23(5):900-4 ### Tefferi A, et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009;23(7):1343-5 ### Kosmider O, et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica 2009;94(12):1676-81 ### Delhommeau F, et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009;360(22):2289-301"
TLR2	any mutation	Myelodysplastic Syndrome	'MDS'	" ### Wei Y, et al. Toll-like receptor alterations in myelodysplastic syndrome. Leukemia 2013;27(9):1832-40 ### Be√† S, et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci U S A 2013;110(45):18250-5"
TP53	any deletion	Adenocarcinoma	'*AC2'	" ### Barbieri CE, et al. The mutational landscape of prostate cancer. Eur Urol 2013;64(4):567-76 ### Kohli M, et al. Mutational Landscapes of Sequential Prostate Metastases and Matched Patient Derived Xenografts during Enzalutamide Therapy. PLoS One 2015;10(12):e0145176"
TP53	any mutation	Acute Myeloid Leukemia/Myelodysplastic Syndrome	'AML'/'MDS'	" ### Malcikova J, et al. The frequency of TP53 gene defects differs between chronic lymphocytic leukaemia subgroups harbouring distinct antigen receptors. Br J Haematol 2014;166(4):621-5 ### Stilgenbauer S, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014;123(21):3247-54 ### Kihara R, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia 2014;28(8):1586-95 ### Kulasekararaj AG, et al. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. Br J Haematol 2013;160(5):660-72 ### M√ºhlbacher V, et al. Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%. Genes Chromosomes Cancer 2014;53(6):524-36 ### Holmfeldt L, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 2013;45(3):242-52 ### Chiaretti S, et al. TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy. Haematologica 2013;98(5):e59-61 ### Baliakas P, et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia 2015;29(2):329-36"
TP53	any mutation	Adenocarcinoma	'*AC2'	" ### Barbieri CE, et al. The mutational landscape of prostate cancer. Eur Urol 2013;64(4):567-76 ### Kohli M, et al. Mutational Landscapes of Sequential Prostate Metastases and Matched Patient Derived Xenografts during Enzalutamide Therapy. PLoS One 2015;10(12):e0145176"
TP53	any mutation	Adenocarcinoma	'*AC2'	" ### Olivier et al. TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use. 2010 Cold Spring Harb Perspect Biol ;2:a001008 ### IARC TP53 Database: (http://www-p53.iarc.fr/)"
TP53	any mutation	Adenocarcinoma	'*AC2'	" ### Olivier et al. TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use. 2010 Cold Spring Harb Perspect Biol ;2:a001011"
TP53	any mutation	Adenocarcinoma/Squamous Cell Carcinoma	'*AC2'/'SCC'	" ### Olivier et al. TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use. 2010 Cold Spring Harb Perspect Biol ;2:a001009"
TP53	any mutation	B Lymphoblastic Leukemia/Lymphoma	'*BLL'/'LY'	" ### Kihara R, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia 2014;28(8):1586-95 ### Kulasekararaj AG, et al. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. Br J Haematol 2013;160(5):660-72 ### M√ºhlbacher V, et al. Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%. Genes Chromosomes Cancer 2014;53(6):524-36 ### Holmfeldt L, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 2013;45(3):242-52 ### Chiaretti S, et al. TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy. Haematologica 2013;98(5):e59-61"
TP53	any mutation	Chronic Lymphocytic Leukemia	'CLL'	" ### Malcikova J, et al. The frequency of TP53 gene defects differs between chronic lymphocytic leukaemia subgroups harbouring distinct antigen receptors. Br J Haematol 2014;166(4):621-5 ### Stilgenbauer S, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014;123(21):3247-54 ### Kihara R, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia 2014;28(8):1586-95 ### Kulasekararaj AG, et al. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. Br J Haematol 2013;160(5):660-72 ### M√ºhlbacher V, et al. Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%. Genes Chromosomes Cancer 2014;53(6):524-36 ### Holmfeldt L, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 2013;45(3):242-52 ### Chiaretti S, et al. TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy. Haematologica 2013;98(5):e59-61 ### Baliakas P, et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia 2015;29(2):329-36"
TP53	any mutation	Glial Neoplasm/Glioblastoma	'*GN''/'GB'	" ### Olivier et al. TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use. 2010 Cold Spring Harb Perspect Biol ;2:a001011"
TP53	any mutation	Langerhans Cell Histiocytosis	'HISLC'	" ### Olivier et al. TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use. 2010 Cold Spring Harb Perspect Biol ;2:a001008 ### IARC TP53 Database: (http://www-p53.iarc.fr/)"
TP53	any mutation	Melanoma	'*M'	" ### Olivier et al. TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use. 2010 Cold Spring Harb Perspect Biol ;2:a001010"
TP53	copy number loss	Acute Myeloid Leukemia/Myelodysplastic Syndrome	'AML'/'MDS'	" ### Malcikova J, et al. The frequency of TP53 gene defects differs between chronic lymphocytic leukaemia subgroups harbouring distinct antigen receptors. Br J Haematol 2014;166(4):621-5 ### Stilgenbauer S, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014;123(21):3247-54 ### Kihara R, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia 2014;28(8):1586-95 ### Kulasekararaj AG, et al. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. Br J Haematol 2013;160(5):660-72 ### M√ºhlbacher V, et al. Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%. Genes Chromosomes Cancer 2014;53(6):524-36 ### Holmfeldt L, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 2013;45(3):242-52 ### Chiaretti S, et al. TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy. Haematologica 2013;98(5):e59-61 ### Baliakas P, et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia 2015;29(2):329-36"
TP53	copy number loss	Adenocarcinoma	'*AC2'	" ### Barbieri CE, et al. The mutational landscape of prostate cancer. Eur Urol 2013;64(4):567-76 ### Kohli M, et al. Mutational Landscapes of Sequential Prostate Metastases and Matched Patient Derived Xenografts during Enzalutamide Therapy. PLoS One 2015;10(12):e0145176"
TP53	copy number loss	B Lymphoblastic Leukemia/Lymphoma	'*BLL'/'LY'	" ### Kihara R, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia 2014;28(8):1586-95 ### Kulasekararaj AG, et al. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. Br J Haematol 2013;160(5):660-72 ### M√ºhlbacher V, et al. Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%. Genes Chromosomes Cancer 2014;53(6):524-36 ### Holmfeldt L, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 2013;45(3):242-52 ### Chiaretti S, et al. TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy. Haematologica 2013;98(5):e59-61"
TP53	copy number loss	Chronic Lymphocytic Leukemia	'CLL'	" ### Malcikova J, et al. The frequency of TP53 gene defects differs between chronic lymphocytic leukaemia subgroups harbouring distinct antigen receptors. Br J Haematol 2014;166(4):621-5 ### Stilgenbauer S, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014;123(21):3247-54 ### Kihara R, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia 2014;28(8):1586-95 ### Kulasekararaj AG, et al. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. Br J Haematol 2013;160(5):660-72 ### M√ºhlbacher V, et al. Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%. Genes Chromosomes Cancer 2014;53(6):524-36 ### Holmfeldt L, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 2013;45(3):242-52 ### Chiaretti S, et al. TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy. Haematologica 2013;98(5):e59-61 ### Baliakas P, et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia 2015;29(2):329-36"
TP53	G245C	Adenocarcinoma/Squamous Cell Carcinoma	'*AC2'/'SCC'	" ### Olivier et al. TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use. 2010 Cold Spring Harb Perspect Biol ;2:a001009"
TSC1	any missense	Adenocarcinoma/Urothelial Carcinoma/Renal Cell Carcinoma/Clear Cell Renal Cell Carcinoma	'*AC2'/'UTH'/'R'/'RCCC'	" ### Crino PB, et al. The tuberous sclerosis complex. N Engl J Med 2006;355(13):1345-56 ### Iyer G, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012;338(6104):221 ### Sj√∂dahl G, et al. A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1. PLoS One 2011;6(4):e18583 ### Sj√∂dahl G, et al. A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1. PLoS One 2011;6(4):e18583 ### Fuchs A, et al. Tuberous-sclerosis complex-related cell signaling in the pathogenesis of lung cancer. Diagn Pathol 2014;9():48"
TSC2	any missense	Adenocarcinoma/Clear Cell Renal Cell Carcinoma/Renal Cell Carcinoma/Urothelial Carcinoma	'*AC2'/'RCCC'/'R'/'UTH'	" ### Crino PB, et al. The tuberous sclerosis complex. N Engl J Med 2006;355(13):1345-56 ### Iyer G, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012;338(6104):221 ### Sj√∂dahl G, et al. A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1. PLoS One 2011;6(4):e18583 ### Sj√∂dahl G, et al. A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1. PLoS One 2011;6(4):e18583 ### Fuchs A, et al. Tuberous-sclerosis complex-related cell signaling in the pathogenesis of lung cancer. Diagn Pathol 2014;9():48"
U2AF1	codon(s) 157 missense	Myeloproliferative Neoplasm/Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia/Acute Myeloid Leukemia	'*MPN2'/'MDS'/'*CMML'/'AML'	" ### Wu SJ, et al. Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression. Am J Hematol 2013;88(11):E277-82 ### Patnaik MM, et al. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance. Am J Hematol 2013;88(3):201-6 ### Thol F, et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 2012;119(15):3578-84 ### Graubert TA, et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet 2011;44(1):53-7 ### Yoshida K, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011;478(7367):64-9 ### Larsson CA, et al. The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome. Mol Cancer Res 2013;11(8):815-27"
U2AF1	codon(s) 34 missense	Myeloproliferative Neoplasm/Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia/Acute Myeloid Leukemia	'*MPN2'/'MDS'/'*CMML'/'AML'	" ### Wu SJ, et al. Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression. Am J Hematol 2013;88(11):E277-82 ### Patnaik MM, et al. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance. Am J Hematol 2013;88(3):201-6 ### Thol F, et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 2012;119(15):3578-84 ### Graubert TA, et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet 2011;44(1):53-7 ### Yoshida K, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011;478(7367):64-9 ### Larsson CA, et al. The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome. Mol Cancer Res 2013;11(8):815-27"
U2AF2	any mutation	Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia	'MDS'/'*CMML'	" ### Larsson CA, et al. The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome. Mol Cancer Res 2013;11(8):815-27"
VHL	any mutation	Clear Cell Renal Cell Carcinoma/Renal Cell Carcinoma	'RCCC'/'R'	" ### Hakimi AA, et al. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol 2013;63(5):848-54 ### Gossage L, et al. Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma. Genes Chromosomes Cancer 2014;53(1):38-51 ### Randall JM, et al. Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art. Cancer Metastasis Rev 2014;33(4):1109-24 ### Haas NB, et al. Hereditary kidney cancer syndromes. Adv Chronic Kidney Dis 2014;21(1):81-90"
WHSC1	any mutation	B Lymphoblastic Leukemia/Lymphoma	'*BLL'/'LY'	" ### Jaffe JD, et al. Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. Nat Genet 2013;45(11):1386-91 ### Oyer JA, et al. Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies. Leukemia 2014;28(1):198-201"
WT1	any mutation	Acute Myeloid Leukemia	'AML'	" ### Paschka P, et al. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 2008;26(28):4595-602 ### Hou HA, et al. Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia. Leukemia 2014;28(1):50-8 ### Gaidzik VI, et al. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Blood 2009;113(19):4505-11 ### Marlton P The many facets of WT1 in acute myeloid leukemia: clarity remains elusive. Leuk Lymphoma 2014;55(2):235-7"
XPO1	any mutation	Chronic Lymphocytic Leukemia	'CLL'	" ### Jeromin S, et al. SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. Leukemia 2014;28(1):108-17 ### Lapalombella R, et al. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood 2012;120(23):4621-34 ### Puente XS, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011;475(7354):101-5"
ZRSR2	any mutation	Myeloproliferative Neoplasm/Acute Myeloid Leukemia/Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia	'*MPN2'/'AML'/'MDS'/'*CMML'	" ### Yoshida K, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011;478(7367):64-9 ### Larsson CA, et al. The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome. Mol Cancer Res 2013;11(8):815-27 ### Thol F, et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 2012;119(15):3578-84 ### Damm F, et al. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood 2012;119(14):3211-8"
